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The Rockefeller University 2016 
During and after transcription in the nucleus, messenger RNAs (mRNAs) undergo a variety of 
processing events before being exported to the cytoplasm through the nuclear pore complex.  
mRNA processing and nuclear export require a wide range of protein factors, which interact with 
maturing transcripts and each other to form dynamic mRNP complexes.  While there are many 
core, essential mRNP factors, the pathways governing mRNA maturation are not uniform, and 
different transcripts can be associated with mRNP complexes of dramatically different 
composition or kinetics.  To date though, it has been difficult to study RNP complexes specific to 
any single mRNA species, as each transcript is relatively unabundant in the cell, and few robust 
techniques exist to specifically purify a particular mRNP for proteomic analysis.  We thus sought 
to develop a method to isolate mRNPs from a single transcript, allowing us to study the dynamic 
RNP compositions of individual mRNA maturation pathways. 
To optimize purifications of the protein tags required for RNP isolations, we first generated high 
affinity reagents targeting key tags like GFP and mCherry.  Instead of traditional antibodies, we 
chose to use nanobodies: recombinant single domain derivatives of a heavy chain-only antibody 
variant found in camelids.  The recombinant nature and small size of nanobodies make them ideal 
reagents for affinity isolations.  We developed an improved pipeline for the identification of 
nanobody repertoires against any antigen of interest, which provided us with 25 nanobodies against 
GFP, the most common and robust protein tag in use.  This pipeline has also allowed us to develop 
nanobodies against a variety of other antigens of biomedical interest. 
With the help of optimized reagents, we developed a two-step purification method allowing highly 
targeted isolations of mRNPs, starting in a budding yeast model system.  In our approach, a single 
target transcript is tagged with MS2 hairpin sequences – these hairpins are bound specifically and 
with high affinity by the bacteriophage MS2 coat protein (MS2CP).  In the first purification step, 
a chosen RNP protein known to be associated with a particular mRNA processing step of interest 
is Protein A-tagged and affinity isolated.  From this material, anti-GFP nanobodies are used in the 
second step to isolate the MS2-tagged transcript of interest, through purification of MS2CP-GFP 
fusion proteins bound to the tag.  This approach is able to efficiently and cleanly isolate a particular 
transcript at a chosen step of mRNP maturation.  The use of an RNP factor as a separate 
purification target both improves overall purity and simplifies analysis by limiting heterogeneity 
of the mRNP mixture. 
Using this novel method for single mRNP isolations, we have performed a preliminary survey of 
transcripts with distinct sequence elements suspected to be associated with unique processing 
machinery.  Mass spectrometric (MS) analysis of RNPs co-purified with these transcripts revealed 
several RNA-specific changes in composition.  Most notably, introns from either a house keeping 
ACT1 gene or the RPS30b ribosomal protein gene led to dramatically different levels of various 
splicing-related proteins.  These differences provide mechanistic insight into changes in the 
kinetics of spliceosome assembly determined by intron sequence.  
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Chapter 1: Introduction 
Maturation of mRNP complexes in the nucleus 
The development of a cell nucleus that separates genetic information from other cellular processes 
was a key evolutionary transition, forcing a multitude of adaptations to allow information from the 
nucleus to be transmitted to and expressed in the cytoplasm.  Messenger RNAs (mRNAs) 
transcribed from DNA in the nucleus must be exported through the nuclear envelope, by way of 
the nuclear pore complex (NPC), for subsequent cytoplasmic translation. Within this genetic 
information pathway, post-transcriptional processing of RNA is a complex step critical to the 
proper propagation and regulation of such genetic information.  Beyond the transcription of a 
gene’s sequence to RNA, distinct combinations of modifications, splicing events, and interactions 
with export and localization factors can be required for normal gene expression.  These nuclear 
maturation and export processes are mediated through an elaborate, hierarchical network of mRNP 
complexes, comprised of dynamically associating RNA processing factors.  While many of the 
essential processing steps along this pathway have been well-characterized, along with their key 
components, many questions remain regarding the timing and ordered assembly of mRNP 
complexes.  Furthermore, while there is evidence that different mRNA transcripts follow 
differential processing and export pathways, the difficulties of analyzing individual subsets of 
mRNPs have made identification of alternative mRNA processing machinery difficult.  However, 
recent methodological advances that, at least potentially, allow high quality isolations of individual 
classes of RNP complexes are permitting new insight into the dynamic organization of maturing 
mRNPs (Tackett et al., 2005; Gavin et al., 2006; Krogan et al., 2006; Oeffinger et al., 2007). 
The basic framework for the biogenesis of a typical mRNP in the model organism Saccharomyces 
cerevisiae (budding yeast) is relatively well-established (Figure 1.1).  During transcription by 
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Figure 1.1. Overview of mRNP maturation pathway.  RNP factors in involved in mRNA 
transcription, processing, and export are shown.
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From Köhler and Hurt, 2007
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RNA polymerase II, the conserved THO/TREX complex associates with the nascent RNA 
transcript, along with splicing factors in the case of intron-containing RNAs (Strasser et al., 2002; 
Gornemann et al., 2005; Lacadie and Rosbash, 2005). RNA polymerase II also recruits the enzyme 
responsible for adding a 5’ 7-methylguanylate cap, which is then bound by the cap binding 
complex (Lewis et al., 1996; Cho et al., 1997; Lewis and Izaurralde, 1997).  While yeast TREX is 
primarily associated with the transcription machinery, in mammals, TREX is recruited in a splicing 
and CBC-dependent manner to the 5’ end of mRNAs (Masuda et al., 2005; Cheng et al., 2006). 
Components of the THO/TREX complex are subsequently able to recruit additional RNA-binding 
proteins, most notably the yeast Mex67-Mtr2 nuclear export factor, or its TAP-p15 homolog in 
metazoans (Gruter et al., 1998; Strasser and Hurt, 2000; Zenklusen et al., 2002; Abruzzi et al., 
2004; Hurt et al., 2004).  The Mex67-Mtr2 complex is primarily recruited by Yra1p (metazoan 
ALY or REF), an RNA-binding adaptor protein in the TREX complex, and mediates export 
through the nuclear pore complex (NPC) by direct interactions with FG-nucleoporins (Segref et 
al., 1997; Hurt et al., 2000; Strasser et al., 2000; Zhou et al., 2000).  In contrast to typical 
karyopherin nuclear export receptors which derive the directionality of their cargo transport from 
how they interact with the GTPase Ran, Mex67-mediated export is Ran independent, and 
directionality is instead believed to be derived from cytoplasmic mRNP remodeling factors.  This 
remodeling relies primarily on the ATP-driven RNA helicase activity of Dbp5p, an mRNP 
associating enzyme required for the removal of Mex67-Mtr2 (Snay-Hodge et al., 1998; Tseng et 
al., 1998; Lund and Guthrie, 2005).  Dbp5p is not fully active until stimulated by Gle1p, which is 
localized to cytoplasmic NPC filaments, in conjunction with inositol hexakisphosphate (IP6), a 
primarily cytosolic signaling small molecule (Alcazar-Roman et al., 2006; Weirich et al., 2006).  
According to this model, as the mRNP molecule passes through the NPC, this cytoplasmic 
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remodeling-dependent removal of Mex67-Mtr2 prevents transport back into the nucleus.  There is 
also evidence that other factors contribute to this export termination, such as the regulated 
recruitment of Mex67-Mtr2 by Npl3p, driven by differential nuclear and cytoplasmic protein 
phosphorylation.   When dephosphorylated in the nucleus, Npl3p can mediate interactions between 
mRNA and Mex67; after export however, it is phosphorylated by Sky1p, destabilizing the Mex67 
interaction and promoting Npl3p import (Gilbert et al., 2001; Gilbert and Guthrie, 2004).  Once in 
the cytoplasm, eIF4A and other translation initiation factors are recruited to the mRNP by the 
CBC, allowing translation to commence (Lewis and Izaurralde, 1997; Gingras et al., 1999). 
Anchoring of a subset of active genes and their transcripts to the NPC is also an important, if 
relatively poorly understood element of RNA processing (Casolari et al., 2004; Iglesias and Stutz, 
2008; Dieppois and Stutz, 2010).  This association appears to involve many different interactions, 
such as binding of the SAGA transcription initiation complex by Sus1p, a member of the mRNP- 
and NPC-associated TREX-2 complex, and interactions between other NPC and mRNP proteins, 
such as Mex67p and Mlp1p (Galy et al., 2004; Rodriguez-Navarro et al., 2004; Dieppois et al., 
2006).  However, how certain genes and their transcripts are selected to undergo anchoring, the 
relative timing of this anchoring, and its relationship with various RNA processing events remain 
unclear. Several quality control mechanisms are also required for proper mRNA processing.  This 
task first depends on the nuclear exosome, which is responsible for the sequestration and 
degradation of unspliced, unadenylated, or misassembled mRNPs (Bousquet-Antonelli et al., 
2000; Hilleren et al., 2001; Zenklusen et al., 2002; Hieronymus and Silver, 2003).  Surveillance of 
transcripts to determine which are faulty and thus targeted for degradation also occurs at the 
nuclear face of the NPC; there, it seems to chiefly require Mlp1p and Mlp2p, which are involved 
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in the retention of unspliced or improperly packaged mRNPs at the nuclear face of the NPC and 
away from the NPC’s transport mechanism (Galy et al., 2004; Vinciguerra et al., 2005). 
While most studies of mRNP maturation have taken a ground-up approach focusing on individual 
processing steps, there has been increasing interest in the characterization of the broader 
interactome of maturing RNP particles.  Several proteomic studies have begun to comprehensively 
identify the factors comprising these dynamic complexes, revealing novel RNP binding proteins 
(Gavin et al., 2002; Gavin et al., 2006; Krogan et al., 2006; Oeffinger et al., 2007).  However, as 
these studies have typically relied on the isolation of tagged RNP proteins rather than individual 
species of RNA, it has been difficult to survey anything other than mixtures of many different 
types of RNPs associating with a highly heterogeneous RNA population.  Furthermore, while these 
types of pullouts have revealed discrete subsets of proteins dynamically interacting with and 
processing maturing RNA, many questions remain about the timing and order of assembly of such 
subcomplexes.   
Alternative mRNP maturation pathways 
There has been an increasing amount of evidence that certain mRNA processing factors associate 
preferentially with different subsets of mRNAs, indicating that there is not a single universal 
mRNP maturation pathway (Hieronymus and Silver, 2003; Kim Guisbert et al., 2005; Hogan et 
al., 2008; Tuck and Tollervey, 2013; Baejen et al., 2014).  This seems to be in contrast to other 
classes of RNA, such as tRNAs, rRNAs, or miRNAs, which may have more defined processing 
mechanisms, consistent with their less variable structures (Venema and Tollervey, 1999; Kohler 
and Hurt, 2007).  In addition to obvious differences such as the presence or absence of introns 
affecting interactions with splicing machinery, other more central RNP-binding proteins, such as 
Npl3p, display different binding preferences to different types of pre-mRNAs (Kim Guisbert et 
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al., 2005; Kress et al., 2008).  Even Mex67-Mtr2 recruitment, central to mRNA export, can occur 
through different adaptor proteins in different transcripts, including Npl3p and the shuttling mRNA 
binding protein Nab2p, in addition to the canonical TREX proteins Yra1p and Sub2p (Gilbert and 
Guthrie, 2004; Iglesias et al., 2010).  Certain transcripts may additionally require another export 
receptor, Crm1p, for proper nuclear export (Gallouzi and Steitz, 2001; Dong et al., 2007). 
A variety of transcript-specific RNP interactions have also been identified that depend on 
sequences in the 3’ UTR.  One of the most well-studied examples is the 3’ UTR of the ASH1 
transcript in budding yeast.  This gene encodes a transcription factor involved in mating type 
switching of daughter cells, and its mRNA localizes to the yeast bud during cell division (Bobola 
et al., 1996; Jansen et al., 1996). This localization is mediated by the interaction of She2p with 
sequence elements in the 3’ UTR – She2p then recruits She3p and Myo4p, which transports the 
mRNA to the bud along actin filaments. This localization activity relies solely on stem-loop 
sequence elements in the transcript, which directly encode the alternative cytoplasmic transport 
through interactions with SHE proteins (Long et al., 2000; Olivier et al., 2005).   
Surprisingly, promoter sequences for a number of genes have been implicated in the regulation of 
alternative post-transcriptional processing of their mRNA products, independent of the transcribed 
RNA sequence.  The promoters of several genes have been shown to confer decreased stability of 
their mRNA products, including CLB2 and SWI5, whose transcripts become rapidly degraded 
during mitosis (Trcek et al., 2011).  Several genes, such as RPL30, whose promoters include 
sequence elements recognized by the Rap1p transcription factor, also produce mRNAs subject to 
rapid degradation in the cytoplasm by the Xrn1 exonuclease (Bregman et al., 2011).  This decrease 
in stability is encoded solely by the promoter elements recognized by Rap1p, not the transcript 
sequence itself.  A similar phenomenon was identified in the case of a number of genes responsive 
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to glucose starvation in yeast, such as heat shock genes (Zid and O'Shea, 2014).  For a number of 
transcripts upregulated during glucose starvation, it was found that promoter sequences alone 
encoded divergent fates for these mRNAs in the cytoplasm: either sequestration to foci and 
inhibition translation, or diffusion and rapid translation.  In all of these cases, the mechanism 
allowing the promoter to determine its transcript’s fate remains largely unclear. 
Surveys of mRNA pools associated with specific RNP factors 
While it appears clear that multiple mRNP maturation pathways exist, it has been difficult to 
comprehensively define any single mRNA’s unique assortment of processing factors or 
intermediate complexes.  The most common approach to this question has been analysis of mRNAs 
associated with a particular tagged RNP factor isolated from cells.  A number of studies have used 
this approach in yeast, surveying co-purifying mRNAs by microarray or RNA-Seq (Hieronymus 
and Silver, 2003; Kim Guisbert et al., 2005; Hogan et al., 2008; Tuck and Tollervey, 2013; Baejen 
et al., 2014).  Fundamentally, these studies used similar straightforward techniques, namely Protein 
A tagging and affinity isolation of major RNP proteins, followed by either RNA-seq or microarray 
analysis of purified RNA.  In some cases, crosslinking was used to allow mapping of protein-
bound RNA sites.  To address these questions in mammalian cells, a more common approach has 
been to identify RNA binding proteins isolated with bulk RNA or synthetic RNA probes, and 
correlate RNPs with different transcript sequences (Butter et al., 2009; Castello et al., 2012).  
Surveys of this kind have generated a great deal of data, but a few general patterns have been 
consistently found in multiple studies, all consistent with the view that mRNAs commonly have 
different preferences in their RNP interactions.  For instance, different members of the shuttling 
hnRNP family, such as Nab2, Npl3, and Hrp1, have strikingly different mRNA specificities.  
Ribosomal protein transcripts in particular (in which introns are most common) have a significant 
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preference for Npl3.  While Mex67 exhibits general affinity for all mRNAs, its adaptor proteins, 
Nab2, Npl3, and Yra1, each have distinct preferences for different groups of mRNAs.  These 
preferences also exhibit certain patterns; longer transcripts, for instance, are preferentially bound 
to Nab2, while shorter ones tend to be preferred by Yra1. 
While this transcriptomic approach has produced much insight on overall trends in RNA 
preferences of many RNPs, it is inherently limited in its ability to correlate such differences to 
higher order mRNP assemblies.  That is, any particular RNP factor will likely be purified from a 
heterogenous mixture of different complexes, with different overall compositions.  Even an mRNP 
protein’s direct interactions with RNAs may be influenced by other components in the broader 
complex.  Such complications could in part be addressed by performing concurrent proteomic 
analysis of such RNP purifications, allowing any identified mRNA enrichments to be correlated 
to overall complex protein composition.  An alternative, however, would be mRNP purifications 
designed to specifically isolate a specific RNA transcript.  By this approach, the association of an 
RNA sequence for any RNP factor could be directly observed in the context of the overall mRNP 
complex, as other proteins present can also be detected. 
Tools for isolating RNP complexes 
A number of labs have made efforts to tag specific RNAs with unique sequences recognized by a 
binding partner and adaptable to a pullout system (Bardwell and Wickens, 1990; Hogg and Collins, 
2007; Said et al., 2009; Hogg and Goff, 2010; Slobodin and Gerst, 2010).  To date, these 
methodologies have shown relatively low purity and yield.  This has allowed detection of major 
cytoplasmic RNA-associated factors, but typically not lower-abundance factors found in the 
nucleus. In theory though, this type of system can allow the characterization of copurifying RNP 
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complexes by mass spectrometry and other analytical techniques, providing for a more direct study 
of an individual RNA processing pathway. 
The use of bacteriophage coat proteins in RNA tagging 
A variety of different RNA tagging systems have been developed over the years, with various 
advantages and disadvantages.  The most common approach has proven to be the use of 
bacteriophage coat proteins binding a cognate RNA hairpin, specifically the MS2 and PP7 systems 
(Kozak and Nathans, 1972; Bertrand et al., 1998; Lim et al., 2001; Chao et al., 2008).  Short 19-
25 bp RNA hairpins found in these bacteriophages bind with high specificity and affinity (KD ~ 
4x10-10 M) to their corresponding MS2 or PP7 binding proteins (Figure 1.2a).  By fusing these 
bacteriophage coat proteins to a tag such as GFP and co-expressing with transcripts genetically 
tagged with the corresponding RNA hairpins, GFP can be targeted to nascent transcripts through 
the coat protein-hairpin interaction (Figure 1.2b). This technique has been extensively used for 
fluorescent visualization of mRNA transcripts in living cells, as well as in tethering proteins to 
RNAs in vivo (SenGupta et al., 1996; Bertrand et al., 1998; Rodriguez et al., 2007; Hocine et al., 
2013). 
In a few cases, MS2 or PP7 have been used with varying levels of success to purify tagged RNAs 
from cells, along with associated RNP proteins.  PP7 hairpins, for instance, were used to tag and 
purify RNP complexes of 7SK non-coding RNA (ncRNA), an abundant snRNP regulating 
transcription (Hogg and Collins, 2007).  The yield in this approach was limited to 20-30% 
however, and further limited by non-specific contaminants.   Related approaches with either PP7 
or MS2 have been used to identify abundant factors from a primarily cytoplasmic mRNA pool, 
with similar limitations (Said et al., 2009; Hogg and Goff, 2010; Tsai et al., 2011).  To date, these 
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Figure 1.2. Bacteriophage hairpins and coat proteins. (a) RNA hairpin structures bound by MS2 or 
PP7 coat proteins. (b) Binding of GFP-tagged MS2 or PP7 coat proteins as dimers to cognate hair-
pins.
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techniques have not been applied to the study of lower abundance mRNP factors typically 
associated with nuclear mRNAs. 
Other bacteriophage proteins have also been successfully used in these approaches.  Effective 
systems have been developed from the N protein from bacteriophage λ, known as λN. This protein 
recognizes a short RNA hairpin structure, BoxB, with binding activity determined by a 22 amino 
acid region that can be independently synthesized or expressed  (Franklin, 1985; Baron-Benhamou 
et al., 2004; Daigle and Ellenberg, 2007).  Similar to MS2 and PP7, this λN peptide specifically 
binds its cognate 15 bp hairpin structure with high affinity, and has been successfully used in RNA 
visualization and protein tethering.   
Alternative approaches to RNA affinity capture 
Beyond the widely-adopted bacteriophage-based systems, alternative RNA purification techniques 
have also been attempted, including the use of antisense oligomers complementary to unique RNA 
sequences.  Immobilized oligomers can potentially recognize complementary RNA sequences in 
cell lysate, particularly using synthetic oligomers such as 2’O-methyl-RNA, LNA (locked nucleic 
acids), or PNA (peptide nucleic acids), which are able to form more stable hybrid structures with 
complementary RNA sequences (Cotten et al., 1991; Kumar et al., 1998; Larsen et al., 1999).  
While these types of reagents have been extensively used for various hybridization techniques, 
few studies have succeeded in adapting this technology to isolating intact RNPs from target RNA, 
and typically only in the case of stable, highly abundant RNA-protein complexes (Grunweller et 
al., 2003; Upadhyay et al., 2013). More typically, these types of approaches have been used to 
isolate direct RNA-binding proteins under stringent, denaturing conditions (Castello et al., 2012).  
This relies on covalent crosslinking between RNAs and interacting proteins, but the conditions 
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required for hybridization and washing of the RNAs to complementary oligomers do not allow for 
recovery of additional complex components. 
Similar techniques have been developed through the use of RNA aptamers, short RNA secondary 
structure-forming sequences that are designed to bind to substrates such as streptavidin, 
streptomycin, and tobramycin. These aptamers have been used to tag RNAs of interest, allowing 
affinity capture by the immobilized ligand (Bachler et al., 1999; Srisawat and Engelke, 2001; 
Hartmuth et al., 2002).  This technology has been used, for example, to isolate transcripts 
containing AU-rich elements (AREs) from HEK293 cells, copurifying major ARE-binding factors 
like HuR (Vasudevan and Steitz, 2007). However, this approach has been limited to some degree 
by slow kinetics of binding to streptavidin, low yield (~20%), and non-specific binders (Bachler 
et al., 1999; Srisawat and Engelke, 2001).  Aptamer tags have also been used in complementary 
techniques, such as immobilization of in vitro-transcribed RNAs in order to capture RNA binding 
proteins from cell lysate (Butter et al., 2009).   
Reagents for affinity isolations 
The most promising methods for tagging and isolating RNA transcripts have tended to rely on 
MS2 or GFP bacteriophage coat proteins fused to GFP or Protein A (Hogg and Goff, 2010; 
Oeffinger, 2012).  As efficient purification of these fusion proteins is critical for a successful 
isolation of their RNA targets, any such technique must rely on high quality reagents to purify 
GFP or Protein A. 
In the case of common protein tags like GFP, mCherry, FLAG, myc, or HA, the vast majority of 
studies make use of high quality commercial antibodies to target the tag, particularly when affinity 
isolation is required (Rigaut et al., 1999; Ho et al., 2002; Cristea et al., 2005; Domanski et al., 
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2012). Although monoclonal or polyclonal antibodies remain the primary bait reagents available 
for these purposes, they have a variety of limitations that can sometimes prove problematic.  They 
are large multimeric proteins, at approximately 150 kDa, and this can result in steric hindrances or 
limit density when attached to surfaces, such as resins used for immobilization.  Furthermore, the 
high cost of commercial reagents, limited availability, and batch to batch variation have often 
proved problematic for providing the large amounts of consistently high quality affinity capture 
reagents needed for such biochemical or proteomic studies (Gingras et al., 2005). 
Single domain antibodies 
Due to the limitations of traditional IgG antibodies, a number of efforts have been made to generate 
alternatives of smaller size, preferably suitable to production as single recombinant proteins.  Some 
of the earliest and most successful such reagents are synthetic single-chain antibodies, often termed 
scFvs, created by tethering variable heavy (VH) and light (VL) chains from monoclonal antibodies 
(Figure 1.3) (Bird et al., 1988; Huston et al., 1988; Skerra and Pluckthun, 1988).  While there have 
been many highly successful examples of such scFvs, whose affinities can rival their monoclonal 
IgG progenitors, they can also prove problematic in terms of stability (Dumoulin et al., 2002).  
Furthermore, development of a traditional scFv first requires generation of a high quality 
monoclonal antibody, followed by engineering of a recombinant sequence able to properly fold 
into its native VH/VL conformation, making this a labor- and time-intensive process.   
The disadvantages of scFvs are largely due to their two-domain structure, so an antibody fragment 
containing only a single variable domain is an appealing alternative.  However, individual VH or 
VL domains are typically not sufficiently stable or soluble on their own, and may not retain high 
antigen affinity when unpaired (Ward et al., 1989).  A promising answer to this problem came with 
the discovery in camels of a novel class of IgG molecules made only of a heavy chain homodimer, 
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Figure 1.3. IgG variants and their derivatives.  Standard IgG structures contain both heavy 
and light chains. Variable regions from both chains must be combined for use as an Fab 
fragment or for recombinant expression as a linked scFv. The camelid VHH IgG variant has 
only heavy chains.  The single variable region can be cloned and expressed independently as 
a nanobody.
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lacking any associated light chains (Figure 1.3) (Hamers-Casterman et al., 1993).  This unusual 
antibody variant, termed VHH, has only been observed in camelid species, including llamas and 
alpacas, though an analogous heavy chain-only Ig (IgNAR), has been identified in cartilaginous 
fish (Greenberg et al., 1995).  The VHH variable region is thus the smallest antigen-binding single 
polypeptide chain naturally found in the antibody world (Arbabi-Ghahroudi et al., 1997; Dumoulin 
et al., 2002; Harmsen and De Haard, 2007; Romer et al., 2011; Muyldermans, 2013). 
As these VHH antibodies retain strong affinity for their antigens, the variable regions responsible 
for binding activity can be cloned out and expressed as independent antigen-binding proteins 
known as nanobodies (Arbabi-Ghahroudi et al., 1997; Cortez-Retamozo et al., 2004; Harmsen and 
De Haard, 2007; Muyldermans, 2013).  Unlike monoclonal antibodies or many other antibody 
fragments, they can be readily produced in large, soluble amounts in bacterial expression systems 
(Arbabi-Ghahroudi et al., 2005; Harmsen and De Haard, 2007). Moreover, nanobodies are usually 
extremely stable, can bind antigens with affinities in the nanomolar or sub-nanomolar range, and 
are much smaller in size (approximately 15 kDa) than other antibody constructs (Bird et al., 1988; 
Skerra and Pluckthun, 1988; Worn and Pluckthun, 2001; Dumoulin et al., 2002; Rothbauer et al., 
2006; Muyldermans et al., 2009).  
However, rapid and robust techniques for the isolation of extensive repertoires of high affinity 
nanobodies have proven elusive – the labor-intensive nature and poor efficiency of current 
approaches have been a major bottleneck for the widespread implementation of these reagents 
(Arbabi-Ghahroudi et al., 1997; Rothbauer et al., 2006; Muyldermans, 2013), explaining why 
demand for these reagents greatly exceeds supply (Muyldermans, 2013). 
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Tools for targeted affinity isolation of single mRNP populations 
To allow closer examination of the multitude of likely alternative mRNP processing pathways, we 
have aimed to develop techniques and reagents for the isolation and analysis of individual subsets 
of mRNPs.  This has involved adapting and optimizing the most promising approaches to tagging 
and isolating mRNAs and their associated mRNP factors.  A key component of these techniques 
is highly efficient protein affinity capture reagents, for which we turned to nanobodies.  Given the 
limitations of existing nanobody development methods, we generated a new pipeline for nanobody 
discovery based on a combination of mass spectrometry (MS) and high-throughput sequencing.  
This has provided optimized nanobodies for the high efficiency anti-GFP isolations required for 
our mRNP purification method.  Secondarily, this pipeline has allowed us to generate repertoires 
of nanobodies against a variety of additional antigens of biomedical interest. 
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Chapter 2: A new pipeline to generate anti-GFP nanobodies 
Strategies for identifying high-affinity nanobody clones 
Given the importance of highly efficient isolations of GFP for an RNA purification scheme making 
use of MS2CP-GFP, we sought optimized reagents targeting this protein tag.  As recombinant 
nanobodies are among the most efficient tools available for protein affinity isolation, and are not 
currently available against GFP in the quantities required, we sought to generate a new repertoire 
of anti-GFP nanobody clones. 
In order to identify camelid VHH clones that can be expressed as a recombinant nanobody against 
an antigen of interest, such sequences must be cloned out and selected from immunized animals.  
Traditionally, this has been done by phage display performed with material from llamas (Arbabi-
Ghahroudi et al., 1997; Conrath et al., 2001; Rothbauer et al., 2006; Alvarez-Rueda et al., 2007; 
Pardon et al., 2014).  In this method, llama lymphocytes are taken from peripheral blood samples, 
and a cDNA library is generated from total mRNA.  DNA primers against conserved constant 
region sequences flanking the VHH region are then used to PCR amplify this variable domain.  
These amplicons are then cloned into a vector that expresses them fused to a bacteriophage coat 
protein, producing a library that can be transformed into E. coli to release phages displaying VHH 
domains on their surface.  These phages can then be bound to the immobilized antigen of interest, 
and target-specific VHH-expressing phages can be collected after washing.  This panning process 
is typically repeated multiple times with the enriched phage populations, after which individual 
clones can be selected and screened to confirm binding activity. 
While this phage display approach has successfully been used to produce nanobodies against a 
variety of targets, it has practical disadvantages.  It is a time and labor intensive process, often 
taking a total of 3-6 months from beginning to end (Pardon et al., 2014).  It carries risk of false 
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negatives, as VHH sequences may not fold correctly when displayed on a phage surface, as well 
as false positives, since increased avidity of multiple displayed proteins on a phage can amplify 
apparent binding of weak or non-specific clones. Furthermore, this approach has often only 
identified only a few stable, high affinity nanobodies, even for well-behaved protein antigens such 
as GFP (Rothbauer et al., 2006).  To overcome these limitations, we sought to develop an 
orthogonal approach to nanobody discovery that avoids all these issues and allows simpler, more 
rapid identification of larger nanobody repertoires. We therefore worked to design a highly 
optimized pipeline that allows the rapid production of repertoires of high affinity nanobodies 
against selected proteins. This concept is inspired by previous efforts that identified circulating 
neutralizing HIV antibodies in humans using MS in conjunction with patient-specific antibody 
cDNA databases (Scheid et al., 2011). The approach is thus based on high-throughput DNA 
sequencing of a marrow lymphocyte VHH cDNA library from an immunized llama combined with 
mass spectrometric (MS) identification of high affinity VHH regions derived from serum of the 
same animal.  
Strategy for nanobody identification 
Our approach to nanobody discovery centers on MS identification of affinity-purified heavy-chain 
antibodies isolated from an individual llama, in correlation with a DNA sequence database 
generated from the same animal (Figure 2.1). Our approach represents a novel pipeline for 
nanobody production where each stage has been highly optimized.  
To generate nanobody repertoires of maximal utility, we chose the GFP (green fluorescent protein) 
and mCherry tags for our first target antigens, due to their central roles in cell biological studies 
(Shaner et al., 2005).  GFP is perhaps the most universally used tag, presenting many advantages 
over other tags.  Most obviously, it permits both localization and interactomic studies in parallel 
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Figure 2.1. Overview of nanobody identification and production pipeline. The example nanobody 
structure shown was obtained from PDB 3K1K (Kirchhofer et al., 2010). LC-MS/MS, liquid 
chromatography–tandem mass spectrometry. 
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(Poser et al., 2008; Hutchins et al., 2010), and many thousands of proteins in many model 
organisms have already been tagged with GFP for visualization, at an enormous cost in both 
research time and expense. Based on PubMed searches, the Rout and Chait groups have 
conservatively estimated that in excess of $1 billion has been spent on GFP-tagged reagents.  
Similarly, mCherry is a very widely used red-fluorescing alternative to GFP, often used as its 
complement.  
Further, while these fluorescent proteins have a broadly similar beta barrel structure, they are 
significantly evolutionarily divergent, making for very distinct immunogens (Shagin et al., 2004). 
After immunization of individual llamas with these antigens and confirmation of an immune 
response, we serially fractionated serum bleeds to obtain exclusively VHH-containing heavy chain 
antibodies (Figure 2.2a), taking advantage of the differential specificity of Protein A and Protein 
G for VHH versus conventional antibodies (Hamers-Casterman et al., 1993). The VHH-containing 
fraction was affinity purified over antigen-coupled resin, washed with MgCl2 at various 
stringencies to remove non-specific and weakly specific binders (Figure 2.2b), and digested with 
papain on-resin to cleave away the constant regions and leave behind the desired minimal VHH 
variable region fragments from the remaining high-affinity binders. Finally, the antigen-bound 
VHH fragments were eluted and separated by SDS-PAGE, allowing the purification of the ~15 
kDa VHH fragments away from residual conventional Fab fragments and Fc fragments (both ~25 
kDa), and undigested antibodies (~50 kDa) (Figure 2.2c). The gel-purified bands were trypsin-
digested and analyzed by liquid chromatography-MS and MS/MS (with Yinyin Li, B. Chait  lab) 
(Figure 2.3). We recovered the highest affinity VHH fragments by using the highest stringency 
washes, which also decreased the complexity of the eluted sample, aiding MS analysis. 
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Figure 2.2. Purification of an antigen-specific VHH fraction. (a) Llama serum fractionated by 
successively binding to Protein G and Protein A agarose resin. VHH variant heavy chains were 
specifically eluted in pH 4.0 (Protein G) and pH 3.5 (Protein A) buffers. (b) The GFP affinity of 
serum VH and VHH IgG was assessed by resistance to high stringency MgCl2 washes. A llama 
serum sample was bound to GFP-sepharose resin, which was then serially washed with increasing 
MgCl2 concentrations, followed by elutions with 0.1M glycine-HCl, pH 2.5 and boiling SDS. (c) 
Pooled VHH fraction was bound to GFP-Sepharose resin, and washed with 3.5 M MgCl2. Bound 
IgG was digested on the beads with papain, releasing Fc fragments. The remaining GFP-bound 
VHH fragments were eluted with ammonium hydroxide.
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Figure 2.3. VHH peptide identification of mass spectrometry. Tandem mass spectra of identified 
peptides (shown boxed), mapped to the CDR regions of three candidate VHH sequences. The 
MS-covered regions of these sequences are underlined. Dashed lines indicate overlapping peaks.  
MS analysis was performed by Yinyin Li.
25
To create an animal-specific antibody sequence database, lymphocyte mRNA samples from 
individual immunized llamas were obtained for high-throughput sequencing. Mononuclear cells 
were isolated from bone marrow aspirates, enriching for long-lived antibody secreting plasma 
cells, which express elevated levels of immunoglobulin RNA (Benner et al., 1981; Dorner and 
Radbruch, 2007; Scheid et al., 2011). Importantly, we do not create expression libraries, and thus 
remove the need for efficient exogenous expression, folding, and presentation of the clones, and 
avoiding issues of codon adaptation incompatibility.  
Total RNA from these lymphocytes was reverse transcribed, and a nested PCR was performed to 
specifically amplify sequences encoding the VHH variable regions (Rothbauer et al., 2006). This 
PCR product was sequenced using high-throughput 454 (GFP) or MiSeq (mCherry), resulting in 
∼800,000 and ∼3,000,000 unique reads, respectively. These reads were translated, filtered and 
trypsin-digested in silico to create a searchable peptide database for MS analysis (Figure 2.1).  
The identification of specific VHH sequences is more challenging than typical proteins, as they 
consist in large part of highly conserved framework regions that are less easily distinguished by 
MS. Moreover, rather than searching well-established databases, a VHH cDNA database must be 
generated for each immunized animal. To deal with both challenges, we developed (with Sarah 
Keegan and David Fenyö, NYU) a bioinformatic pipeline that is able to identify the highest 
probability matches from a large pool of related VHH sequences (Llama Magic; 
http://www.llamamagic.org). In this pipeline, VHH sequences were ranked by a metric based on 
MS/MS sequence coverage of complementarity determining region 3 (CDR3, the most diverse 
VHH region) as well as CDR1 and CDR2 coverage, total VHH coverage, sequencing counts, mass 
spectral counts, and the expectation values of matched peptides. Preliminary attempts to identify 
VHH sequences solely by their CDR3 regions revealed that identical CDR3 sequences are 
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frequently shared between multiple distinct VHH sequences, with diverse CDR1 and CDR2 
sequences. It is possible that this is a result of somatic gene conversion, in which, after V(D)J 
recombination, secondary recombination occurs between upstream V gene segments and already 
rearranged V(D)J genes (Becker and Knight, 1990; Knight, 1992).  Alternatively, PCR 
amplification could possibly produce apparent recombination of this type, if a conserved region 
on an incomplete PCR product serves to prime an unrelated sequence, thus fusing two different 
VHH sequences.  Our automatic ranking pipeline, coupled with careful manual inspection, 
overcame these issues and provided us 44 high-probability hits against GFP, classified as LaG 
(Llama antibody against GFP) 1-44, which we subjected to further screening. A smaller subset of 
eight clones was similarly chosen for follow up (LaM 1-8) for mCherry.  
Codon optimized genes for these hits were synthesized and cloned into a bacterial expression 
vector. After expression, lysates were passed over antigen-coupled resin to identify nanobodies 
that displayed both robust expression as well as high and specific affinity. From these screens, we 
found 25 specific nanobodies against GFP (LaGs) and 6 against mCherry (LaMs). Phylogenetic 
analysis of the verified nanobodies revealed substantial sequence diversity among clones (Figure 
2.4). While not directly analogous, the high success rate of this single screening step (57-75%) is 
favorable in comparison to the final panning and selection steps of phage display, in which batches 
of up to 107 clones are screened repeatedly to identify even a few positive clones (Arbabi-
Ghahroudi et al., 1997; Conrath et al., 2001; Rothbauer et al., 2006; Alvarez-Rueda et al., 2007). 
The affinity of these nanobodies was further assessed by either surface plasmon resonance (SPR) 
or in vitro binding assays with immobilized nanobodies. For the larger repertoire of LaGs, these 
experiments revealed a wide range of affinities, with Kds from 0.5 nM to over 20 µM (Table 1), 
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MAQVQLVE-SGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREFVAAISWTGVSTYYADSVKGRFTISRDNDKNTVYVQMNSLIPEDTAIYYCAAVRARSFSDTYSRVNEYDYWGQGTQVTV-
MAQVQLVE-SGGRLVQAGDSLRLSCAASGRTFSTSAMAWFRQAPGREREFVAAITWTVGNTILGDSVKGRFTISRDRAKNTVDLQMDNLEPEDTAVYYCSARSRGYVLSVLRSVDSYDYWGQGTQVTVS
MAQVQLVE-SGGGLVQAGGSLRLSCAASGRTFSTSAMGWFRQAPGREREFVAAITWTVGNTIYGDSMKGRFTISRDRTKNTVDLQMDSLKPEDTAVYYCTARSRGFVLSDLRSVDSFDYKGQGTQVTVS
MAQVQLVE-SGGGLVQAGGSLRLSCAASGRTYSISAMGWFRQAPGKEREFVAGISRSGGTTYYADPVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARARGWT-TFPAREIEYDYWGQGTQVTV-
MAQVQLVE-SGGGLVQAGGSLRLSCAASGRTFSTSAMAWFRQAPGKEREFAAGITWISSSTYYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAKSEGYFG-FPRVENEYPYWGQGTQVTV-
MAQVQLVE-SGGGLVQAGDSLQLSCAFSGGTFSTYAMGWFRQAPGKEREFVGGISRSGATTNYEDSVKGRFTISKDNTKNTVYLQLNSLKPEDTAVYYCAARNN--I-LPVTTIDKYEYWGQGTQVTV-
MADVQLVE-SGGGLVQPGGSLRLSCEASGGAFSTVAMGWFRQAPGKEREFVGAITWTAGSTYYADSAKGRFTISRDNAKNTVHLQMNSLKPEDTAVYYCAQRVRGFFGPLRTTPSWYEYWGQGTQVTVS
MAQVQLVE-SGGGLVQAGGSLRLSCAASGPTG---AMAWFRQAPGKEREFVGGISRSGTDTYYVDSVKGRFTIDRDNAKNTVYLQMNSLKPEDTAVYYCAARRS--Q-ILFTSRTDYEFWGQGTQVTVS
MADVQLVE-SGGGLVQAGGSLRLSCAASGRTFSTSAMGWFRQAPGKEREFVARITWSAGYTAYSDSVKGRFTISRDKAKNTVYLQMNSLKPEDTAVYYCASRSAGYSSSLTRRED-YAYWGQGTQVTVS
MADVQLVE-SGGGLVQPGGSLRLSCAASGEIASIIAIGWYRQAPGKQRESVALITRS-GMITYGDSAQGRFTISRDDAKNTVYLHMDDLVPEDTAVYYCNAKKVSFG----------DYWGQGTQVTVS
MADVQLVE-SGGGLVQAGDSLRLSCAASGPTG---AMAWFHQGLGKEREFVGGISPSGDNIYYADSVKGRFTIDRDNAKNTVSLQMNSLKPEDMGVYYCAARRR--V-TLFTSRTDYEFWGRGTQVTVS
MADVQLVE-SGGGLVQAGGSLRLSCTVSGRTFSNYAMGWFRQAPGKEREFVAGISWTGGHTLYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTALYYCAADRAADF---FAQRDEYDYWGQGTQVTVS
MAQVQLVE-SGGGLVQHGGSLRLSCVTSGFTFDIHDMGWFRQAPGKERDIVARISKSGDITYYADSVKGRFIISRDNTKNTVYLQMNSLKPEDTAVYYCAATLR----ATITSFDEYVYRGQGTQVTVS
MAQVQLVE-SGGGLVQAGAALRLSCAASGGTFSFYNMGWFRQAPGKEREFVVSISRSGGGTAYADSVKGRFTISRDNAKNTAYLQMNSLKPEDTAVYYCAAGLR--D-WGREG--EPHYWGQGTQVTVS
MAQVQFVE-SGGGTVQDGDFLRLSCTASGDTFSNYHAGWFRQPPGREREFVAAISWTGEGTLYADSVKGQFTISRDNAKNAMYLQMNRLKPEDTAVYYCAAARSVGFTWRSSKSNDYAYWGQGTQVTV-
MADVQLVE-SGGRSVRAGDSLRLSCLASGGTFSLYAMGWFRQAPGKEREFVAAVTWSGGSTYYTDSVKGRFSISRDNAKNTVYLQMNSLKPEDTAVYYCAVRTSGFFGSIPVTERAFDYWGQGTQVTVS
MAQVQLVE-SGGGLVQAGGSLRLSCAASGPTG---AMAWFRQAPGMEREFVGGISGSETDTYYADFVKGRLTVDRDNVKNTVDLQMNSLKPEDTAVYYCAARRR--V-TLFTSRADYDFWGQGTQVTVS
MAQVQLVE-SGGGLVQAGGSLRLSCAASGSIFSSNAMAWYRQTPEKQRELICDITR-GGITKCADSVKGRFTISRDNTKNTVYLQMNSLKSEDTAVYYCAAKSEGYFG-FPRVENEYPYWGQGTQVTV-
MAQVQLVE-SGGGLVQAGASMRLSCAASGITFSLYHWVWFRQAAGREHEFVAGIIRSGGETLSADSVKDRFIISRDDAKNTLYLQMNMLQPEDTATYYCAATHRA-D-WYSSAFREYIFRGQGTQVTVS
MAQVQLVE-SGGGLVQAGGSLRVSCAASGRTYSDYAMGWFRQAPGKERDFVAGISGSGGDTYYADSVKGRFTISRDNAKNTMYLQMNSLKPEDTAVYFCAARTG--T-VLFTSRVDYRYWGQGTQVTV-
MADVQLVE-SGGGLVQAGGSLRLSCAASGPTG---AMAWFRQAPGKEREFVGGISGSETDTYYVDSVKGRFTVDRDNVKNTVYLQMNSLKPEDTAVYYCAARRR--I-TLFTSRTDYDFWGRGTQVTV-
MAQVQLVE-SGGGLVQTGGSLKLSCTASVRTLSYYHVGWFRQAPGKEREFVAGIHRSGESTFYADSVKGRFTISRDNAKNTVHLQMNSLKPEDTAVYYCAQRVRGFFGPLRSTPSWYDYWGQGTQVTVS
MADVQLVE-SGGGLVQAGGSLRLSCAASGRTISMAAMSWFRQAPGKEREFVAGISRSAGSAVHADSVKGRFTISRDNTKNTLYLQMNSLKAEDTAVYYCAVRTSGFFGSIPRTGTAFDYWGQGTQVTVS
MASGAAGGGLGEGLVQAGGSLRLSCAASGRTFNSYPMAWFRQAPGKEREFVAALGWSGGSTDYADSVKGRFTISRDNSKNTVYLEMNSLKPDDTGVYYCALRRRGGVYNTYSGEKDYDYWGQGTQVTVS
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Figure 2.4. Phylogenetic analysis of nanobody sequences. (a) LaG and (b) LaM sequences were 
aligned, and (c) a phylogenetic tree was generated from LaG sequences, using the Phylogeny.fr 
web service.
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Table 1. Characteristics of LaG, LaG Dimer, and LaM proteins. Kd values for GFP and mCherry 
binding were determined by SPR unless otherwise noted. Kd values are also listed for LaG dimers 
fused by a glycine-rich peptide linker (three repeats of GGGGS, or G4S) or by a 3xFlag linker. For 
yeast Nup84-GFP and mammalian RBM7-GFP affinity isolations using LaGs, Coomassie-stained 
bands from elutions separated by SDS-PAGE were quantified, and known specific and nonspecific 
bands were used to calculate signal-to-noise (S:N) ratios. Bead binding assays were used to 
determine affinity for fluorescent proteins, and the table highlights differences in specificity for A. 
macrodactyla CFP among LaGs and for DsRed among LaMs. GFP epitopes for LaGs were 
determined by NMR and classified into three groups according to their location (I–III). Also shown 
are the number of residues identified in the binding site and the site’s calculated accessible surface 
area (ASA). MW, molecular weight; nd, not determined; N/A, not applicable. 
aKd determined by bead binding assay. 
29
  
 
Clone ID MW (Da) Kd (nM) 
Nup84
-GFP 
S:N 
RBM7-
LAP 
S:N 
Binds 
AmCFP 
(LaG) / 
DsRed (LaM) 
GFP 
Epitope 
No. of 
binding site 
residues 
ASA of 
binding site 
residues (A2) 
LaG-2 15,919 19a, 16 1.03 0.42 – III 55 2,204 
LaG-3 15,329 25 0.77 1.13 + nd nd nd 
LaG-6 15,700 310 0.12 nd + nd nd nd 
LaG-9 16,062 3.5 1.02 1.04 + I 62 2,551 
LaG-10 15,748 97 0.17 nd + nd nd nd 
LaG-12 16,090 56 0.20 nd + nd nd nd 
LaG-14 16,002 1.9 0.84 0.58 + I 66 2,519 
LaG-16 16,306 0.7 1.05 0.92 + I 60 2,605 
LaG-17 15,823 50 0.67 nd + I 60 2,543 
LaG-19 15,528 24.6a 0.95 1.06 + II 54 2,404 
LaG-21 15,452 7 1.09 nd + II 56 2,340 
LaG-24 14,763 41 1.05 1.09 – III2 nd nd 
LaG-26 16,221 2.6 1.00 nd + II 53 2,070 
LaG-27 15,565 9.5 1.04 nd + II 57 2,216 
LaG-29 15,449 110 0.31 nd + nd nd nd 
LaG-30 16,159 0.5 1.04 nd + nd nd nd 
LaG-35 16,010 23.5a 0.70 nd + nd nd nd 
LaG-37 16,329 24 0.36 nd + nd nd nd 
LaG-41 15,471 0.9 1.12 0.41 + II 53 2,091 
LaG-42 15,490 600 0.21 nd + nd nd nd 
LaG-43 16,167 11 0.69 nd + I 55 2,381 
LaG-5 15,589 14,200a 0.11 nd nd nd nd nd 
LaG-8 15,953 20,000a 0.10 nd nd nd nd nd 
LaG-11 16,221 22,900a 0.10 nd nd nd nd nd 
LaG-18 16,459 3,800a 0.13 nd nd nd nd nd 
LaG16-
G4S-2 30,791 0.036 nd nd nd nd nd nd 
LaG16-
3xFLAG-2 32,972 0.268 nd nd nd nd nd nd 
LaG41-
G4S-2 29,956 0.150 nd nd nd nd nd nd 
LaM-1 15,380 22 N/A N/A – N/A N/A N/A 
LaM-2 15,151 0.49 N/A N/A – N/A N/A N/A 
LaM-3 15,196 1.9 N/A N/A + N/A N/A N/A 
LaM-4 14,866 0.18 N/A N/A + N/A N/A N/A 
LaM-6 14,428 0.26 N/A N/A – N/A N/A N/A 
LaM-8 14,666 63 N/A N/A – N/A N/A N/A 
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and identified 16 nanobodies with very high affinity binding (≤50 nM). The Kds of the six LaMs 
were consistently strong, ranging from 0.18 nM to 63 nM (Table 1). 
Specificity and efficacy of recombinant nanobodies 
We performed a variety of experiments to assess our nanobodies. Affinity isolations were 
performed on endogenous GFP- and mCherry-tagged proteins in yeast and human cells. All 25 
positive LaGs were used for the isolation of GFP-tagged Nup84, a structural nuclear pore complex 
component, in budding yeast (Figure 2.5a) (Brohawn et al., 2009; Fernandez-Martinez et al., 
2012). We plotted each LaG’s observed Kd against a quantification of either signal to background 
or yield from a Nup84-GFP affinity capture (Figure 2.5c,d and Table 1). Almost all LaGs were 
able to pull down detectable amounts of Nup84-GFP and its associated proteins, and many 
performed as well or better than either our best affinity-purified polyclonal antibodies (Cristea et 
al., 2005), or than the single commercially available GFP-Trap® anti-GFP nanobody (ChromoTek 
GmbH), which has a Kd of 0.6 nM (Figure 2.5a,f) (Kirchhofer et al., 2010). When determining 
depletion of Nup84-GFP by Western blot, LaG-16, for instance, displays slightly higher yields 
than GFP-Trap®. Generally speaking, a strong correlation is seen between low Kd and both high 
signal to background and high yield. This correlation is consistent with the relationship 
theoretically predicted for the percentage of the low abundance yeast target proteins bound in 
solution (Ghaemmaghami et al., 2003) (Figure 2.5c). Our ability to compare structurally similar 
nanobodies raised against a single antigen provides a unique opportunity to demonstrate the 
importance of very low Kd to high quality antibody performance in this type of application. Even 
nanobodies with Kds around 10 nM, typically considered high affinity for an antibody, start 
displaying a precipitous decline in affinity purification performance. These findings highlight the 
 
31
Figure 2.5. Characterization of VHH IgG and recombinant nanobodies. (a,b) Affinity isolations of 
Nup84-GFP from S. cerevisiae (a) or RBM7-GFP from HeLa cells (b) using LaGs, GFP-Trap or 
polyclonal anti-GFP llama antibody (PC). Eluted proteins were analyzed by SDS-PAGE followed 
by MS. Kd values for GFP are listed. MW, molecular weight. ND, not determined. Contaminant 
bands are identified by asterisks. aKd taken from published value (Kirchhofer et al., 2010). (c) 
Relative yields of affinity-isolated Nup84-GFP protein plotted against LaG in vitro affinities for 
GFP (green dots). Theoretical curves of the expected fraction of ligand bound to an immobilized 
binding partner at various Kd values are shown for three hypothetical ligand concentrations (blue 
lines). (d) Signal-to-noise ratio of three Nup84-complex components plotted against each LaG’s 
Kd. (e) Affinity isolation of mCherry-tagged histone H2B (Htb2) from S. cerevisiae by LaMs or 
RFP-Trap. Eluted proteins were analyzed by SDS-PAGE and identified by MS. Breakdown 
products of H2B are labeled ΔH2B-mCherry. Asterisk indicates LaM nanobody that leaked during 
the affinity-purification procedure. LaM lanes are labeled with the Kd for mCherry. (f) Affinity 
isolations of yeast Nup84-GFP using the commercial nanobody GFP-Trap, polyclonal anti-GFP 
or a LaG-16–LaG-2 dimer with a glycine-rich peptide linker. The complex was isolated at various 
time points, and relative yield was determined by quantification of Coomassie-stained bands of 
known Nup84-complex components. Data are representative of two experiments (a–b,e) or are 
means from two experiments ± s.e.m. (c,d,f). 
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importance of ultra-high affinity reagents, such as the nanobodies described here, for proteomic 
and interactomic studies. 
Affinity capture experiments were also performed on GFP-tagged Rbm7, a component of the 
human nuclear exosome, from HeLa cells (Figure 2.5b) (Domanski et al., 2012), yielding 
performances comparable to those seen with Nup84-GFP. However, differences in the amount of 
contaminants were seen for certain LaGs, notably LaG-41, from purifications in yeast versus HeLa 
cells (Figure 2.5a,b). These results underscore how even high affinity reagents can give 
unpredictable background in certain cell types, demonstrating the utility of obtaining and testing 
large repertoires of such affinity reagents to improve the chances that at least one is likely to be 
optimal for any particular application. Similarly, Dynabead-conjugated LaMs were used to isolate 
mCherry-tagged histone H2B from yeast (Figure 2.5e). For all six LaMs tested, the core 
nucleosome complex was efficiently isolated, demonstrating the affinity and specificity of this 
second group of nanobodies. Consistent with the low Kds of all the identified LaMs, the yield and 
specificity of all affinity isolations were similarly high. Commercial RFP-Trap® nanobody 
(ChromoTek GmbH) was tested in parallel, giving consistently lower yields. 
Nanobodies are powerful new tools for fluorescence microscopy, both standard and super-
resolution(Ries et al., 2012). We therefore tested the effectiveness of a selection of the LaG and 
LaM repertoire for immunofluorescence microscopy (Figure 2.6). As target proteins, we first 
made use of emGFP-tagged tubulin and mitochondria-targeted emGFP, transiently transfected 
into HeLa cells (Dolman et al., 2013). Fixed cells were stained with LaG-16 conjugated to Alexa 
Fluor® 568, giving specific and strong staining of GFP-tagged microtubule or mitochondrial 
structures respectively, with negligible non-specific staining of untransfected cells (Figure 2.6a,b). 
To demonstrate the versatility of these reagents, we also used them for immunofluorescence in a  
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Figure 2.6. Efficacy of LaG and LaM nanobodies in immunofluorescence microscopy. (a,b) HeLa 
cells transiently transfected with tubulin-EmGFP or an EmGFP-tagged mitochondrial marker (in 
green) were fixed and immunostained with LaG-16 conjugated to Alexa Fluor 568 (AF568, in 
red). Nuclei were counterstained with DAPI (blue). (c) T. brucei cells expressing EGFP-tagged 
Sec13 were mixed 1:1 with wild-type cells, fixed and stained with LaG-16–AF568, with DAPI 
counterstaining. (d) An S. cerevisiae strain with mCherry-tagged histone H2B was fixed, 
permeabilized and then directly stained with LaM-4 conjugated to Alexa Fluor 488 (AF488). Scale 
bars, 10 μm. Images are representative of at least three experiments. 
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Trypanosoma brucei strain with eGFP-tagged Sec13. This protein localizes to both the nuclear 
pore complex and COPII-coated vesicles, and indeed the AF568-nanobody signal colocalized with 
GFP to give the expected nuclear rim and endoplasmic reticulum staining (DeGrasse et al., 2009) 
(Figure 2.6c). To determine if our anti-mCherry nanobodies were similarly well-suited for 
immunofluorescence microscopy, we conjugated LaM-4 to Alexa Fluor® 488 and stained S. 
cerevisiae expressing mCherry-tagged histone H2B; this also showed specific, colocalized nuclear 
staining (Figure 2.6d).  
We also compared the fluorescence spectra of GFP in the presence or absence of various LaGs to 
look for spectral shifts upon binding, as have previously been reported, and observed moderate 
increases in fluorescence for several LaGs, with a maximum increase in fluorescence intensity of 
approximately 60% (Kirchhofer et al., 2010). 
One additional question of specificity we sought to address was the ability of our nanobodies to 
recognize other fluorescent homologs of Aequorea victoria GFP and Discosoma mCherry. We 
tested the 13 highest affinity LaGs against a variety of fluorescent proteins: eGFP, two YFP 
variants, two CFP variants, BFP, mCherry, and DsRed (Figure 2.7a). None of these nanobodies 
bound DsRed or mCherry, two Discosoma sp.-derived proteins with low sequence identity to 
eGFP (<30%), or TurboYFP, derived from Phialidium sp., which has 53% sequence identity to 
eGFP(Matz et al., 1999; Shagin et al., 2004; Shu et al., 2006). All bound standard Aequorea 
victoria-derived CFP, YFP, and BFP variants (>96% eGFP identity). Two LaGs did not bind a 
moderately divergent (78% eGFP identity) CFP sequence from Aequorea macrodactyla, while all 
others did (Xia et al., 2002). These results indicate that while identified LaGs bind specifically to 
fluorescent proteins with high identity to eGFP, differential binding activities can be obtained 
through selection of variants from other species. Our anti-mCherry LaM nanobodies bound to  
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Figure 2.7. Nanobody fluorescent protein binding. (a,b) SDS-PAGE analysis of high-affinity LaGs (a) 
or LaMs (b) that were conjugated to magnetic beads and incubated with various recombinant 
fluorescent proteins: A. victoria (Av) GFP and its variants CFP, BFP and YFP; a cyan fluorescent 
protein derived from A. macrodactyla (Am CFP); a yellow fluorescent protein from Phialidium (Phi 
YFP); and mCherry and DsRed from Discosoma (Ds). Structural models were obtained from PDB 
1EMA (Av) (Ormo et al., 1996), PDB 4HE4 (Phi) (Pletneva et al., 2013) and PDB 1GGX (Ds) (Wall 
et al., 2000); the Am CFP model is a Phyre server prediction (Xia et al., 2002; Kelley and Sternberg, 
2009). Gels are representative of at least two experiments.
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mCherry, but not to any form of GFP, YFP, or CFP tested (Figure 2.7b). Interestingly, two LaMs 
(LaM-3 and LaM-4) bound to standard DsRed, which has approximately 80% sequence identity 
to mCherry. Given the different fluorescent protein affinities observed with the LaG and LaM 
nanobodies, including specificity for AmCFP and DsRed, these reagents have diverse potential 
uses in differential labeling and affinity capture experiments from cells simultaneously expressing 
different fluorescently-tagged proteins. 
Mapping of the nanobody epitopes on GFP 
We identified the epitopes on GFP recognized by the twelve highest affinity LaGs using chemical 
shift perturbation, a well-established nuclear magnetic resonance (NMR) technique (with Ilona 
Nudelman). This method allows the mapping of binding sites on a protein by following changes 
in its characteristic “fingerprint” spectrum (typically the 15N-1H HSQC) occurring as a result of 
adding an unlabeled ligand into a 15N-labeled protein sample (Goldflam et al., 2012). 
Because previous studies have already made backbone 15N-1H chemical shift assignments of the 
GFPuv variant (Georgescu et al., 2003; Khan et al., 2003) (closely related to standard eGFP with 
97% sequence identity), we prepared 15N-labeled GFPuv, measured its 15N-1H HSQC spectrum 
and obtained chemical shift assignments based on those published (Georgescu et al., 2003; Khan 
et al., 2003). We then tested complexes between 12 high affinity LaGs and 15N-labeled GFPuv and 
measured their 15N-1H HSQC spectra. For 11 out of the 12 cases, we observed clear and specific 
changes in chemical shifts of a large percentage of cross-peaks compared to the 15N-1H HSQC 
spectrum of GFPuv alone. In the 12th case, LaG-24, the nanobody did not bind the GFPuv variant. 
A chemical shift difference was calculated for all spectra, and residues exhibiting a difference 
higher than 0.03 ppm were judged to be in the binding interface (Zuiderweg, 2002; Goldflam et 
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al., 2012). All the identified epitopes corresponded to large interfaces comprising more than 50 
amino acids, consistent with the high affinity binding observed (Figure 2.8 and Table 1). The 
binding epitopes of the nanobodies can be divided into 3 distinct groups. The binding site of group 
I, containing 5 nanobodies (LaG-16, LaG-9, LaG-14, LaG-43 and LaG-17) overlaps with the 
binding site of group II, also containing 5 nanobodies (LaG-19, LaG-21, LaG-26, LaG-27 and 
LaG-41), whereas the two group III nanobodies (LaG-2 and LaG-24) exhibit a binding epitope on 
the opposite side of the GFP molecule compared to groups I and II. As a control, we also used this 
NMR approach to determine the GFPuv binding site of the commercial GFP-Trap® nanobody, the 
structure of whose complex with GFP has been crystallographically determined (PDB ID 
3K1K)(Kirchhofer et al., 2010), and showed that the NMR-mapped epitope matched the published 
results (Battistutta et al., 2000; Kirchhofer et al., 2010). Comparing the binding epitopes of our 
nanobodies with that of GFP-Trap®, groups I and II show little or no overlap with the GFP-Trap® 
binding site, while group III, which binds on the same face of GFP, shows significant overlap 
(Figure 2.8).  
Generalizability of the pipeline 
Our optimized pipeline for the production and generation of nanobodies allows for the rapid 
generation of a large antibody repertoire against multiple epitopes in a chosen antigen. Notably, 
this approach identifies high affinity nanobody sequences directly from animal serum, taking 
advantage of the complex selection and maturation processes occurring in the animal’s immune 
system, avoiding intermediary expression systems. The pipeline allows for the rapid production of 
a comprehensive repertoire of specific high affinity nanobodies for use in the characterization of 
target macromolecules, such as the GFP- and mCherry-tagged proteins shown here. The laboratory 
effort required after the collection of samples from llamas (50-70 days after initial immunization,  
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Figure 2.8. Mapping of nanobody binding epitopes on GFP by NMR. Binding epitopes of the 11 
highest-affinity nanobodies on GFPuv are shown in three groups according to their location. For 
each nanobody, two opposite sides of GFPuv are shown (via a 180° rotation along a vertical 
axis), with the binding site of the respective nanobody colored green. All GFPuv molecules are 
represented in space-filling mode and have the same orientation in all panels. Maps below Group 
III in the right column show the GFP-Trap nanobody’s binding epitope (top) and GFPuv’s 
homodimerization interface (center). For reference, the ribbon diagram at bottom right depicts 
secondary structure elements of GFPuv, in the same orientation as other panels. NMR 
experiments and analysis were performed by Ilona Nudelman.
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once an immune response is generated) is modest. The direct work required, including IgG 
purification (2 days), MS (2 days), cDNA generation and PCR (2 days), and final cloning and 
screening (3-6 days), can be performed over approximately 10 days. High-throughput sequencing 
and gene synthesis can be readily outsourced (as can animal handling and MS), and depending on 
turnaround times, each can typically be carried out in 1-2 weeks.  The entire process can take as 
little as 4-6 weeks after an immune response is generated, with only standard techniques required 
in the primary laboratory.  This is faster and more direct than other approaches available, which 
often require specialized high-throughput capability. Our approach puts the generation of large 
repertoires and quantities of high affinity single chain antibodies into the hands of the average 
researcher. Our LaM and LaG reagents, generated against the widely used GFP and mCherry tags, 
will be of immediate general use for the affinity isolation and enhanced visualization of these tags.  
Applications of anti-GFP nanobodies 
For the purposes of proteomics studies, the most immediate application of our highest performing 
nanobodies is affinity isolations of GFP-tagged proteins.  Our lab has transitioned to anti-GFP 
nanobodies for most GFP-based experiments, with results equivalent to or better than those with 
polyclonal antibodies.  Several collaborations have also led to improved affinity isolations using 
these nanobodies, for instance allowing improved analysis of the interactomes of supervillin and 
anillin, proteins regulating the actin and myosin cytoskeleton during cytokinesis (Smith et al., 
2013). 
We have also worked to develop new techniques using engineered nanobodies, taking advantage 
of the flexibility of these recombinant proteins.  Specifically, we have mutated the high affinity 
LaG16 nanobody to remove both lysines, changing these to arginines instead (Shi et al., 2015).  
These residues are located away from the antigen binding interface, and the mutations did not 
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significantly affect the affinity or solubility of the nanobody (Figure 2.9).  Removing lysines makes 
these nanobodies insensitive to commonly used amine-targeting crosslinkers like 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) or disuccinimidyl suberate (DSS), after chemical 
blocking of the amino terminus.  Among other applications, crosslinking protein complexes with 
these types of reagents has emerged as an increasingly useful tool for obtaining structural 
information.  Crosslinked peptides can be identified by MS, providing information on distances 
between crosslinked residues within a protein complex, revealing connectivity and aiding 
modeling of protein assemblies when integrated with other experimental data (Walzthoeni et al., 
2013).   
By developing nanobodies insensitive to crosslinkers, we were able to isolate complexes of 
structural interest and crosslink them on nanobody-conjugated beads.  As the complex is not 
crosslinked to the immobilized nanobody, it can then be easily eluted for MS analysis identifying 
crosslinks (Shi et al., 2015).  In comparison to alternative approaches, this is a simpler and more 
efficient sample processing approach, allowing effective cross-linking/MS of even small amounts 
of endogenous material.  As a result, in addition to complexes like the yeast exosome or low 
abundance anaphase promoting complex, we were able to dissect the structures of assemblies from 
highly limited material, including tissue specific Beclin 1 from mouse liver. Our approach has thus 
allowed efficient, streamlined cross-linking analysis of endogenous protein complexes through the 
use of an engineered anti-GFP nanobody.  
Dimerized nanobodies as ultra-high affinity reagents 
Because NMR identified multiple epitopes for the 12 LaGs we characterized, we engineered 
heterodimers of LaGs with non-overlapping binding sites on GFP that could potentially bind with 
higher affinity, an approach that has been successfully used in various applications to develop high  
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Figure 2.9. Lysineless mutants of anti-GFP nanobodies. (a) Protein sequence alignments of 3K1K 
and LaG-16. The lysine residues are highlighted in cyan. CDRs: complementarity determining 
regions. CDR1, CDR2 and CDR3 sequences are color coded in blue, pink and orange, 
respectively. (b) Localizations of the three lysine residues on the crystal structure of nanobody 
PDB 3K1K (Kirchhofer et al., 2010), which were mutated to arginine (R) or glutamine (Q) for the 
present work. The lysine residues are presented as red spheres.
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avidity reagents (Neri et al., 1995; Silverman et al., 2005). A LaG16-LaG2 fusion with a flexible 
glycine-rich peptide linker (encoding three repeats of GGGGS) showed the highest affinity by 
SPR, with a Kd of 36 pM. Dimers of other LaGs or with a different linker (a 3xFLAG tag), 
displayed Kds in the range of 100-200 pM. We also sought to determine whether the higher affinity 
of these dimers could yield faster affinity isolations after conjugation to magnetic beads, compared 
to single nanobodies or polyclonal anti-GFP. We therefore performed time courses of yeast 
Nup84-GFP isolations and compared the relative yields of known Nup84 complex components. 
The LaG16-LaG2 dimer showed higher yields at earlier time points, reaching approximately 80% 
of maximum yield after only 5 minutes and 90% after 10 minutes (Figure 2.5f). These picomolar 
affinity reagents open the door for increasingly rapid affinity isolations, potentially allowing the 
capture of weakly or transiently associated complex components for interactome studies. In 
addition, their high avidity would allow for the detection of low abundance antigens, as is required 
for many diagnostic applications.  As the LaG16-LaG2 dimer is the most effective affinity reagent 
we identified, we are now using this construct for the most demanding GFP isolations, such as 
those involved in mRNP purifications. 
Improvements to the nanobody pipeline 
Subsequent to our development of nanobodies against GFP and mCherry, we have made a variety 
of improvements to our general nanobody identification pipeline, and have succeeded in 
generating repertoires against several new antigens of biomedical interest.  A full discussion of 
this additional work is included in the Appendix.  In brief, we found that eliminating papain 
digestion of purified VHH IgG led to significantly less non-specific degradation of many antigens, 
and therefore provided much higher yields of material and more reliable MS results.  As a 
45
substitute, we determined that IdeS, a far more specific protease targeting IgG (von Pawel-
Rammingen et al., 2002), could efficiently remove Fc fragments from isolated IgG.   
A further improvement in the pipeline involved selection of llamas or alpacas more likely to 
produce the strong immune response we have found to be important in generating large nanobody 
repertoires.  By pre-screening sera from candidate animals for activity against standard commercial 
vaccines, we determined that we could improve the chances of selecting immuno-responsive 
animals for antigen injections (Thompson et al., 2016).  As immunization is the most costly step 
in antibody generation, this ability to screen out less productive animals early on can significantly 
improve the efficiency of our method. 
We have also begun to apply these methodological improvements to the identification of new sets 
of nanobodies.  Beginning with two cancer-associated proteins, CTLA4 (Leach et al., 1996) and 
EPHA2 (Oricchio et al., 2011), we have generated nanobodies against multiple novel antigens.  By 
immunizing llamas with 10 or more antigens at once, it has also been possible to rapidly identify 
nanobodies against multiple targets in parallel, with no apparent reduction in efficiency.  We are 
thus continuing to pursue nanobodies against a multitude of new proteins, including a large set of 
nucleoporins implicated in cancer (Simon and Rout, 2014). 
Finally, in the process of our investigations, we identified strong affinity between a subset of our 
nanobodies and staphylococcal Protein A (PrA).  This affinity was independent of CDR sequences, 
and appears to be a result of non-canonical binding of PrA to the backbone of certain Fab-like 
domains (Frenken et al., 2000).  To take advantage of this, we engineered a minimal nanobody 
construct with strong PrA affinity, but with no other antigen-binding activity (Fridy et al., 2015).   
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This protein, along with an even higher affinity homodimer variant, has proven to be a highly 
effective PrA-targeting reagent, able to achieve results as good as the much larger and more 
heterogeneous IgG preparations typically used.  
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Chapter 3: A method to tag and isolate single mRNP species from cells 
Identifying a robust RNA tagging system 
As discussed above, a key element of this thesis is the development of an RNP purification 
technique capable of isolating a specific population of complexes associated with a single RNA.  
Many strategies for genetically tagging and purifying RNAs have been attempted, and we therefore 
first sought to compare a number of these established methods and determine the most promising 
approach.  We began by surveying techniques based on anti-sense oligomers, as well as those 
involving bacteriophage coat protein / hairpin systems.  
Anti-sense nucleic acids as capture reagents 
One of the simplest methods we assessed was the use of immobilized anti-sense oligomers to bind 
an exogenous, complementary RNA sequence.  If this sequence were accessible in the context of 
a native mRNP complex, it should theoretically be able to bind virtually irreversibly to the 
antisense oligo by hybridization, allowing efficient capture on resin (Grunweller et al., 2003; 
Upadhyay et al., 2013).  To assess this method, we designed a unique 18 bp sequence to be added 
to transcripts as either a series of repeats, or as a loop in a stem-loop structure, potentially aiding 
in the accessibility of the sequence.  To maximize the stability of the RNA hybrid, we began with 
2’O-methylated RNA as the immobilized oligomer, as this analogue forms significantly more 
stable hybrids with RNA than DNA (Inoue et al., 1987).  These oligomers were synthesized with 
either a biotin or thiol group at the 5’ end, allowing capture by streptavidin magnetic Dynabeads 
or covalent conjugation to epoxy-activated Dynabeads, respectively.  
To test the binding ability of these immobilized oligomers, we first performed binding tests with 
in vitro-transcribed RNA transcripts and synthetic RNA oligomers.  Using native buffer conditions 
routinely used for our RNP affinity purifications, these early tests showed positive but limited 
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RNA binding (Figure 3.1a).  Notably, binding activity rapidly decreased as the target RNA length 
increased from an 18 bp complementary oligomer.  A 110 bp tagged transcript showed very limited 
binding, while a similar 350 bp transcript had no detectable binding at all.  Presumably, steric 
hindrance or interference from RNA secondary structure prevented efficient binding of longer 
RNAs in these conditions.  Even heating binding reactions to 75°C, which would theoretically 
promote RNA denaturation and allow more efficient annealing for capture, did not allow binding 
of larger transcripts.  Given the difficulties observed in these in vitro binding assays, it was 
assumed that this oligomer-based approach would not be readily useful in ex vivo RNP 
purifications, given the longer lengths of natural transcripts and the further complications likely in 
the presence of cell lysate.  We also performed similar in vitro experiments with other types of 
nucleic acids to identify any oligomer-specific effects, but alternatives including RNA, DNA, or 
PNA all showed comparable results. 
Assessing the λN/BoxB system 
The most common approaches to tagging RNAs in cells make use of naturally occurring 
bacteriophage coat proteins that bind specifically to a cognate RNA hairpin structure.  One 
example of this is the bacteriophage λN protein, which includes a minimally necessary 22 amino 
acid peptide region that binds to the 15 nt BoxB hairpin sequence (Franklin, 1985).  This small 
peptide has high affinity for its target RNA (about 22 nM) and has successfully been used in both 
in vitro and in vivo applications to tag or visualize RNA (Austin et al., 2002; Baron-Benhamou et 
al., 2004; Daigle and Ellenberg, 2007). 
To determine if this system could be used for efficient mRNP affinity isolations, we first 
synthesized the λN peptide and conjugated it to epoxy-activated Dynabeads.  This immobilized 
peptide was capable of binding in vitro-transcribed RNAs with 4-16 copies of the BoxB hairpin  
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Figure 3.1. In vitro RNA binding to anti-sense oligos or BoxB peptide. (a) An 18 bp RNA 
oligomer (left), or 110 bp (middle) or 350 bp (right) in vitro-transcribed transcripts were incubated 
in excess with Dynabead-immobilized 2’O-methylated RNA oligomers with 18 bp of sequence 
complementarity.  (b) In vitro-transcribed RNA transcripts with 4, 8, or 16 repeats of a BoxB 
hairpin were incubated in excess with Dynabeads coated with λN peptide.  In all experiments, 
bound RNA was eluted by heating in loading buffer, and run alongside load and flow-through 
(FT) samples on TBE-urea gels.  RNA was visualized by SYBR gold staining.
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sequence, even at transcript lengths up to 750 bp (Figure 3.1b).  While the yield was not 
exceptional (<25%), these experiments did show substantially more promise for use in endogenous 
RNA isolations than immobilized oligomers, as transcripts of a typical mRNA’s length could be 
recovered.  
We next attempted to isolate RNA ex vivo, starting by tagging a model Protein A gene with BoxB 
hairpins (0, 4, 8, or 16 repeats) on a high copy plasmid, under a strong, constitutive TDH3 
promoter, and transforming this into wild-type budding yeast.  We then grew and prepared these 
cells for affinity isolations according to our lab’s routine cryomilling strategy, and reconstituted 
frozen, milled cell material in a mild buffer known to stabilize mRNP complexes and that is 
compatible with their affinity capture (Oeffinger et al., 2007).  After centrifuging to remove cell 
debris, soluble lysate was incubated with Dynabead-conjugated λN peptide.  These beads were 
then washed, and bound protein and RNA was eluted with hot LDS or phenol extraction, 
respectively.  While some nonspecific protein binding was observed in the untagged negative 
control, enrichment of specific bands was in fact observed with 8xBoxB- or 16xBoxB-tagged 
transcripts (Figure 3.2a).  Furthermore, qRT-PCR on input and elution samples revealed specific 
recovery of the PrA transcript when a BoxB tag was present.  However, the yield of transcript was 
found to be at most 0.5%, even in the case of the 16xBoxB tag (Figure 3.2b).  Thus, while the 
λN/BoxB system did seem capable of specific mRNP purification, the very low efficiency seen in 
these pilot experiments suggested that this would not be an immediately practical approach. 
Optimizing direct MS2 and PP7-based RNA isolations from yeast 
The most common approach to in vivo RNA visualization and targeting has been the MS2 
bacteriophage coat protein system, or its close relative PP7 (Querido and Chartrand, 2008).  This 
was therefore the most promising methodology for an RNA isolation technique, which we  
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Figure 3.2. Affinity capture of BoxB-tagged mRNA from yeast. A Protein A transcript tagged with 
0, 4, 8, or 16 repeats of the BoxB hairpin was expressed in yeast.  Cells were cryomilled, and 
soluble lysate was incubated with Dynabeads conjugated to λN peptide.  Dynabeads were washed 
and split; protein was eluted with hot SDS and RNA was eluted with hot phenol. (a) Protein 
elutions were separated by SDS-PAGE and silver-stained. (b) Levels of Protein A transcript in the 
RNA elutions were quantified by qRT-PCR, relative to the total amount in the input lysate.
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investigated extensively.  The MS2 and PP7 coat proteins (MS2CP or PP7CP) are both known to 
bind their corresponding ~20bp MS2/PP7 stem-loop RNA structures with high affinity (~0.5-1nM) 
and specificity (106-fold over other RNA sequences) (Carey et al., 1983; Lim et al., 2001).  In vivo, 
this has allowed visualization of single RNAs through specific binding of hairpin tags by GFP-
tagged MS2CP or PP7CP, as well as protein tethering to RNA via these same interactions 
(SenGupta et al., 1996; Bertrand et al., 1998; Hocine et al., 2013). To a limited extent, this has also 
been used to isolate abundant RNAs and their protein binding partners from cells (Hogg and 
Collins, 2007; Tsai et al., 2011).  Given a high enough relative concentration of a hairpin-tagged 
RNA in cells, MS2CP or PP7CP should theoretically be able to provide a significant enrichment 
in a purification. 
To assess this approach, we began by co-expressing MS2CP-PrA in yeast with a model transcript 
encoding GFP, with or without a tag of 6 MS2 hairpin repeats (6xMS2).  We started with a GFP 
transcript as a simple, exogenous gene, one encoding an essentially inert protein to allow for 
nontoxic overexpression (Heim et al., 1994; Okabe et al., 1997).  This is an important concern, as 
one of the main barriers to the isolation of single mRNAs is the low abundance of any one 
transcript.  A number of microarray studies have suggested that transcript copy numbers are 
typically 1-2 per cell, going up to a maximum of a few hundred copies for the most highly 
expressed genes (Velculescu et al., 1997; Wodicka et al., 1997; Holstege et al., 1998; Arava et al., 
2003).  More recent single-cell studies, however, have suggested that true copy numbers may be 
as much as an order of magnitude higher, at least for weakly-expressed transcripts (Zenklusen et 
al., 2008; Larson et al., 2009).  In either case, it can be conservatively estimated that 100 transcripts 
per cell may be observed for a strongly expressed gene.  Identification of proteins by mass 
spectrometry requires a minimum protein concentration of 10-20 fmol present in the complex, 
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though in practice amounts in the hundreds of fmol or more are preferred (Geiger et al., 2010).  
Our cryolysis technique typically handles ~1.2x1010 yeast cells/g powder, so if a model mRNA 
with ~100 copies per cell is selected, an associated protein would be present in a concentration of 
~2 pmol/g.  Thus, even with losses taken into account, a few grams of grindate should theoretically 
be sufficient to reliably detect most complex components. 
In studies using similar approaches to directly isolate PrA-tagged RNPs, our lab has demonstrated 
the feasibility of isolating very low abundance proteins such as Sac3p, reported to have only a few 
hundred copies per cell (Ghaemmaghami et al., 2003; Oeffinger et al., 2007).  Furthermore, 
expression levels of tagged RNAs can be significantly increased by using strong promoters like 
TDH3 (~400 transcripts/cell),  and expressing off of high copy 2µ plasmids, which can themselves 
have 20-40 of copies per cell, or even 100-200 in some cases (Futcher and Cox, 1984; Lopes et 
al., 1989; Velculescu et al., 1997).  As the total number of mRNA transcripts per cell is estimated 
to be between 15,000 and 60,000, and only makes up about 5% of all RNA transcripts, even this 
high level of overexpression should not significantly affect, much less overwhelm, the processing 
machinery (Hereford and Rosbash, 1977; Warner, 1999; Zenklusen et al., 2008). 
Thus, our initial model transcript target was GFP on a 2µ plasmid (pRS426) under a TDH3 
promoter, with or without a 6xMS2 tag (Figure 3.3a).  MS2CP-PrA was co-expressed on a 
centromeric plasmid (pRS414) under a moderately strong inducible MET3 promoter, and with an 
SV40 nuclear localization signal (NLS).  This NLS localizes MS2 to the nucleus to allow more 
efficient association with nascent transcripts, and has been shown to have no significant effect on 
subsequent nucleocytoplasmic transport of bound RNAs (Grunwald and Singer, 2010).  Cells co-
expressing these MS2CP-PrA and GFP constructs were grown and cryomilled, and we performed 
single step affinity purifications of MS2CP-PrA using IgG Dynabeads.  With low level MS2CP  
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Figure 3.3. Affinity isolation of MS2-tagged RNA using MS2CP-PrA. (a) GFP transcripts with or 
without a six MS2 hairpin tag were co-expressed in yeast with an MS2CP-Protein A fusion 
protein.  MS2CP-PrA was expressed under a MET3 promoter, either repressed (+MET) or 
induced (–MET).  MS2CP-PrA was purified from cell lysate using Dynabeads coated with rabbit 
IgG. (b) Co-isolating mRNP proteins were eluted using ammonium hydroxide, separated by 
SDS-PAGE, and stained with Coomassie Blue.  IgG heavy chain (HC) and light chain (LC) 
leakage is labeled. (c) Indicated bands from a MS2CP-GFP (+MET) purification were excised 
and analyzed by MALDI MS.  Bands are labeled with the corresponding protein ID.  
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expression (MET3 repressed by growth in methionine), a number of protein bands copurified only 
in the presence of the tagged transcript, with little background observed in the untagged negative 
control (Figure 3.3b,c).  By qRT-PCR analysis, 14% of the tagged GFP transcript was found in the 
final elution (Figure 3.4a).  By contrast, under high level MS2CP expression (no methionine), this 
yield went up to 22%, but was also accompanied by a significant increase in protein contaminants 
in the untagged control sample (Figures 3.3b and 3.4a).  Given potential inefficiencies in the 
recovery and quantification of the small amounts of RNA in these elution samples, assessing 
depletion of the GFP transcript from input to IgG bead flow-through may be a more accurate 
measure of yield; in this case yields could be as high as 30% or 65% with high or low MS2CP 
expression, respectively. 
To identify the major proteins copurified with the 6xMS2-tagged GFP transcript, we performed 
MALDI-MS on the prominent bands specific to that affinity purification (Figure 3.3c).  This 
identified proteins consistent with expected compositions of a typical RNP population.  In addition 
to multiple ribosomal proteins, most likely associated with RNAs undergoing translation, Pab1p 
was identified, a general polyA RNA binding protein, as well as Nam7p, characteristic of mRNA 
surveillance for cytoplasmic nonsense mediated decay (Sheth and Parker, 2006).  Thus, the major 
proteins identified in these mRNP isolations reflect the most highly abundant factors known to 
associate with cytoplasmic mRNAs undergoing translation.  This is consistent with reports that up 
to 70% of the total mRNA population is cytoplasmic and associated with ribosomes, indicative of 
rapid mRNA export and a relatively small pool of nuclear mRNA (Arava et al., 2003).   
To determine if the yield and purity of this single-step MS2 purification could be improved, we 
also tested a variety of modifications to the above approach.  First, we attempted to avoid co-
expression of MS2CP-GFP in cells by using recombinant MS2CP immobilized to beads as a bait  
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Figure 3.4. qRT-PCR quantification of MS2-tagged transcript recovery. (a) RNA samples from 
load, flow-through (FT), and elutions of MS2CP-PrA-purified material (Figure 4.3) were used to 
quantify relative levels of the target GFP transcript using qRT-PCR.  Levels of untagged GFP or 
tagged GFP-6xMS2 transcript relative to the lysate load sample are shown.  Experiments were 
performed with either low level (repressed) or high level (induced) expression of MS2CP-PrA. 
(b) Relative yields of GFP transcripts tagged with 0-24 repeats of MS2 were determined as in (a), 
with low level MS2CP-PrA expression. 
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for MS2-tagged transcripts.  Alternatively, soluble MS2CP tagged with PrA was mixed with cell 
lysate, then purified on IgG Dynabeads.  In both cases however, significant nonspecific binding 
was observed in negative control samples lacking an MS2-tagged transcript.  It is likely that the 
relative concentration of M2SCP protein in these conditions was so high that extensive off-target 
RNA binding was occurring, expected in extreme cases given MS2CP propensity to bind very 
weakly to any RNA (Carey et al., 1983).  Furthermore, there did not appear to be a point to which 
recombinant MS2CP could be titrated to allow sufficient recovery of specific MS2-associated 
material while avoiding excessive background binding of contaminants.  Presumably, co-
expressing MS2CP in cells allows more time for it to associate with tagged mRNAs as they are 
transcribed and processed in the nucleus, which makes it possible to use the relatively low levels 
of the protein necessary to avoid non-specific binding. 
In theory, the MS2 tag’s hairpins are saturated in the higher expression conditions used. Under a 
MET3 promoter on a centromeric plasmid (~8 copies per cell), MS2CP could be expected to be 
present at approximately 3,200 copies per cell (Newman et al., 2006).  Given an abundant 
transcript with four MS2 hairpins, at approximately 400 copies in a typical yeast cell of 41 µm3 
volume, MS2CP and mRNA concentrations would be 128 nM and 64 nM respectively.  Assuming 
30% of mRNA and all NLS-containing MS2CP is in the nucleus (~2.5 µm3), nuclear 
concentrations could be estimated at 2,100 nM MS2CP and 315 nM RNA (Jorgensen et al., 2007).  
With MS2CP binding as a dimer, >99% of MS2 hairpins would be bound, and ~85% of MS2CP-
GFP would be free.  In practice, this led to efficient isolation of tagged RNA, but significant 
background binding.  Under low MS2CP expression, MET3 repression is predicted to be ~16-fold 
lower (Jorgensen et al., 2007), giving a theoretical MS2 hairpin saturation of ~20%, and no 
58
unbound MS2CP.    This is also consistent with our results, with low background but low yield of 
tagged mRNA. 
As a final comparison, we also attempted equivalent affinity isolations using PP7 coat protein 
(PP7CP) and its corresponding PP7 hairpin tag in place of MS2.  When either coexpressing 
PP7CP-GFP or using recombinant protein as bait, the results with this alternative bacteriophage 
system were essentially equivalent to MS2.  After assessing the different hairpin types, using 
different numbers of hairpins in the RNA tag, we ultimately found that MS2 allowed slightly more 
efficient isolations, with an optimal tag length of four hairpin repeats (Figure 3.4b).     
Sequential protein-RNA affinity purifications  
While the direct purification of 6xMS2-tagged RNA by MS2CP-PrA was successful in the specific 
isolation of mRNAs at a yield consistent with past studies (Hogg and Goff, 2010), these 
experiments revealed certain inherent difficulties with this one-step approach.  Given the much 
larger pool of mRNA in the cytoplasm compared to the nucleus, no matter how effective the 
isolation of total mRNA, it is likely that analysis of lower abundance nuclear proteins would be 
hampered by the far more abundant cytoplasmic mRNP factors.  While more sensitive mass 
spectrometry is capable of detecting far lower abundance proteins than our initial analysis, the high 
complexity of these samples and the far higher abundance of cytoplasmic factors would 
nonetheless make robust analysis and quantitative comparison of different samples extremely 
difficult.  
Additionally, it proved difficult to achieve mRNP purifications at both high yield and high 
specificity.  While MS2CP expression levels could be titered to achieve specific isolations, RNA 
yield in these conditions remained in the 14-30% range.  For robust analysis of different mRNPs, 
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particularly when the associated protein factors of interest are at relatively low abundance, this 
compromise in yield would be a significant hindrance.  We believe this is an inherent limitation of 
the MS2 system, as MS2CP’s nonspecific affinity for RNA, while very weak, will lead to excessive 
off-target binding if MS2CP’s expression level is brought high enough to capture MS2-tagged 
RNA at an acceptable yield.   
To address the dual concerns of non-specific MS2CP binding and unwanted purification of high 
abundance cytoplasmic mRNPs, we incorporated a second purification step into our protocol.  
While various orthogonal purifications approaches could potentially help address these issues, we 
found the most promising option to be isolating a known PrA-tagged mRNP protein in an initial 
purification step, before using GFP-tagged MS2 to isolate the specific mRNA subpopulation of 
interest (Figure 3.5).  First, this additional purification step provides a significant enrichment in 
purity simply by providing an independent, highly efficient enrichment of an mRNP population.  
Our lab has successfully used this approach to routinely isolate dozens of tagged mRNPs at high 
purity and >90% yield (Oeffinger et al., 2007).  Beyond this enhancement of purity, the use of an 
mRNP protein as a second tagged target has the additional advantage of allowing the isolation of 
mRNP complexes at defined processing stages; as a great deal is known of the basic functions and 
associated factors of many nuclear mRNP proteins, it is possible to select a number of such proteins 
with distinct, well-established roles in mRNP processing as targets.  This allows us to isolate a 
chosen subset of the mRNP processing machinery, before using the MS2 tag to purify the specific 
mRNA of interest, providing high enrichment at a particular maturation step defined by the tagged 
mRNA’s association with a given mRNA processing factor.  
As a starting point, for instance, tagged Nab2p can be used to isolate a large pool of transcripts at 
steps ranging from transcription to export, but largely excluding the cytoplasmic population  
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Figure 3.5. Outline of sequential RNP and MS2 RNA isolation method.   
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(Batisse et al., 2009; Schmid et al., 2015). Similarly, Cbp80p would be expected to associate with 
virtually all nascent mRNAs, remaining bound up until the first round of translation (Lewis and 
Izaurralde, 1997). Conversely, Cdc33/eIF4E, part of the cytoplasmic cap-binding complex, would 
pre-enrich for cytoplasmic mRNPs (Gingras et al., 1999; Fortes et al., 2000).  
Starting with these general mRNA-binding factors, we performed preliminary sequential 
purifications using MS2-tagged mCherry transcript.  Like GFP, this fluorescent protein was chosen 
for its ease of overexpression and detection.  In theory, either the PrA-tagged RNP or MS2CP-
GFP could be purified first in our method; for practicality, we chose to purify the RNP first, as 
IgG is more readily available in large quantities, and the first step must necessarily be done at a 
larger scale.  Additionally, PrA would be likely to bind anti-GFP antibodies given its general IgG 
affinity, making it better to remove this tag first.  To allow a second, independent purification, we 
also needed a means of releasing bound protein from the first affinity isolation.  We chose to do 
this by inserting a PreScission protease cleavage site upstream of the C-terminal PrA tag.  This 
protease (a derivative of the rhinovirus 3C protease) is highly active even at low temperatures, 
allowing the RNP protein to be cleaved from the tag and bound IgG resin in under an hour at 4°C 
(Cordingley et al., 1989).  The released material can then be directly incubated with anti-GFP 
Dynabeads, with PrA no longer present.  To start with, we coexpressed MS2CP-GFP under an 
unrepressed MET3 promoter on a centromeric plasmid, conditions which led to high yield but non-
specific single-step isolation of tagged RNA. 
In preliminary pullouts using this sequential method, purifications of transcripts tagged with MS2 
isolated significant amounts of protein, with a banding pattern similar to an equivalent single-step 
isolation of the corresponding tagged RNP (Figure 3.6).  In contrast, negative controls with 
untagged transcripts had essentially no associated protein, indicating very little non-specific  
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Figure 3.6. Sequential Nab2 RNP and RNA purification of mCherry-4xMS2.  mCherry transcripts 
with or without a 4xMS2 hairpin tag were co-expressed with MS2CP-GFP in yeast and purified in 
two steps with Nab2-PrA and MS2CP-GFP.  Samples of PPX protease elutions from IgG beads 
(step 1), and flow-throughs (FT) and elutions from anti-GFP beads (step 2) were separated by 
SDS-PAGE and stained with Coomassie Blue. RNPs are only co-purified in the presence of the 
4xMS2 tag. In parallel, equivalent samples were directly eluted from anti-GFP beads with 
ammonium hydroxide and analyzed by MS.  RNP protein IDs from that analysis are listed, 
categorized according to function.
Cdc33
64
binding due to MS2CP.  This indicates that even in conditions with saturating levels of MS2CP, 
the addition of the PrA purification step essentially eliminates the non-specific binding previously 
observed.  As we expect the tagged model mCherry transcript to behave as a typical mRNA, it was 
not surprising that the final protein isolated appeared generally similar to the mixed RNP 
population observed in a single step RNP purification.  However, the relative intensities of a 
number of bands do in fact appear to differ in the mRNA-specific isolation, and fewer super-
stoichiometric bands are present, indicating differences in the purified RNP pools, and in particular 
less free protein. 
Assessing efficiency of sequential isolations 
To determine the efficiency of each purification step at the protein level, we did Western blotting 
of each tag (PrA and GFP) across the procedure (Figure 3.7).  Depending on the cellular abundance 
of the PrA-tagged RNP and amount of IgG Dynabeads used, the yield of the PrA isolation was as 
high as 90%.  Judging from the amount of uncleaved PrA-RNP protein remaining on the IgG 
beads, the efficiency of the cleavage step was highly variable from protein to protein, but generally 
above 50%.  We have observed this type of variability in many protein complexes studied in the 
lab, and suspect it to be due to protein-specific differences in the accessibility of the cleavage site, 
or other structural influences.  Similar variability is found in the propensity of complexes to stick 
to the Dynabeads even after tag cleavage, and these issues have shown little dependence on the 
isolation conditions used.  When following GFP signal, MS2CP-GFP was detected in the IgG bead 
elution only when a tagged transcript was used. This protein was then depleted at high efficiency 
by anti-GFP Dynabeads.  As expected, less than 5% of the total MS2CP-GFP in the lysate was 
depleted in the initial PrA purification; this is consistent with the small fraction of total mRNA 
predicted to be associated with any one RNP factor, as well as the excess of MS2CP-GFP present  
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Figure 3.7.  PrA and GFP yield of sequential Nab2-PrA and MS2CP-GFP purification of mCherry-
4xMS2.  Samples from a sequential purification of untagged or 4xMS2-tagged mCherry were 
analyzed by Western blot, probing either PrA or GFP.  15 times less material was loaded for PrA 
Load and flow-through (FT) samples.  More than 80% of Nab2-PrA was recovered in the PrA 
purification step, and more than 90% of this was cleaved by PPX, as judged by cleaved vs 
uncleaved PrA remaining on beads after protease elution.  MS2CP-GFP is recovered after both 
purification steps only when the mCherry transcript contains a 4xMS2 tag.  Due to both free 
MS2CP-GFP and the mCherry-4xMS2 population not associated with Nab2, only a small fraction 
of MSCP-GFP is co-purified with Nab2-PrA. 
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in these expression conditions.  The relative amounts of GFP and total protein obtained in these 
purifications were also dependent on the tagged RNP protein used.  Consistent with the higher 
abundance of cytoplasmic versus nuclear mRNA, Cdc33 isolations had significantly more material 
than those of Cbp80 or Nab2. 
We also performed MS analysis on the material purified from these initial Nab2, Cbp80, and 
Cdc33-based RNA purifications (Figures 3.6 and 3.8).  As expected, the proteins identified were 
essentially the same as those previously identified from purifications of these RNP factors 
themselves (Oeffinger et al., 2007).  For Cbp80-based isolations, this includes major RNA binding 
proteins like Pab1p and Yra1p, cap complex components Cbp80p and Cbp20p, members of the 
THO/TREX complex, and spliceosomal factors. For Cdc33, we identified expected cytoplasmic 
factors like members of the cytoplasmic cap (eIF4E and eIF4GA), Pab1p, and translation initiation 
factors. For Nab2, we identified Pab1p, a variety of export factors like Yra1p and members of the 
TREX-2 complex, as well as a number of nuclear pore complex (NPC) components, consistent 
with transcripts actively undergoing export. Additional quantitative analysis would be necessary 
to identify transcript-specific RNP factors from these purifications (Chapter 5). 
The purity and yield of MS2-tagged transcript was also assessed from these pilot affinity 
purifications.  Quantitative real-time RT-PCR (qRT-PCR) was also performed on various samples 
from these isolations (Figure 3.9a).  In the case of Cbp80-PrA purifications, this analysis showed 
a recovery of approximately 20% of mCherry transcript in the first purification step, with or 
without a tag present.  This is broadly consistent with the amount of bulk mRNA expected to be 
capped and not undergoing translation.  In the second MS2CP-GFP purification step, ~75% of this 
material is recovered, only in the presence of the 4xMS2 hairpin tag.  Thus, MS2-tagged transcripts 
do appear to be efficiently and specifically recovered by this technique.   As a control, 18S rRNA  
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Figure 3.8. Sequential purifications of mCherry-4xMS2 using Cbp80-PrA or Cdc33-PrA.  mCherry 
transcripts with or without a 4xMS2 hairpin tag were co-expressed with MS2CP-GFP in yeast and 
purified in two steps with Nab2-PrA or Cdc33-PrA and MS2CP-GFP.  Final elutions from anti-GFP 
beads were separated by SDS-PAGE and stained with Coomassie Blue.  In parallel, equivalent 
samples were directly eluted from anti-GFP beads with ammonium hydroxide and analyzed by MS. 
RNP protein IDs from that analysis are listed, categorized according to function.
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Figure 3.9.  RNA yield in sequential Cbp80 and MS2CP-GFP purification of mCherry-4xMS2. (a) 
qRT-PCR was performed on RNA samples taken at each purification step in isolations of untagged 
or 4xMS2-tagged mCherry transcripts.  Primers were used against the mCherry targer sequence, 
or 18S rRNA to assess non-specific binding of an abundant RNA contaminant.  Transcript levels 
were normalized to total input level (1 and 6).   
2) and 7) 0-20% depletion of mCherry is observed in the first step purification of Cbp80-PrA
3) and 8) ~20% of mCherry transcript was recovered in native elutions after the first purification
step.  This is consistent with the small proportion of mRNA expected to associate with Cbp80, 
independent of the MS2 tag.  No 18S rRNA is detected in this purification step, consistent with 
Cbp80’s specificity for mRNA over rRNA. 
4) and 9) After anti-GFP isolation of MS2CP-GFP, the mCherry transcript is strongly depleted
only when 4xMS2-tagged.  This reflects MS2CP-GFP’s presence only when bound to the tagged 
transcript. 
5) and 10) In elutions from anti-GFP beads, no untagged transcript is detected.  Tagged mCherry-
4xMS2 is efficiently recovered from the Cbp80-PrA-associated pool (8). 
(b) Northern blots were performed against RNA samples equivalent to (a).  Radiolabeled probes 
were complementary to either mCherry or 18S rRNA transcripts.  Signals are consistent with the 
qRT-PCR results. 
70
Ig
G
 F
T
Ig
G
 E
lu
t.
G
FP
 F
T
G
FP
 E
lu
t.
mCherry mC-4xMS2
In
pu
t
mCherry Northern:
18S rRNA Northern:
0%
20%
40%
60%
80%
100%
120%
140%
Input IgG
FT
IgG
Elut.
GFP
FT
GFP
Elut.
Input IgG
FT
IgG
Elut.
GFP
FT
GFP
Elut.
0%
20%
40%
60%
80%
100%
120%
140%
Input IgG
FT
IgG
Elut.
GFP
FT
GFP
Elut.
Input IgG
FT
IgG
Elut.
GFP
FT
GFP
Elut.
mCherry mC-4xMS2
mCherry mC-4xMS2
Ig
G
 F
T
Ig
G
 E
lu
t.
G
FP
 F
T
G
FP
 E
lu
t.
In
pu
t
R
N
A 
yi
el
d
R
N
A 
yi
el
d
ba
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
qPCR quantification of mCherry±4xMS2 
transcripts throughout MS2 isolation
qPCR quantification of control RNA 
(18S rRNA) throughout MS2 isolation
1 2 3 4 5 6 7 8 9 10
71
Figure 3.10. RNA-seq analysis of total RNA isolated by sequential purification of 
mCherry-4xMS2.  After sequential purification using the indicated PrA-tagged RNP factor and 
MS2CP-GFP, RNA was eluted and directly prepared for RNA-seq on an Illumina HiSeq 2000 
system.  Reads were categorized as either mCherry-4xMS2, rRNA, or other snRNA or mRNA.  
Depending on the tagged RNP used, 50-70% of all RNA recovered was specific to the tagged 
mCherry transcript. 
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Figure 3.11. Comparing anti-GFP beads in sequential Cdc33-PrA and MS2CP-GFP purifications 
of mCherry-4xMS2.  Tagged or untagged mCherry transcripts were purified first over IgG 
dynabeads (GFP Input), and then over Dynabeads conjugated to either polyclonal anti-GFP 
antibodies (Polyclonal), LaG16 nanobody, or the LaG16-LaG2 dimeric nanobody.  Protein was 
eluted with LDS and visualized by Coomassie Blue staining after SDS-PAGE.
73
was also quantified by qRT-PCR, and ~0.02% was ultimately recovered, with only ~0.2% detected 
after the first purification step (Figure 3.9a).  This is consistent with the divergent pre-rRNA 
processing pathway expected for this rRNA, and shows that even highly abundant non-specific 
RNAs are not significantly co-isolated in this method.  As a further assessment of RNA recovery, 
Northern blots were performed probing mCherry and 18S RNA (Figure 3.9b).  This recapitulated 
the qRT-PCR results, and while some degradation is observed, the majority of the RNA purified 
appears intact.   
We also assessed the purity of the final RNA pool recovered in these mRNP isolations by RNA-
Seq.  This technique allows unbiased quantification of the relative amounts of all transcripts in our 
samples by sequencing all RNA present (Wang et al., 2009).  By this analysis, we determined that 
the mCherry-4xMS2 transcript comprised approximately 60-70% of purified RNA, depending on 
the tagged RNP used (Figure 3.10).  An additional 5-10% was rRNA, and the remainder was from 
low levels of other non-specific RNAs.  Given the heterogeneity of the non-specific RNA 
contaminants in these pullouts, it is likely that the final RNP content is largely representative of 
the highly enriched tagged transcript. 
To further optimize the efficiency of the MS2CP-GFP purification step, we transitioned from using 
polyclonal anti-GFP antibodies from llama serum for the final GFP-MS2 isolations to our own 
anti-GFP nanobodies (Chapter 2).  Both LaG-16 nanobody and the LaG16-G4S-LaG2 dimeric 
nanobody gave higher yield and lower background in these pullouts, with the dimer performing 
best in both regards (Figure 3.11).  We are thus using this reagent for all subsequent purifications. 
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Chapter 4: Pilot survey of RNPs associated with single mRNAs 
A survey of RNA sequence elements associated with unique processing factors 
As a pilot study to demonstrate the efficacy of the sequential protein-RNA isolation technique, we 
conducted a survey of several transcripts of interest.  As a first step, transcripts were based on a 
model mCherry sequence, modified in various ways by the introduction of different sequence 
elements.  This allowed us to use the exogenous mCherry sequence as a control, with no expected 
atypical processing in yeast, and easily expressible at high levels with no biological effects (Shu 
et al., 2006; Fink et al., 2010; Kafri et al., 2016).  This base sequence was then modified with the 
addition of other promoters, introns, and 3’ UTR elements (Figure 4.1).  Specifically, we studied 
introns of different classes, for example comparing those found in highly expressed housekeeping 
genes like ACT1 to those of ribosomal proteins like RPS30b, whose transcripts are reported to 
have atypical mRNP compositions (Schmid et al., 2012; Tuck and Tollervey, 2013).  An additional 
interest is comparison of transcripts expressed from promoters with different regulatory 
mechanisms, such as those from housekeeping or stress-inducible genes.  Multiple promoters have 
also been implicated in post-transcriptional regulation of mRNA stability, and the mRNP complex 
dynamics involved in these processes are still poorly understood (Bregman et al., 2011; Trcek et 
al., 2011; Zid and O'Shea, 2014).  We began to assess these questions by adding promoters 
implicated in this downstream transcript regulation to our model mCherry transcript.  For these 
various transcripts of interest, we performed a survey using sequential affinity isolations, 
beginning with general RNP factors for initial purification. 
Confirming recovery of Ash1 transcript-specific mRNP factors 
As a first step in determining whether changes in a model transcript affect the co-isolating mRNP 
composition, we tested transcripts with sequence elements understood to be differentially targeted  
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TDH3 prom. mCherry
TDH3 prom. GFP 4xMS2mCherry
TDH3 prom. GFP 4xMS2mCherry Ash1 3’UTR
TDH3 prom. GFP 4xMS2mC mCACT1 intron
HSP26 prom. GFP 4xMS2mCherry
GLC3 prom. GFP 4xMS2mCherry
GFP 4xMS2mC mCRPS30b intronTDH3 prom.
Figure 4.1.  MS2-tagged constructs used in survey of mRNPs.  An mCherry coding sequence was 
expressed on a high copy yeast 2µ plasmid under a strong constitutive TDH3 promoter (Mumberg 
et al., 1995), or promoters from HSP26 or GLC3 genes (Zid and O'Shea, 2014).  A 4xMS2 tag was 
inserted immediately following the mCherry stop codon.  As modifications, either the 3’UTR 
from the ASH1 gene was inserted after the 4xMS2 tag (Bertrand et al., 1998), or intron sequences 
from ACT1 or RPS30b were inserted 31 bp into the mCherry sequence.
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by RNP processing machinery.  A particularly well-studied example is 3’ UTR region of the Ash1 
transcript.  Sequence motifs in this UTR recruit She2p and She3p, which target the transcript to 
the bud tip after export (Long et al., 2000; Olivier et al., 2005). We therefore added the ASH1 3’ 
UTR to our model TDH3-driven mCherry gene, with a 4xMS2 tag between the coding sequence 
and UTR.  The general cap binding protein for nuclear mRNA, Cbp80p, was then used as a PrA-
tagged first target for sequential affinity isolation (Chapter 3).   
As expected, MS analysis of protein purified from these pullouts identified significant amounts of 
She2p and She3p, as well as Myo4p, known to be involved in cytoplasmic localization of Ash1 
mRNA on actin filaments (Figure 4.2) (Bertrand et al., 1998).  Interestingly, we found significant 
amounts of two other proteins, Htb2p (histone H2B) and Hir3p, part of a nucleosome assembly 
complex that regulates histone gene expression (Prochasson et al., 2005).  Hir3p in particular is a 
low abundance protein not typically found as a contaminant, but it is unclear what connection 
might exist between its chromatin remodeling activity and ASH1 transcription.  If Hir3p 
association is confirmed, this connection could be investigated by genetic experiments to assess 
changes to ASH1 transcription in HIR3 mutants, as well as more targeted proteomics of the HIR 
complex. 
Beyond She2p and She3p, there are other factors reported to be involved in Ash1 localization that 
were not identified in our purification, notably Loc1p, which stabilizes She2p association, and 
Puf6p.  This may be due to the different dynamics of these proteins’ interactions with Ash1 RNA; 
Loc1p for instance is only bound in the nucleus, and is released upon export through displacement 
by She3p (Niedner et al., 2013).  As we detect She3p but not Loc1p, it may be that Cbp80p-
associated Ash1 RNA is highly enriched for the She3p-bound state, presumably due to the rapid 
kinetics of Loc1p association and dissociation.  Puf6p binds Ash1 RNA independently of She2  
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Figure 4.2. Sequential Cbp80-PrA and MS2CP-GFP isolation of mCherry-4xMS2-Ash1 3’UTR 
mRNPs.  A Coomassie-stained gel of the purification was imaged, and protein identifications 
were made by MS on a whole sample purified in parallel as a gel plug.  IDs are shown at predicted 
molecular weights, and proteins uniquely identifed with the Ash1 3’UTR are shown in bold.
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and is thought to remain bound through export.  However, it is also highly enriched in the nucleus, 
and may be less abundant in the purified RNP population due to similar kinetic differences as 
Loc1p.   
Alternatively, it is possible that these proteins are simply less stably associated with the RNA, and 
are thus not retained throughout the purification process, or else rely on other ASH1 sequence 
elements not present in the UTR used.  In this and other cases though, there is evidence that we 
are not seeing substantial loss of RNP factors in our isolations.  First, previous studies have shown 
that certain dynamic mRNP proteins, such as Yra1p, do not exchange between mRNAs under our 
typical purification conditions (Oeffinger et al., 2007).  Furthermore, our preliminary mRNP 
isolations have purified factors suspected to be relatively unstable and dynamic.  Intron containing 
transcripts, for instance, have co-purified with essentially all expected splicing proteins, including 
relatively transitory proteins like those involved in the second step of catalysis, including Slu7p, 
Prp16p, and Prp43p (Fabrizio et al., 2009).  However, to confirm that dissociation during 
purification is not a complicating factor, we plan to test this by performing isolations at different 
time scales, as well as with UV treatment to create RNA-protein crosslinks.  By determining if 
shorter incubations or UV stabilization significantly affects mRNP composition, we can assess the 
stability of our natively purified complexes.  
mRNP factors specific to introns 
We next performed isolations of a 4xMS2-tagged mCherry transcript containing artificially 
inserted introns. First, we inserted an intron from the ACT1 gene, a well-studied, highly expressed 
yeast cytoskeletal gene with a 309 nt intron (Gallwitz and Sures, 1980).  In comparison to Nab2p-
based pullouts with mCherry transcripts lacking an intron, pullouts of the ACT1 intron-containing 
mRNA show clear changes in the banding pattern of the co-isolated mRNP complex (Figure 4.3).  
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Figure 4.3. Sequential Nab2-PrA and MS2-GFP isolations of mCherry-4xMS2 and 
mCherry(Act1 intron)-4xMS2 mRNPs, alongside negative controls from transcripts with 
no MS2 tag.  Coomassie-stained gels of the purifications were imaged, and protein 
identifications were made by MS on directly eluted whole samples prepared in parallel. IDs 
are shown at predicted molecular weights.
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Mass spectrometric analysis of protein elutions from these pullouts provided a finer look at these 
distinctions. While the intronless mCherry transcript was associated strongly with many nuclear 
pore complex components, transcripts containing an intron were instead strongly associated with 
numerous spliceosomal factors (Figure 4.3).  This difference is likely explained by a change in the 
rate-limiting step of the processing of Nab2p-associated mRNA from export to splicing.  It is clear 
that export of intron-containing mRNAs is dependent on completion of splicing, which seems to 
be required for co-transcriptional recruitment of the Yra1p export adapter (Lei and Silver, 2002).  
However, the relative kinetics of transcription, splicing, and export in yeast remain somewhat 
unclear.  While a number of studies have shown that splicing occurs co-transcriptionally, it is 
possible that some transcripts with shorter second exons are spliced post-transcriptionally (Kotovic 
et al., 2003; Gornemann et al., 2005; Tardiff et al., 2006).  There is increasing evidence, though, 
that transcriptional pausing occurs in terminal exons, leading to primarily co-transcriptional 
splicing in genes, regardless of exon length (Carrillo Oesterreich et al., 2010; Churchman and 
Weissman, 2011).  Assuming the necessity of splicing for export, this relatively slow process, 
reported to be in the range of 60 sec (Tardiff et al., 2006; Alexander et al., 2010), would be 
expected to be rate-limiting in comparison to relatively rapid nuclear export (~180 ms) (Grunwald 
and Singer, 2010). 
As Cbp80p plays a direct role in spliceosome recruitment and is expected to be present in mRNPs 
undergoing splicing (Lewis et al., 1996), we performed an equivalent pair of affinity isolations 
with Cbp80p used as the initial mRNP target (Figure 4.4).  In this case, all major spliceosomal 
factors were identified by MS in the presence of an intron, compared to a subset of U1 components 
with the intronless transcript.  Given Cbp80p’s involvement in early splicing and the persistence  
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of the cap complex, it is expected to be associated with the active spliceosome, consistent with the 
presence of the full spliceosome in our isolations of intron-containing RNAs (Lewis et al., 1996).   
It has been less clear which spliceosomal factors, if any, associate with intronless transcripts.  The 
U1 snRNP, generally the earliest spliceosome component to bind, is known to recognize the 5’ 
splice site of introns, and is therefore predicted to be highly enriched on intron-containing 
transcripts (Seraphin and Rosbash, 1989; Will and Luhrmann, 2011).  Despite this enrichment, U1 
components have been found at low but detectable levels on many intronless genes (Kotovic et al., 
2003).  While little has been known of U1 snRNP’s nonspecific mRNA interactions, our 
identification of U1 factors on intronless transcripts supports a model in which recognition of true 
splice site sequences depends on promiscuous scanning, or transitory binding of all transcripts.  
However, it is also conceivable that the mCherry sequence used in these experiments includes 
uncharacterized cryptic splice sites, so other transcripts would have to be tested to confirm this 
model.  
Label free protein quantification by mass spectrometry 
While observing the presence or absence of different RNP factors has proved informative in the 
case of the clear-cut changes in composition seen with the Ash1 3’ UTR or an intron, it would be 
useful to detect changes in the relative abundance of such factors as well.  It is likely that important 
variations in RNA processing could be associated with several-fold differences in RNP protein 
abundance, and identifying even the approximate stoichiometry would be useful in these more 
subtle cases. 
As a straightforward method for quantifying protein levels both between and within samples, we 
pursued label-free MS quantification techniques (with Erica Jacobs, B. Chait lab).  This avoids the 
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technical difficulties involved in differential stable isotope labeling of all cells to be compared 
(Oda et al., 1999; Ong et al., 2002), while retaining sufficient accuracy to identify significant 
changes in protein abundances.  While many variations of label-free quantification approaches 
have been described, it has generally been found that the most reliable methods make use of peak 
intensities of three or more peptides from proteins to be quantified (Old et al., 2005; Silva et al., 
2006; Bantscheff et al., 2007; Schwanhausser et al., 2011).  This has led to reported accuracies 
within 20%, sufficient to detect the multi-fold differences in abundance of most interest to us, and 
has been found to be somewhat more accurate than similar spectral counting approaches.  While 
most accurate in comparing the relative abundance of the same protein in different samples, this 
technique has also been successfully used to identify the stoichiometry of different proteins within 
a single complex (Smits et al., 2013; Taylor et al., 2013). This is a further advantage of label-free 
quantification, as isotope-based quantification in these cases would require the laborious and 
difficult production of labeled reference peptides for each protein to be measured (Pratt et al., 
2006). 
While we attempted a number of different variations of quantification by peptide intensity, 
including iBAQ, we found that straightforward quantification by proteins’ three most intense 
peptides (TOP3), gave similar, consistent results (Silva et al., 2006; Schwanhausser et al., 2011).  
Due to the difficulties of detecting multiple peptides from smaller molecular weight proteins, it is 
also important to note that results from this analysis are most reliable for larger proteins.   
We first applied this quantification method to triplicate isolations and MS analyses of mCherry 
transcripts with or without an Act1 intron, purified with a first step isolation of Cbp80-PrA (Figure 
4.5).  Not surprisingly, MS2CP-GFP and Pab1p were dominant proteins, with about 5-fold higher 
intensities than any others.  This reflects MS2CP-GFP’s ability to bind to four MS2 hairpins as a  
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Figure 4.5. Label free quantification of sequential Cbp80-PrA and MS2CP-GFP purifications of 
mCherry with or without an Act1 intron.  MS was performed on triplicate isolations of mCherry-
4xMS2 or mCherry(Act1 intron)-4xMS2.  Proteins were quantified by their top 3 peptide 
intensities, and normalized to MS2CP-GFP.  After filtering out known contaminants, the top 47 
protein hits were grouped according to function (U1, U2, or catalytic snRNPs, members of the 
Prp19 complex, or other RNPs) and visualized.  While similar levels of non-splicing RNPs or U1 
splicing factors were detected in both samples, other splicing proteins are strongly enriched with 
the intron-containing transcript. 
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dimer, giving it a predicted stoichiometry of 8 per transcript, and Pab1p’s tendency to bind the 
polyA tail in multiple copies (Sachs et al., 1987).  These and other non-splicing related RNPs were 
found at roughly similar amounts in both intron and non-intron samples.  Looking at splicing 
factors, we also detected similar quantities of U1 snRNPs with both transcripts.  However, later 
spliceosomal factors, such as U2 and catalytic snRNPS or Prp19 complex components, were highly 
enriched with the ACT1 intron-containing transcript.  While most of these factors were not 
identified in the intronless sample, those that were appeared at 10-100 fold lower levels.  
To allow visualization of the relative levels of all identified proteins in two isolations, we also 
graphed these data in a variation of a volcano plot (Figure 4.6).  In this representation, each protein 
is shown as a point, with the y-axis value indicating its maximum abundance in either sample, and 
the x-axis value equal to the log value of its enrichment in one condition versus the other.  Looking 
at this plot to compare the presence and absence of the ACT1 intron, it is clear that all U1 snRNPs 
are detected at approximately the same modest enrichment in the intron sample.  A stronger 
consistent enrichment is also seen for elements of the Prp19 complex, where it can also be noted 
that Prp19p, which forms a tetrameric core of this complex, is roughly 4-fold more abundant than 
other members of the complex.  Finally, general mRNA-binding proteins like Pab1 and Cbp80 are 
found along the y-axis, reflecting the expected equivalent abundances between the intron-
containing and intronless transcripts. 
Promoter-driven changes in transcript maturation 
Several recent studies have revealed that promoter regions can independently confer downstream, 
transcript-level regulatory alterations in their gene products (Bregman et al., 2011; Trcek et al., 
2011).  As representative examples, we pursued classes of promoters responsive to glucose 
starvation that confer different translational activity to their transcripts (Zid and O'Shea, 2014).   
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Figure 4.6. Volcano plot of quantifications from sequential Cbp80-PrA and MS2CP-GFP 
purifications of mCherry with or without an Act1 intron.  Proteins quantified as in Figure 4.5 were 
plotted according to the log2 ratio of relative abundance in the mCherry(Act1 intron) sample over 
the mCherry sample (x-axis).  Y-axis values reflect protein abundance in the enriched sample, 
relative to MS2CP-GFP.  Proteins from the same complex, like U1 snRNPs, tend to be enriched 
at similar levels.  Proteins found in only one sample are shown at the corresponding edge of the 
plot. 
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While many genes are up-regulated at the mRNA level in response to glucose stress, only some, 
such as HSP26, have concomitant increases in protein expression, while others, like GLC3, 
surprisingly show no protein increase at all.  The transcripts of these genes have been found to 
localize to P bodies and stress granules, and are not actively translated during starvation.  The 
differential regulation of these two types of transcripts was found to be due solely to the 
corresponding promoter sequence, and was independent of the transcript sequence.  We thus 
sought to identify possible RNP determinants of this regulation by expressing MS2-tagged 
mCherry with either GLC3 or HSP26 promoters, and performing mRNA isolations under glucose 
starvation conditions. 
As promoter-driven changes in transcript composition would be predicted to occur co-
transcriptionally, we isolated mRNA using Thp2-PrA as the tagged mRNP.  Thp2p is a member 
of the THO/TREX complex, recruited during transcription and involved in transcriptional 
elongation (Jimeno et al., 2002; Strasser et al., 2002).  One notable difference in RNP composition 
was found in mCherry transcripts driven by the HSP26 promoter, rather than GLC3 or the TDH3 
control (Figure 4.7 and 4.8).  While members of the Prp19 complex are found at significant levels 
with GLC3 or TDH3, these were not identified with the HSP26 sample.  While the Prp19 complex 
is predominantly recognized as an activator of splicing, it has more recently been shown to recruit 
the TREX complex to at least some actively transcribed genes (Chanarat et al., 2011).  The Prp19 
complex appears to associate with RNA polymerase II, and is required for full association of the 
THO/TREX complex to active genes, even those without introns.  It has not been clear whether 
the Prp19 complex is in fact required for efficient transcription at all genes, and our results suggest 
that there may be cases, such as HSP26, where it is not necessary for THO/TREX recruitment.   
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Figure 4.7. Label free quantification of sequential Thp2-PrA and MS2CP-GFP purifications of 
mCherry expressed from HSP26 or GLC3 promoters.  MS was performed on duplicate isolations 
of HSP26-mCherry-4xMS2 or GLC3-mCherry-4xMS2 from yeast starved of glucose for 30 
minutes.  Proteins were quantified by their top 3 peptide intensities, and normalized to MS2CP-
GFP.  After filtering out known contaminants, the top 34 protein hits were grouped according to 
function (U1, U2, or catalytic snRNPs, members of the Prp19 or THO/TREX complexes, or other 
RNPs) and visualized.  While similar levels of THO/TREX and other non-splicing RNPs were 
found in each sample, significantly more splicing proteins, particularly factors associating after 
U1, were detected with the GLC3 promoter-driven transcript. 
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Figure 4.8. Volcano plot of quantifications from sequential Thp2-PrA and MS2CP-GFP 
purifications of mCherry expressed from an HSP26 or GLC3 promoter.  Proteins quantified as in 
Figure 4.7 were plotted according to the log2 ratio of relative abundance in the GLC3 promoter 
sample over the HSP26 promoter sample (x-axis).  Y-axis values reflect protein abundance in the 
enriched sample, relative to MS2CP-GFP.  Later splicing factors like U2 or Prp19 complex 
components are uniquely identified with the GLC3 promoter sample, while general factors like 
Pab1p or THO/TREX factors are equally abundant in both experiments.  Proteins found in only 
one sample are shown at the corresponding edge of the plot. 
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While we do isolate THO/TREX in these pullouts (a TREX component is in fact used to isolate 
the associated transcript), it remains possible that the lack of Prp19 components found with the 
HSP26 sample reflect different kinetics of this recruitment.   
While more evidence is needed before we can suggest any link between the Prp19 complex and 
the different fates associated with HSP26 and GLC3 transcripts once exported from the nucleus, 
it is an intriguing possibility.  We can thus perform additional controls to determine whether this 
complex is indeed required for promoter-dependent regulation of these transcripts.  First, we can 
repeat Thp2-based mRNP isolations of all transcripts with and without glucose starvation.  If Prp19 
is playing a role in transcriptional response to this stress, it should be detected at different levels 
when cells are starved.  We can also tag a Prp19 factor rather than Thp2 for RNA purifications – 
this could aid detection of other proteins involved in transcript-specific regulation that interact 
with the Prp19 complex.  Further, to confirm that the conditions used are in fact leading to changes 
in cytoplasmic processing, we will repeat these purifications using a cytoplasmic mRNP, such as 
Cdc33p.  This would be expected to isolate P body or stress granule components in the case of 
activated GLC3, but not HSP26. 
It is also possible that Prp19 is intrinsically required for full transcription from some promoters 
and not others, independent of activation of the stress-response genes we investigated.  To pursue 
this, we can investigate the Thp2-bound mRNP composition of a broader range of transcripts, 
including those with either constitutive or inducible promoters.  This could demonstrate 
differential involvement of Prp19, and potentially reveal other factors able to take the place of 
Prp19 in THO/TREX recruitment. 
 
95
 Ribosomal protein introns 
A number of studies have suggested differences in the ways that certain introns are processed.  
This has been clearest in the case of a number of ribosomal protein genes that appear to be 
differentially degraded and spliced.  For instance, pre-mRNAs of a number of such genes, but not 
intron-containing genes generally, were found to be targeted for degradation by the nuclear 
exosome in a Nab2p-dependent manner (Schmid et al., 2012).  Moreover, it has been seen that 
different classes of spliced genes have distinct mechanisms of splicing, as observed by differences 
in splicing efficiency and sensitivity to various spliceosome mutants (Pleiss et al., 2007).  
Ribosomal protein genes are notable for their atypically high relative levels of spliced versus 
unspliced precursor RNA, as well as for their distinct susceptibilities to different spliceosomal 
defects. 
To investigate these questions of intron-dependent processing, we compared mCherry transcripts 
containing an intron from either ACT1 or RPS30b, a representative ribosomal protein gene, as 
well as an intronless control.  The lengths of these introns (309 bp and 411 bp, respectively) are 
similar, and thus not expected to contribute to significant differences in splicing activity.  We MS2-
tagged and isolated these transcripts for MS analysis, using Cbp80-PrA as the RNP purification 
target to maximize yield of spliceosome-associated RNA.  Quantitative comparison of associated 
RNP factors revealed striking differences between these samples (Figure 4.9 and 4.10).  First, U1 
and U2 snRNPs, the earliest to bind an intron as part of the prespliceosome complex (complex A), 
are enriched about 3-fold in the ACT1 vs RPS30b intron.  Conversely, elements of the activated 
and catalytic spliceosome (complex Bact or C) are enriched 3-fold in the RPS30b intron.  This 
includes the Prp19 complex, all members of which are enriched to similar extents with the RP30b  
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Figure 4.9. Label free quantification of sequential Cbp80-PrA and MS2CP-GFP purifications of 
4xMS2-tagged mCherry containing an intron from either Act1 or Rps30b.  MS was performed 
after mRNP isolations performed in triplicate.  Proteins were quantified by their top 3 peptide 
intensities, and normalized to MS2CP-GFP.  After filtering out known contaminants, the top 47 
protein hits were grouped according to function (U1, U2, or catalytic snRNPs, members of the 
Prp19 complex, or other RNPs) and visualized.  Similar levels of non-splicing RNPs are seen in 
each sample, but while the Act1 intron co-purifies higher levels of U1 and U2 components, factors 
from later spliceosome subunits are strongly enriched with the Rps30b intron sample. 
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Figure 4.10. Volcano plot of quantifications from sequential Cbp80-PrA and MS2CP-GFP 
purifications of mCherry with an intron from either Act1 or Rps30b.  Proteins quantified as in 
Figure 4.9 were plotted according to the log2 ratio of relative abundance in the Rps30b intron 
sample over the Act1 intron sample (x-axis).  Y-axis values reflect protein abundance in the 
enriched sample, relative to MS2CP-GFP.  While earlier U1 and U2 splicing subunits are enriched 
with the Act1 intron, later catalytic subunits are more abundant in the Rps30b intron sample.  In 
all cases, proteins associated with a particular splicing complexe are found at a similar relative 
enrichment. Proteins found in only one sample are shown at the corresponding edge of the plot. 
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intron.  Notably, two U2-associated proteins, Lea1p and Msl1p, are present at equivalent amounts 
in both samples; these proteins directly associate in a complex with U2 snRNA, and may therefore 
persist with the core U2 snRNP through the splicing process, in contrast to the other U2 proteins 
detected. 
The differential enrichments of these complexes could be explained by several factors.  Most 
obviously, different kinetics of the splicing process for each intron could lead to varying 
enrichment of transcripts in earlier versus later steps of splicing.  Thus if the ACT1 intron remains 
associated longer with the prespliceosome before catalytic splicing occurs, we could expect the 
observed increase in prespliceosomal U1 and U2 snRNPs over catalytic proteins (Figure 4.11).  
There is in fact reason to believe this is the case – a number of ribosomal protein genes have been 
seen to have proportionally less unspliced pre-mRNA than ACT1 (Pleiss et al., 2007).  While the 
reason for this has not been clear, our results would suggest that the ACT1 intron is delayed at the 
presplicesome step, before components of the precatalytic splicesosome (complex B) associate. 
Related evidence is also consistent with, and may help explain, our results.  Relative to the RPS30b 
gene, ACT1 shows a significantly different response to a number of spliceosome mutations.  Most 
dramatically, in response to a temperature-sensitive PRP19 mutation, the level of spliced, mature 
ACT1 mRNA is dramatically reduced (with no change in pre-mRNA level), while RPS30b shows 
only a strong increase in pre-mRNA (Pleiss et al., 2007).  This suggests a difference in the limiting 
steps of splicing for each of these introns.  While a defect in Prp19p (but not other splicing factors, 
interestingly) impairs the removal of the ACT1 intron, the pool of pre-mRNA is not affected.  This 
may be consistent with a predominance of pre-spliceosome-associated ACT1 mRNA, with a 
highly active Prp19 complex required for efficient processing of the small subset of mRNA 
proceeding to splicing.  In contrast, the RPS30b intron, which is predominantly associated with  
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Figure 4.11.  Hypothetical model of kinetic differences in splicing of the Act1 and Rps30b introns.  
Due to its relative enrichment of U1 and U2 snRNPs, the Act1 intron appears to be rate-limited in 
its transition to the precatalytic form of the spliceosome (Complex B).  The Rps30b intron is 
instead more strongly associated with components of this complex.  More efficient procession to 
Complex B could result from this intron’s specific recruitment of Npl3, known to promote 
recruitment of certain splicing factors. 
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the catalytic spliceosome, continues to be processed even with a defective Prp19 complex, 
presumably due to the large pool of mRNA consistently associated with this complex.  More 
thorough investigation of the dynamics of splicing for these and other introns will be necessary to 
conclusively determine the factors differentiating their processing. 
Additional differences of note were observed between the ACT1 and RPS30b introns.  
Interestingly, only the RPS30b intron was found to co-isolate with Npl3p.  This SR protein is 
primarily known for its role in mRNA export, but has also been shown to promote splicing for a 
subset of intron-containing genes by aiding recruitment of other splicing factors (Kress et al., 
2008).  Consistent with our results, efficient splicing of RPS30b, but not ACT1, was found to 
depend on Npl3p activity.  As Npl3p was only detected in the presence of the RPS30b intron, its 
enhancement of splicing activity appears to depend on intron-specific association.  Conceivably, 
the inability of the ACT1 intron to recruit Npl3p may be associated with its distinctive pattern of 
early spliceosome association (Figure 4.11).  Finally, as expected, Nab2p was found at 
significantly higher levels in the RPS30b intron sample.  This is consistent with studies showing 
that pre-mRNA of RPS30b and other ribosome protein genes is specifically regulated by the 
exosome in a Nab2p-dependent manner (Schmid et al., 2012). 
The differences in splicing factor occupancy we found in our initial isolations of Cbp80p-
associated ACT1 or RPS30b introns suggest a number of avenues for future investigation.  First, 
as Npl3p appears to be a key mRNP factor with a role in splicing specific to the RPS30b intron, 
this is a promising protein to target in future sequential purifications of intron-containing 
transcripts.  Such mRNA isolations could provide additional evidence relating to the mechanism 
of Npl3p’s apparent activation of splicing.  As Npl3p has a number of different roles in multiple 
steps of mRNA processing, this RNA-specific approach is uniquely able to differentiate 
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interactions specific to RPS30b intron processing from those involved in generic mRNA 
maturation.  In addition, given the broad differences we observed in introns’ enrichment of early 
versus late splicing factors, a more comprehensive and detailed view of the divergent splicing-
related factors could be obtained through sequential isolations using representative spliceosome 
proteins.  Snu71p and Snu114p, for instance, would enrich either the U1-dominated 
prespliceosome or the catalytic spliceosome, respectively.  This more precise targeting would 
allow us to isolate specific stages of splicing, giving a finer picture of where intron-specific protein 
factors act during the splicing process.  This should indicate, for instance, whether the difference 
we observe in ACT1’s relative enrichment of early splicing factors is only a kinetic phenomenon 
– in this case a purification with Snu114p should purify the same catalytic spliceosome as one 
obtained with the RPS30b intron.  Differential isolation of intron-specific proteins like Npl3p in 
these experiments could also suggest where these factors might act to generate differences in 
splicing activity. 
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Chapter 5: Discussion 
Development and applications of new nanobodies 
The novel mass spectrometry and DNA sequencing-based approach to nanobody discovery that 
we developed has a range of long-term applications.  Our method is well-suited to the development 
of nanobody reagents against various types of protein targets, including proteins that are difficult 
to tag. The versatility and potential of nanobodies is huge, as reflected by the interest of the 
research community (Huang et al., 2010; Romer et al., 2011; Vanlandschoot et al., 2011; 
Muyldermans, 2013). Nanobodies have great potential in drug development, as they are much 
smaller than antibodies, resistant to aggregation, and can be readily humanized (Revets et al., 2005; 
Vincke et al., 2009; Muyldermans, 2013); they can bind with great specificity and efficacy to 
disease targets such as tumor cells, either independently (as a monomer or an ultra-high affinity 
nanobody dimer), or as a fusion with other protein domains, molecules, or drugs (Els Conrath et 
al., 2001; Jahnichen et al., 2010; Roovers et al., 2011; Ulrichts et al., 2011). As demonstrated here, 
the ability of our method to quickly and easily identify large repertoires of high affinity bacterially-
expressed nanobodies against a chosen target antigen has the potential to significantly advance a 
field that otherwise can take months or years to generate such reagents (Muyldermans, 2013). 
Nanobodies have a number of unique properties that make them well-suited for certain other 
applications.  In microscopy, their small size allows for improved permeability into cell and tissue 
samples, improving performance, for instance, in super-resolution studies (Ries et al., 2012).  
These reagents have further potential to improve other techniques reliant on efficient fluorescent 
labeling.  Volume imaging of tissue samples is a particularly demanding technique, as 
immunolabeling and clearing of these large structures can take weeks with standard antibodies 
(Renier et al., 2014).  Fluorescently labeled nanobodies, being an order of magnitude smaller, are 
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a promising alternative for these studies, and preliminary results have indeed indicated their 
suitability for more effective large tissue labeling.  An additional advantage of nanobodies’ small 
size and monovalency is their ability to bind their target at an equimolar ratio.  When covalently 
conjugated with dye, this means that their fluorescent signal will increase linearly with the amount 
of target protein.  This allows for quantitative labeling of samples, as we have observed in 
preliminary experiments (with the M. Tessier-Lavigne lab).  Finally, in all microscopy 
applications, the ability of multiple nanobodies to simultaneously bind separate epitopes on their 
antigen means that total signal intensity can be correspondingly increased.  With our anti-GFP 
nanobody repertoire, we have found that up to three nanobodies with distinct epitopes can be used 
to label GFP samples without effect on each other’s binding, leading to three-fold higher signal. 
More broadly, our pipeline for nanobody identification has allowed us to simultaneously immunize 
llamas with many antigens at once, and successfully generate several repertoires concurrently.  
While we have only begun taking advantage of this ability, we are already significantly increasing 
the output of nanobodies against many new targets of interest.  As a start, we have generated 
several nanobodies against three proteins of recent biomedical interest: the cancer-associated 
CTLA4 and EPHA2 receptors, and dystrophy-linked dysferlin protein.  CTLA4 and EPHA2 
nanobodies are being actively assessed for in vivo effects on their targets’ signaling pathways, and 
dysferlin nanobodies are undergoing validation.  Given the medical importance of these three 
proteins, biologically active nanobodies can potentially be of immediate diagnostic or therapeutic 
use.  Moving beyond these three targets, with which we have found early success, we are actively 
pursuing nanobodies against novel targets of interest.  This includes BTLA and HVEM, two 
receptors expressed by a variety of lymphocytes, normally involved in inhibiting T cell activation 
when they interact with each other (Gavrieli et al., 2006).  Similar to CTLA4 however, changes in 
107
expression of these two receptors are common features of certain types of cancer, resulting in 
suppression of the immune response to these tumors (Pasero and Olive, 2013).  Antibodies to these 
two proteins blocking their interactions could thus be valuable therapeutic tools, and we are 
currently working to generate nanobodies for this purpose. 
Alongside our efforts on immediately relevant biomedical targets, we are also developing 
nanobodies against a number of other biologically significant proteins.  Given our lab’s interest in 
the structure and function of the nuclear pore complex, we have begun generating nanobodies 
against a variety of nucleoporins.  This has started with immunizations of 11 different mammalian 
proteins, with a particular focus on those factors implicated in cancer biology (Simon and Rout, 
2014).  Lastly, we are aiming to develop nanobody reagents against several mammalian RNA 
processing factors, as well as key retrotransposition factors (Taylor et al., 2013). 
In sum, the ability to rapidly generate sets of nanobodies has allowed us to produce reagents 
enabling diverse avenues of research.  We can generate nanobodies against more than ten antigens 
in parallel with limited labor, making this an efficient and widely available pipeline.  The 
nanobodies identified can be readily produced in unlimited quantities, and are immediately useful 
for affinity capture or related techniques.  Moreover, the recombinant proteins are easily modified 
to allow for myriad other uses, from straightforward dye labeling for fluorescent imaging, to 
protein engineering of customized nanobodies designed for specialized applications. 
Tools for the study of single mRNP complexes 
For our investigations into yeast mRNP processing pathways, high efficiency anti-GFP nanobodies 
were one element enabling the development of a new approach to the isolation of RNA-specific 
pools of RNP complexes.  With the use of highly efficient isolations of affinity tags, we are able 
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to perform robust purifications of MS2-tagged RNAs associated with any RNP factor of interest.  
This has allowed us to begin investigating the composition of mRNP complexes associated with 
the many different alternative processing pathways suspected to regulate mRNA transcripts.  Until 
now, only the highest abundance RNP factors have been successfully identified through isolations 
of tagged RNAs (Said et al., 2009; Hogg and Goff, 2010; Tsai et al., 2011), in contrast to the many 
specialized proteins we have identified in our two-step approach.  Aside from greater overall 
sensitivity, the use of a tagged RNP factor as a first purification target allows analysis of a specific 
step or mechanism of mRNA processing. 
We have started to take advantage of this novel RNP purification approach in a preliminary survey 
of RNA sequence elements of interest.  In addition to confirming the efficacy of our approach by 
identifying known protein interactors of well-studied mRNA elements like the ASH1 transcript’s 
3’ UTR, our survey has already begun to provide insight into potentially novel mRNP interactions.  
For example, isolations of transcripts containing either ACT1 or RPS30b introns has revealed 
significant differential enrichment in various subcomplexes of the spliceosome.  While the ACT1 
intron predominantly isolates early prespliceosome factors, the RPS30b intron shows significant 
enrichment of catalytic spliceosomal proteins, along with specialized activators of splicing like 
Npl3p (Kress et al., 2008).   
While previous studies in yeast have provided strong evidence that certain introns, particularly 
those of ribosomal protein genes, require different factors for efficient splicing, or are spliced at 
different rates, these conclusions have largely relied on indirect observations (Pleiss et al., 2007; 
Kress et al., 2008; Schmid et al., 2012).  This has typically involved observing changes in the 
relative amounts of spliced and unspliced transcript in various mutant strains.  While instructive, 
this experimental approach provides only indirect genetic insight into the mechanisms behind these 
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intron-specific differences.  Through proteomic analysis of isolated intron-containing transcripts, 
we have now directly identified changes in the composition of mRNP components specific to 
different types of introns.  While still preliminary, this data has been consistent with the previous 
genetic work on these introns, and has provided insight into potential mechanisms involved in 
transcript-specific differences in splicing.   
Potential applications of sequential RNP purifications   
Beyond the set of mCherry derivatives that we used for our preliminary survey of mRNA sequence 
elements, there are countless other questions of RNA biology that could be studied with variations 
of our sequential purification methodology.  An obvious next step is to tag and isolate wholly 
endogenous transcripts.  Given a moderate level of transcriptional activity, our approach is likely 
to allow equally efficient purifications of any transcript – there is nothing in our system uniquely 
tailored to the mCherry sequence so far used.  There are many questions that could be addressed 
by isolations of such RNAs.  As it is unclear how a coding sequence itself does or does not affect 
mRNP composition, this could be examined by comparing the RNPs co-purified with different 
types of mRNA sequence.  Transcripts of different lengths, for instance, could be examined to 
identify factors whose stoichiometry are or are not dependent on transcript size.  Evidence from 
genome-wide studies suggests that different RNPs may in fact have different length-dependence 
(Baejen et al., 2014).  Alternatively, transcripts expressed at different levels could be similarly 
investigated, with a potential focus on codon adaption index, which is closely associated with a 
gene’s protein expression level (Sharp and Li, 1987; Jansen et al., 2003).  Beyond these questions 
of RNPs preferentially associated with certain broad transcript characteristics, any specific mRNA 
believed to have unique RNP components of interest can be easily tagged and purified with our 
sequential method.  More and more such transcripts continue to be identified by various groups, 
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and there remain many such outstanding candidates: heat shock proteins with unique RNA-level 
regulation, or transcripts regulated during the cell cycle are two examples of many (Saavedra et 
al., 1997; Trcek et al., 2011). 
Importantly, our system of RNA isolation is not specific to mRNA at all.  As long as an MS2 
hairpin tag can be inserted into a sequence of interest without undue effect on RNA structure, a 
fundamentally identical approach can be taken with any class of RNA, such as rRNAs or non-
coding RNAs (ncRNAs).  ncRNAs in particular have been of increasing interest to the scientific 
community, and comparatively little is known about processing specific to such sequences, 
particularly long ncRNAs (lncRNAs) (Mattick and Makunin, 2006; Gupta et al., 2010; Tuck and 
Tollervey, 2013).  While often degraded in the nucleus by surveillance machinery, studies have 
suggested that certain ncRNA sequences are exported to the cytoplasm (Xu et al., 2009).  Hrp1p 
and Nab2p have been implicated in these different outcomes through preliminary genome-wide 
studies (Tuck and Tollervey, 2013), and are thus prime candidates for targets in RNP-specific RNA 
isolations.  Cytoplasmic factors can similarly be used to identify possible roles for these transcripts 
after export. 
Finally, while our work in MS2-based RNA isolations has so far been limited to yeast, there is 
nothing preventing these techniques from being directly applied to other systems, such as 
mammalian cells.  The MS2/MS2CP system itself has been extensively used in mammalian cell 
culture (Rodriguez et al., 2007; Querido and Chartrand, 2008), and our lab has optimized our 
protein tagging and affinity isolation approach to achieve results comparable to those in yeast in a 
multitude of model organisms, including mammalian tissue culture and even tissue (Domanski et 
al., 2012; Shi et al., 2015; Obado et al., 2016).  As the sequential RNA purification method 
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fundamentally relies only on the combination of these two technologies, there is little reason to 
believe it cannot be easily adapted to any common laboratory model system. 
Conclusions 
The work presented here has aimed to provide a methodological framework first and foremost for 
the isolation of RNA-specific mRNPs.  This involved identifying highly effective reagents for 
affinity isolation of protein tags, primarily PrA and GFP.  In the process of generating such 
reagents in the form of high affinity nanobodies, we have also developed a pipeline for rapid 
identification of nanobody repertoires against any antigen of interest.  This has allowed us to 
efficiently pursue sets of novel affinity reagents against a variety of targets of biomedical interest.   
With improved nanobodies available, we have been able to develop a specific and efficient 
sequential affinity technique for isolating a single species of mRNA transcript associated with a 
given RNP factor.  After confirming and optimizing the effectiveness of this approach, we began 
applying it to a small number of transcript sequence elements suspected to undergo unusual mRNA 
processing.  While this survey is still in progress, initial results have revealed a number of 
transcript-specific changes in mRNP composition.  Specifically, we have isolated confirmed 
factors associated with the well-studied Ash1 3’UTR, and identified potential new interacting 
factors.  We have also found differences in patterns of spliceosome association with different 
introns, offering potential mechanistic insight into differences in splicing activity previously 
associated with these introns.  Moreover, early experiments have suggested possible RNP factors 
responsible for mediating promoter regions’ determination of their transcripts’ downstream 
cellular fate.  While more work remains to confirm and explore our preliminary results relating to  
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the biology of the mRNA transcripts we surveyed, the methods we have developed are already 
allowing routine investigation of RNA-specific RNP complexes.  This will enable expansion of 
our survey to additional mRNAs or ncRNAs of biological interest.  
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Chapter 6: Materials and Methods 
Nanobody generation and characterization 
Isolation of VHH antibodies 
A 5 year old female llama, Barbie, was immunized with recombinant GFP-His6, and a 4 year old 
male llama, Marley, with recombinant mCherry-His6 through subcutaneous injections of 5 mg of 
protein with CFA.  Three additional injections of 5 mg protein, with IFA, were performed at three 
week intervals.  Serum bleeds were obtained 10 days after the final injection.  2.5 ml of serum was 
diluted ten-fold in 20 mM sodium phosphate, pH 7.0, and incubated with Protein G-agarose resin 
for 30 min.  The flow-through was then incubated for 30 min with Protein A-agarose resin.  Both 
resins were washed with 20 mM sodium phosphate, pH 7.0, and bound VHH IgG was eluted with 
100 mM acetic acid, pH 4.0 and 500 mM NaCl (Protein G resin) or 100 mM acetic acid, pH 3.5 
and 150 mM NaCl (Protein A resin).  These elutions were pooled and dialyzed into PBS.  3 mg of 
this VHH fraction was then incubated with Sepharose-conjugated GFP.  This resin was washed 
with 10 mM sodium phosphate, pH 7.4 and 500 mM NaCl, followed by 1-4.5 M MgCl2 in 20 mM 
Tris, pH 7.5, and then equilibrated in PBS.  The resin was then digested with 0.3 mg/ml papain in 
PBS plus 10 mM cysteine, for 4 hours at 37°C.  The resin was then washed with 1) 10 mM sodium 
phosphate, pH 7.4 and 500 mM NaCl 2) PBS plus 0.1% Tween-20 3) PBS 4) 0.1 M NH4OAc, 0.1 
mM MgCl2, 0.02% Tween-20.  Bound protein was then eluted for 20 min with 0.1 M NH4OH and 
0.5mM EDTA, pH 8.0.  These elutions were dried down in a SpeedVac and resuspended in LDS 
plus 25 mM DTT.  The samples were alkylated with iodoacetamide and run on a 4-12% Bis-Tris 
gel.  The ~15 kDa band corresponding to the digested VHH region was then cut out and prepared 
for MS. 
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RT-PCR and DNA sequencing 
Bone marrow aspirates were obtained from immunized llamas concurrent with serum bleeds.  
Bone marrow plasma cells were isolated on a Ficoll gradient using Ficoll-Paque (GE Healthcare).  
RNA was isolated from approximately 1-6 x 107 cells using Trizol LS reagent (Thermo Fisher), 
according to the manufacturer’s instructions.  cDNA was reverse-transcribed using Ambion 
RETROscript (Thermo Fisher).  A nested PCR was then performed with IgG specific primers.  In 
the first step, CALL001 (5’-GTCCTGGCTGCTCTTCTACAAGG-3’) and CALL002 (5’-
GGTACGTGCTGTTGA ACTGTTCC-3’) primers were used to amplify the IgG variable domain 
into the CH2 domain (Conrath et al., 2001).  The approximately 600-750 bp band from VHH 
variants lacking a CH1 domain was purified on an agarose gel.  Next, for 454 sequencing, VHH 
regions were specifically reamplified using framework 1- and 4-specific primers with 5’ 454 
adaptor sequences: 454-VHH-forward (5’-CGTATCGCCTCCCTCGCGCCATCAG 
ATGGCT[C/G]A[G/T]GTGCAGCTGGTGGAGTCTGG-3’) and 454-VHH-reverse 
(5’-CTATGCGCCTTGCCAGCCCGCTCAG GGAGACGGTGACCTGGGT-3’) (adaptor 
sequences are underlined) (Conrath et al., 2001).  The approximately 400 bp product of this 
reaction was gel purified, then sequenced on a 454 GS FLX system after emPCR amplification, 
on one Pico Titer Plate. For Illumina MiSeq sequencing, the second PCR was instead performed 
with random 12-mers replacing adaptor sequences, to aid in cluster identification: MiSeq-VHH-
forward (5’-NNNNNNNNNNNN ATGGCT[C/G]A[G/T]GTGCAGCTGGTGGAGTCTGG-3’) 
and MiSeq-VHH-reverse (5’-NNNNNNNNNNNN GGAGACGGTGACCTGGGT-3’).  The 
product of this PCR was gel purified, ligated to MiSeq adaptors before library preparation using 
Illumina kits, and run on a MiSeq sequencer with 2 x 300 bp paired end reads. 
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Database preparation 
The protein sequence databases used for identification were prepared by translating sequencing 
reads in all 6 reading frames, and for each read the longest Open Reading Frame (ORF) was 
selected. The selected ORF was digested with trypsin in silico and a list of unique tryptic peptides 
of 7 amino acids or longer was constructed and saved in a FASTA file. It is important to construct 
a FASTA file only containing unique peptides because even though most search engines can 
handle some sequence redundancy, they are not well equipped to handle the extreme redundancy 
that is provided by next generation sequencing of the single chain antibody locus and search 
engines either become very slow or crash if presented with such an extreme redundancy. 
Mass spectrometry 
Gel sections containing VHH domains were excised, destained, and dehydrated.  MS analysis was 
performed by Yinyin Li as follows.  The dehydrated gel slices were subjected to in-gel digestion 
with proteomic-grade trypsin (80 µL; 25 ng trypsin, 25 mM ammonium bicarbonate) (Promega) 
at 37 °C overnight. The gel was extracted once with extraction solution (140 µL; 67% acetonitrile, 
1.7 % formic acid). The resulting proteolytic digest was cleaned with a STAGE tip(Rappsilber et 
al., 2003) and loaded onto a home-packed reverse phase C18 column (75 µm I.D., 15 µm tip) (New 
Objective) with a pressurized bomb. The loaded peptides were subsequently separated with a linear 
gradient (0 % to 42 % acetonitrile, 0.5 % acetic acid, 120 min, 150 nL/min after flow splitting) 
generated by an Agilent 1260 HPLC and directly sprayed into an LTQ-Velos-Orbitrap mass 
spectrometer (Thermo Scientific) for analysis. In the mass spectrometer, a survey scan was carried 
out in the orbitrap (resolution = 30,000, AGC target = 1E6) followed by tandem MS in the ion trap 
(AGC target = 5E3) of the top twenty most intense peaks. Tandem MS was carried out with 
collision induced dissociation (isolation width = 2 Th, CE = 35 %, activation time = 5 ms). Internal 
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calibration was used for improved mass accuracy (lock mass m/z = 371.1012). In order to scan 
more peptides, both predictive AGC and dynamic exclusion were enabled (Repeat counts: 2, repeat 
duration: 12 s, exclusion duration: 60 s). Single and unassigned charge species were excluded from 
tandem MS scans.  The raw files were converted into mzXML format with ReAdW (version 4.3.1). 
MS-based identification of VHH sequences 
Searching and ranking of candidate sequences was carried out by Yinyin Li and Sarah Keegan. 
The MS search was performed on the custom database of tryptic peptides using the X! Tandem 
search engine.  Then, the identified peptides filtered by expectation value were mapped to the 
sequences translated from 454 reads (longest ORF only, as described above).  The CDR regions 
were located within the sequence based on approximate position in the sequence and the presence 
of specific leading and trailing amino acids.  For example, to locate the CDR3 region, the algorithm 
searched for the left anchor YXC (X representing any amino acid) between position 93 and 103 of 
the sequence, and the right anchor WG between position n-14 and n-4 of the sequence, where n is 
the length of the sequence.  Once the peptides were mapped to the sequences and their CDR 
regions, a metric was calculated to rank each sequence as a potential candidate based on the 
bioinformatics evidence available.  The factors included in the metric were: MS coverage and 
length of individual CDR regions with CDR3 carrying highest weight, overall coverage including 
framework region, and a count of the 454 reads producing the sequence.  Finally, sequences with 
similar CDR3 regions were grouped together, allowing for the identification of the highest 
confidence sequence corresponding to a particular CDR3.  A sequence was assigned to a group 
where its hamming distance to an existing member was 1, i.e. there was one amino acid difference 
in the sequence, and different groups that have one shared sequence were further combined. By 
choosing sequence hits from different groups for production, we maximized the overall sequence 
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diversity of the candidate pool. The candidate list was displayed for manual inspection as an 
interactive HTML page with CDR regions annotated, peptide mapping information and the ranking 
metrics shown for each sequence.  All algorithms described above were implemented in Perl. 
Web-based application for nanobody sequence identification: “Llama-Magic” 
The pipeline that was used for identification of the Nanobody sequences has been automated and 
can be accessed through a web-based interface at http://www.llamamagic.org.  Llama-Magic 
allows upload of FASTA files containing reads from High-throughput DNA sequencing.  Once 
uploaded, the reads will be automatically translated and digested to create an MS searchable 
database of tryptic peptides, as described above.  Next, the MS (mgf) files can be uploaded for a 
selected tryptic peptide sequence database, and the parent and fragment error can be chosen for 
the X! Tandem search.  Once the mgf files are uploaded, the X! Tandem search will be executed 
and the matching peptides saved.  Then (1) annotation of CDR regions, (2) mapping of the 
identified peptides and (3) ranking and grouping of candidates are performed automatically, 
producing an interactive display of the candidate list showing detailed information regarding each 
sequence and its corresponding rank.  Llama-Magic is implemented in Perl, HTML and JavaScript. 
Manual inspection was performed to make sure a) long CDR3 peptides, which embrace both 
variable regions and framework regions,  have fragmentation pattern within the variable regions; 
b) CDR3 peptides are unique enough (uniqueness score < 100);  
Cloning 
Nanobody sequences were codon-optimized for expression in E. coli and cloned into pCR2.1 after 
gene synthesis (Eurofins MWG Operon), incorporating BamHI and XhoI restriction sites at 5’ and 
3’ ends, respectively.  A pelB leader sequence was cloned into pET21b at NdeI and BamHI 
restriction sites using complementary primers: 5’-tatgaaatacttattgcctacggcagccgctggattgttattact 
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cgcggcccagccggccatggctg-3’ and 5’-gatccagccatggccggctgggccgcgagtaataacaatccagcggctgccgtag 
gcaataagtatttca-3'. Nanobody sequences were then subcloned into pET21b-pelB using BamHI and 
XhoI restriction sites, with primers also encoding a PreScission Protease cleavage site just before 
the C-terminal 6xHis tag. 
Purification of nanobodies 
pelB-fused nanobodies were expressed under a T7 promoter in Arctic Express (DE3) cells 
(Agilent), induced with IPTG at a final concentration of 0.1 mM.   Cells were induced for 18-20 
hours at 12°C, then pelleted by a 10 min spin at 5000 x g.  The periplasmic fraction was then 
isolated by osmotic shock(Skerra and Pluckthun, 1988).  This fraction was bound to His-Select 
nickel affinity resin (Sigma), washed with His wash buffer (20 mM sodium phosphate pH 8.0, 1 
M NaCl, 20 mM imidazole), and eluted with His elution buffer (20 mM sodium phosphate pH 8.0, 
0.5 M NaCl, 0.3 M imidazole).  The elution was then dialyzed into PBS.  
Fluorescent protein binding assays 
2 µg of fluorescent protein was added to 50 µl of 2 mg/ml E. coli lysate diluted in binding buffer 
(20mM HEPES, pH 7.4, 350 mM NaCl, 0.01% Tween-20, 0.1 M PMSF, 3 µg/ml pepstatin A). 
This was incubated with 25 µl of nanobody-Dynabead slurry.  After a 30 minute incubation at 4°C, 
beads were washed with binding buffer and bound protein was eluted with 15 µl LDS.  Elutions 
were run on a 4-12% Bis-Tris gel. 
Kd determinations 
SPR measurements were obtained on a Proteon XPR36 Protein Interaction Array System (Bio-
Rad).  Recombinant 1xproA, 2xproA, and 4xproA was immobilized on a ProteOn GLC sensor 
chip: the chip surface was first activated with 50 mM sulfo-NHS and 50 mM EDC, run at a flow-
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rate of 30 µl/min for 300 sec.  The ligand was then diluted to 2-6 µg/ml in 10 mM sodium acetate, 
pH 5.0, and injected at 25 µl/min for 75 sec.  Finally, the surface was deactivated by running 1 M 
ethanolamine-HCl (pH 8.5) at 30 µl/min for 300 sec.  This led to immobilization of approximately 
200-600 response units (RU) of ligand. 
Kds of recombinant nanobodies were determined by injecting 4 or 5 concentrations of each protein, 
in triplicate, with a running buffer of 20 mM HEPES, pH 8.0 / 150 mM NaCl / 0.01% Tween. 
Proteins were injected at 50 µl/min for 120 sec, or 100 µl/min for 90 sec, followed by a dissociation 
time of 600 sec.  Between injections, residual bound protein was eliminated by regeneration with 
4.5 M MgCl2 in 10 mM Tris, pH 7.5, run at 100 µl/min for 36 sec.  Binding sensorgrams from 
these injections were processed and analyzed using the ProteOn Manager software. Binding curves 
were fit to the data with a Langmuir model, using grouped ka, kd, and Rmax values.   
Immunofluorescence microscopy 
HeLa cells were cultured on coverslips in DMEM media with 10% FBS and 
penicillin/streptomycin at 37°C with 8% CO2 in a humidified environment.  Cells tested negative 
for mycoplasma. Cells were transfected with CellLight Tubulin-GFP or Mitochondria-GFP 
BacMam 2.0 reagents (Thermo Fisher) using 4 µL of reagent per 5,000 cells, and processed after 
18-20 hrs. Cells were fixed in ice-cold methanol for 10 minutes (for Tubulin-GFP) or in 2% 
paraformaldehyde for 10 minutes (for Mitochondria-GFP).  Cells were permeabilized with 0.5% 
Triton for 10 min. and blocked for 1 hr with 10% goat serum / 1% BSA in PBS.  They were then 
incubated for 1 hr at room temperature with recombinant nanobody conjugated to Alexa Fluor® 
568 succinimidyl ester (Thermo Fisher), diluted to 100 ng/ml in 1% BSA in PBS.  Cells were 
washed four times with PBS / 0.01% BSA, with 300 nM DAPI included in the final wash, then 
mounted with ProLong Diamond (Thermo Fisher). 
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Wild-type and Sec13-GFP tagged T. brucei strains were cultured to a cell density of 1x107 as 
previously described (DeGrasse et al., 2009).  Cells from each strain were mixed 1:1, and fixed for 
10 minutes with cold 4% formaldehyde. Approximately 1x106 cells were spotted onto coverslips, 
allowed to settle for 30 min., permeabilized with 0.1% Triton for 5 min., and blocked with 10% 
goat serum / 1% BSA in PBS for 30 minutes. Cells were then stained, washed, and mounted 
identically to HeLa cells. 
A S. cerevisiae W303 strain with Htb2 genomically tagged at the C-terminus with mCherry was 
grown to mid-log phase, and allowed to settle on Concanavalin A-coated coverslips. Yeast were 
fixed in 4% paraformaldehyde / 2% sucrose / PBS, and blocked and permeabilized for 30 minutes 
in 0.25% Triton / 2% milk / PBS(Ries et al., 2012).  Cells were stained overnight at 4°C with 
nanobody diluted to 3.3 µg/ml in 0.25% Triton / 1% BSA / PBS. They were then washed 5 times 
with 0.01% BSA in PBS, the final two washes for 5 min. Cells were mounted in 70% glycerol / 
PBS. 
All images were obtained on a Deltavision Image Restoration Microscrope (Applied 
Precision/Olympus), with an Olympus 100x/1.40 numerical aperture objective, or 60x/1.42 
objective in the case of HeLa cells. Raw images were processed by a deconvolution algorithm 
using softWorX software (Applied Precision/GE Healthcare). 
Affinity isolations of tagged protein complexes 
Recombinant nanobodies were conjugated to epoxy-activated magnetic Dynabeads (Thermo 
Fisher), with minor modifications to published IgG coupling conditions (Alber et al., 2007).  10 
µg recombinant protein was used per 1 mg of Dynabeads, with conjugations carried out in 0.1 M 
sodium phosphate, pH 8.0 and 1 M ammonium sulfate, with an 18-20 hour incubation at 30°C.  
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Affinity isolations of yeast Nup84-GFP were carried out as previously described, using binding 
buffer consisting of 20 mM HEPES, pH 7.4, 500 mM NaCl, 2 mM MgCl2, 0.1% CHAPS, 0.1M 
PMSF, and 3 µg/ml pepstatin A(Alber et al., 2007).  For each experiment, 50 µl of bead slurry was 
used with 0.5 g of yeast cells.  Similar conditions were used for HTB2-mCherry isolations (from 
yeast with HTB2 genomically tagged at the C-terminus with mCherry(Rout et al., 2000)), except 
lysate was sonicated 4 times for 10 s before centrifugation, and the binding buffer consisted of 20 
mM HEPES, pH 8.0, 300 mM NaCl, 110 mM KOAc, 0.1% Tween-20, 0.1% Triton X-100, 0.1M 
PMSF, and 3 µg/ml pepstatin A.  Isolations of RBM7-LAP from HeLa cells were performed as 
previously described(Domanski et al., 2012).  10 µl of bead slurry was used with 100 mg of cells, 
using a binding buffer of 20 mM HEPES, pH 7.4, 300 mM NaCl, 0.5% Triton X-100, with 
cOmplete Protease Inhibitor, EDTA-free (Roche). 
To determine affinity isolation yields, samples of resuspended lysate were taken before and after 
Dynabead binding. These were run on a 4-12% Novex Bis-Tris gel in MES running buffer (Thermo 
Fisher), and probed by Western blotting using mouse anti-GFP antibody (Roche, cat. no. 11 814 
460 001) diluted 1:1,000 in TBST / 2% dry milk and an anti-mouse, HRP-conjugated secondary 
(GE Healthcare, cat. no. NA931V) diluted 1:3,000 in TBST / 2% dry milk. Signals were quantified 
using ImageJ software. 
Fluorescence spectra 
Samples of recombinant GFP at 0.5 µM in PBS were mixed with either buffer or 10 µM of a LaG 
protein. Fluorescence spectra were obtained on a Synergy Neo microplate reader (BioTek).  
Excitation spectra from 300 nm to 530 nm were taken at an emission wavelength of 560 nm, and 
emission spectra were measured from 450 nm to 600 nm at an excitation wavelength of 425 nm. 
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Phylogenetic analysis 
Phylogenetic trees and alignments were generated from LaG amino acid sequences using the 
Phylogeny.fr web service (Dereeper et al., 2008; Dereeper et al., 2010). 
Mapping of nanobody binding epitopes on GFP by NMR 
Three variants of GFP were used in the preparation of NMR samples. GFP-His6 (eGFP), the 
variant used for immunization; GFPuv, the variant for which backbone 15N-1H chemical shift 
assignments were available from BMRB file 5666 (Khan et al., 2003) and a crystal structure was 
available from PBD ID 1B9C (Battistutta et al., 2000); GFPuv_A206K (GFPuv_M), a monomeric 
version of GFPuv (Zacharias et al., 2002).  
All NMR samples contained between 500 and 20 µM 15N-GFP either alone or in the presence of 
a 1-1.2 molar excess of LaG, 10mM sodium phosphate buffer, pH 7.4, 150mM NaCl and 90% 
H2O/10% D2O. All NMR spectra (2D 1H-15N HSQC) were measured at 310K on a Bruker Avance 
DPX-600 MHz spectrometer equipped with a TCI cryoprobe.  NMR experiments and analysis 
were performed by Ilona Nudelman. 
Backbone 1H-15N assignments of GFPuv were obtained from a comparison between a 1H-15N 
HSQC spectrum of GFPuv alone and a simulated 1H-15N HSQC based on BMRB 5666 (Khan et 
al., 2003).  Due to a very high similarity between the two, 1H-15N backbone assignment of GFPuv 
was obtained for 97% of 1H-15N backbone resonances for which assignment was available in 
BMRB5666. The accuracy of the GFPuv assignment was verified by mapping the binding site of 
a previously identified nanobody, GFP-Trap, on GFPuv. The crystal structure of the GFP/GFP-
Trap complex is available in the PDB (PDB ID 3K1K)(Kirchhofer et al., 2010) and a comparison 
between the X-ray crystallography-derived binding site (obtained by analysis of 3K1K by PISA - 
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'Protein interfaces, surfaces and assemblies' service at the European Bioinformatics Institute 
(http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) (Krissinel and Henrick, 2007)) and the one 
determined by the chemical shift perturbation method, reveals they overlap, thereby confirming 
our assignment of GFPuv residues.  
Backbone 1H-15N assignments of GFPuv_M were obtained from a comparison between a 1H-15N 
HSQC spectrum of GFPuv and that of GFPuv_M. Assignment was verified by mapping the 
dimerization site of GFPuv and comparing it to the crystal structure of PDB ID 1B9C(Battistutta 
et al., 2000) (analyzed for interacting residues using PISA(Krissinel and Henrick, 2007)). 
All chemical shift differences were calculated using equation (1) where CSD is the total  
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chemical shift difference and ∆δN and ∆δH are the chemical shift differences in the free and bound 
states between the amide nitrogens and protons, respectively. The CSD cutoff for binding site 
residues was 0.05ppm for GFP-Trap binding site and for GFPuv dimerization site and 0.03ppm 
for all LaG binding sites. 
mRNP purifications 
Cloning 
The MET3 promoter was subcloned from p404MET3 into pRS414 (from N. Buchler and F. Cross) 
using SacI and SpeI restriction sites to create pRS414-MET3. HA-MS2(ΔFG)-eGFP-SV40NLS 
was PCR-amplified from pMS2-GFP (Fusco et al., 2003) and cloned into pRS414-MET3 to create 
pRS414-MET3-MS2CP-GFP.  Wild-type eGFP and mCherry sequences were PCR-amplified and 
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cloned into pRS426-TDH3 (Mumberg et al., 1995) using SpeI and XmaI restriction sites.  Four 
repeats of the MS2 hairpin were inserted after these sequences between XmaI and XhoI sites, using 
complementary primers: 5’- ccgggCCTAATTGCCTAGAAAACATGAGGATCACCCATGT 
CTGCAGGTCGACTCTAGAAAACATGAGGATCACCCATGTCTGCAGGTCGACTCTAGA
AAACATGAGGATCACCCATGTCTGCAGGTCGACTCTAGAAAACATGAGGATCACCC
ATGTCTGCAGTATTCc-3’ and 5’-tcgagGAATACTGCAGACATGGGTGATCCTCATGTTT 
TCTAGAGTCGACCTGCAGACATGGGTGATCCTCATGTTTTCTAGAGTCGACCTGCAG
ACATGGGTGATCCTCATGTTTTCTAGAGTCGACCTGCAGACATGGGTGATCCTCATG
TTTTCTAGGCAATTAGGc-3’.  
ACT1 and RPS30b intron sequences were amplified from yeast w303 genomic DNA, and then 
blunt-end ligated into pRS426-mCherry-4xMS2 and pRS426-mCherry plasmids digested with 
MscI.  HSP26 and GLC3 promoters were PCR amplified from yeast genomic. A 2x repeat 
sequence of Rap1p binding sites (5’GTGGTGCACAGATGTAACGTTCCAAAATGTATG 
GATGGTA-3’) was synthesized and inserted immediately upstream of the TDH3 promoter. These 
promoters were subcloned into the pRS426-mCherry and pRS426-mCherry-4xMS2 plasmids 
using SacI and SpeI restriction sites.  Finally, ASH1 and CTH2 3’ UTR sequences were amplified 
from yeast genomic DNA and subcloned into pRS426-mCherry and pRS426-mCherry-4xMS2 
plasmids after the 4xMS2 tag using XhoI and EagI restriction sites.   
Strains 
Strains used in this work were derived from wild-type W303 (MATa ade2-1 ura3-1 his3-11,15 
trp1-1 leu2-3,112 can1-100).  NAB2, CBP80, CDC33, and THP2 were genomically tagged at the 
C-terminus using a PPX-Protein A::HIS5 cassette (Rout et al., 2000).  The PPX sequence 
(GLEVLFQGPS) is the target of human rhinovirus 3C protease.  For sequential RNA purifications, 
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pRS414-MS2CP-GFP was transformed into the appropriate strain, followed by transformation 
with the transcript-encoding pRS426 plasmid.  Transformations were performed using standard 
lithium acetate techniques.  Cells were grown at 30°C in complete synthetic defined medium 
lacking L-tryptophan, uracil, and L-methionine.   
Sequential RNA affinity purifications 
Yeast cells were grown, harvested at mid-log phase and cryogenically milled as previously 
described (Alber et al., 2007; Oeffinger et al., 2007).  2 g of frozen cell powder was resuspended 
in 8 ml of RNP buffer (20 mM HEPES, pH 7.4; 150 mM NaCl; 110 mM K-acetate; 1 mM DTT; 
0.1% Tween 20; 0.5% Triton X-100; 1:5000 RNasin (Promega); 1:5000 Antifoam B; 1 mM PMSF; 
3 µg/ml pepstatin A).  Lysate was spun at 10,000 x g for 10 min., and the supernatant incubated 
with a 200 µl suspension (30 mg beads) of IgG-conjugated Dynabeads equilibrated in RNP buffer 
(Thermo Fisher).  After a 30 min. incubation at 4°C, beads were washed 3 times with 1 ml RNP 
buffer, and resuspended in 150 µl RNP with 80 ng/µl PreScission Plus protease.  This was 
incubated for 1 hr at 4°C, and the supernatant was collected.  This was pooled with an additional 
75 µl RNP wash of the beads, and the combined solution was incubated for 30 min with a 10 µl 
suspension (1.5 mg beads) of Dynabeads conjugated to LaG16-G4S-LaG2 nanobody.  After 3 
washes with RNP buffer, protein was eluted at 72°C for 10 min. with 25 µl NuPAGE LDS buffer.  
When prepared for MS analysis, this elution was reduced for 10 min. at 72°C with 25 mM DTT, 
then alkylated with 0.1 M iodoacetamide for 30 min. at room temperature.  For RNA isolation, 
beads were instead resuspended in 600 µl RLT buffer for RNeasy purification (Qiagen). 
To determine yields, samples of resuspended lysate were taken before and after each binding step. 
These were run on a 4-12% Novex Bis-Tris gel in MES running buffer (Thermo Fisher), and 
probed by Western blotting using, for GFP, mouse anti-GFP antibody (Roche, cat. no. 11 814 460 
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001) diluted 1:1,000 in TBST / 2% dry milk and an anti-mouse, HRP-conjugated secondary (GE 
Healthcare, cat. no. NA931V) diluted 1:3,000 in TBST / 2% dry milk.  For PrA, membranes were 
instead probed with peroxidase anti-peroxidase (Sigma, cat. No. P1291) diluted 1:5,000 in TBST. 
Signals were quantified using ImageJ software. 
Mass spectrometry-based proteomic analysis 
Alkylated affinity isolation elutions were purified as single gel plugs by SDS-PAGE: samples were 
run at 125 V for 7 min. on a 10% Bis-Tris gel (Thermo Fisher), which was then stained with 
Coomassie Blue dye.  Bands were then excised as a single piece, destained, and dehydrated.  In-
gel digestion with trypsin was performed on destained dehydrated gel pieces overnight with 0.5-1 
µg trypsin in 50 µl 50 mM ammonium bicarbonate (ABC) buffer with 10% acetonitrile (ACN). 
Tryptic peptides were extracted with POROS20 C18 beads (Krutchinsky et al., 2001), desalted on 
Zip Tips (0.6 µl C18 resin, Millipore), sequentially eluted with 40% and then 90% acetonitrile / 
0.1% acetic acid, and the eluates pooled, concentrated by vacuum centrifugation, and suspended 
in 10 µl of 0.1% formic acid (FA).  Desalted peptides (2 µl) were analyzed by direct injection onto 
a C18 analytical column (EASY-Spray 3 µm, 150 mm x 0.075 mm) using a Thermo EASY-nLC 
100 nanoLC coupled online to an Orbitrap Q Exactive Plus (QE+) or Fusion mass spectrometer 
(Thermo Fisher). Peptide separation and MS detection was performed over 60 min at ~300 nl/min 
using a discontinuous ACN gradient from 0 to 30 % mobile phase B over 60 min, followed by 30 
to 100% B over 15 min (mobile phase A, 0.1% FA; mobile phase B, 97% ACN in 0.1% FA). The 
spray voltage was set at 1.9–2.3 kV. The instruments were operated in the data-dependent mode, 
in which the most abundant ions were fragmented by higher-energy collisional dissociation (HCD) 
(HCD collision energy 30 (QE+) or 35 (Fusion)), and analyzed in the Orbitrap mass analyzer. The 
target resolution for MS1 was 70,000 (QE+) and 120,000 (Fusion), and for MS2 was 17,500 (QE+) 
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and 30,000 (Fusion). Ions (300–1,700 m/z QE+, 400-1500 m/z Fusion) with a charge state of >1 
were selected for fragmentation. A dynamic exclusion of 10 s (QE+) and 30 s (Fusion) and a 'lock 
mass' at 371.1012 Da were used. 
Mass spectrometry data processing and quantitation 
Combined MS/MS spectra were extracted from Thermo RAW files derived from three biological 
replicate samples, and searched by Proteome Discoverer/SEQUEST (version 2.0/2.1, Thermo 
Fisher) against a Saccharomyces cerevisiae protein sequence database and a common 
contaminants database. SEQUEST search parameters were as follows: full trypsin specificity with 
2 missed cleavages, precursor and fragment tolerances of 20 ppm and 0.6 Da, fixed modification 
of carbamidomethylation of cysteine, and variable modification for methionine oxidation. Putative 
SEQUEST peptide-spectrum matches (PSMs) were scored by the Percolator algorithm (Spivak et 
al., 2009) to assign individual expectation scores (PEP). PSMs were filtered to achieve an 
estimated 1% peptide false discovery rate (q-value < 0.01) and then PSMs were assembled into 
protein groups using the “strict maximum parsimony principle” option.  Relative label-free 
quantitation was performed using the Proteome Discoverer precursor ions area quantification 
workflow on the top 3 most intense peptides per protein.  Results were exported to Excel for 
downstream analysis.  Abundances for the three biological replicates were averaged.  Proteins with 
fewer than three peptides were not analyzed. 
RNA-Seq and real-time PCR 
RNA from sequential affinity purifications was purified using the RNeasy kit (Qiagen).  RNA was 
fragmented and ligated to adaptors before library preparation using Illumina kits, and run on a 
HiSeq 2500 sequencer with 50 bp single reads.   
128
For qRT-PCR, RNA was reverse transcribed using SuperScript VILO (Thermo Fisher).  Real-time 
PCR was then with using PowerUp SYBR Green mix (Thermo Fisher) on a QuantStudio 12K Flex 
system using standard conditions (Thermo Fisher).  The following primer pairs were used to 
quantify each gene: mCherry, AGATCAAGCAGAGGCTGAAGCTGA and TGTGGGAGG 
TGATGTCCAACTTGA; GFP, TGGTGTTCAATGTTTTGCGAG and GCTCTGGTCTTGT 
AGTTACCG; 18S rRNA, GAGTCCTTGTGGCTCTTGGC and AATACTGATGCCCCCGACC 
(Merz et al., 2008). 
Northern hybridization 
RNA samples were separated on a 6% TBE-Urea acrylamide gel, and Northern blotting was 
performed as previously described (Tollervey, 1987).  Briefly, gels were electrotransferred to 
Hybond N+ (GE Healthcare), and hybridized at 37°C overnight with probe diluted in a buffer of  
50% formamide, 5x SSPE, 5x Denhardt’s buffer, 0.2 mg/ml fish sperm DNA, and 0.2% SDS.  
Blots were then washed twice for 15 min. at 42°C with 6xSSPE before being exposed to a 
Phosphorimager screen. The following DNA oligomers were end-labeled with [γ-32P]-ATP and 
used as probes: mCherry, TGTGGGAGGTGATGTCCAACTTGA; 18S rRNA, 
GACATGCATGGCTTAATCTTTGAGAC. 
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Appendix: Improving and extending the nanobody pipeline 
Improvements to the nanobody discovery pipeline 
Our initial efforts to development a new method for identifying nanobodies were based on GFP 
and mCherry antigens (Fridy et al., 2014).  As the GFP tag in particular is a key part of our mRNP 
isolation protocol, and mCherry nanobodies could be used as an important control (Chapter 4), 
nanobodies against these targets were of the greatest practical interest to our lab.  Given the success 
of this first application of our new approach, we have since sought to apply it to other antigens of 
biomedical interest, taking advantage of the relative ease and flexibility of the approach.  In the 
process of producing nanobodies against new antigens, we have also made a variety of 
improvements in the methodology, allowing more reliable identification of nanobody repertoires 
against many antigens at once.   
After GFP and mCherry, we first aimed to target three human proteins of biomedical interest: 
CTLA4, EPHA2, and dysferlin.  CTLA4 is a T-cell receptor that inhibits the activation of cytotoxic 
T-cells; inhibition of CTLA4 thus enhances T-cell activation, and an inhibitory antibody, 
ipilimumab, has in fact been shown to promote anti-tumor immune responses in clinical trials of 
cancer patients (Leach et al., 1996; Hodi et al., 2010).  Similarly, ephrin receptor A2 (EPHA2) has 
been implicated as a key oncogene in certain cancers, and inhibition of this receptor has been 
shown to suppress tumor growth (Oricchio et al., 2011; Udayakumar et al., 2011).  The current use 
of monoclonal antibodies in these cancer therapeutic approaches is hindered by both high cost (e.g. 
$120,000 per course of ipilimumab treatment), and the difficulties of delivery into dense tumors 
(Couzin-Frankel, 2013; Maleki et al., 2013).  Smaller and less complex nanobodies are expected 
to avoid some of these issues, and in fact a number of nanobodies are showing success as 
therapeutic agents (Van Bockstaele et al., 2009; Roovers et al., 2011). 
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Beyond these two cancer targets, we are also attempting to generate nanobody reagents against 
dysferlin.  Mutations in this gene are associated with multiple forms of muscular dystrophy, such 
as Miyoshi myopathy and limb girdle muscular dystrophy (Barthelemy et al., 2011).  The dysferlin 
protein is a very large (~240 kDa) transmembrane protein highly enriched in muscle cells; its 
functions are not fully understood, but it appears to play an important role in membrane 
maintenance and muscle repair.  Due to its involvement in disease and the many questions related 
to its function, reagents able to target dysferlin’s many domains have long been sought.  To date, 
very few antibodies have been generated against dysferlin, possibly due to the difficulties in 
producing stable protein and subsequently raising a response against this structurally and 
proteolytically unstable target.  We therefore aimed to generate a large repertoire of nanobodies 
against dysferlin, with the goal of improving the reagents available for research and diagnostic 
purposes.  While some efforts have been made to produce nanobodies against dysferlin, so far only 
two clones have been generated using traditional phage display approaches (Huang et al., 2005). 
We immunized animals with these three antigens, as part of a mixture with four other proteins of 
interest to collaborators.  It has been reported that up to five antigens can be simultaneously 
injected into an animal with no adverse effect on the immune response, and informal accounts 
suggest that responses can even be generated against dozens of proteins at once (Pardon et al., 
2014).  This is perhaps not surprising, as animals in the wild are expected to be exposed to many 
natural invaders at once, each presenting multiple antigens, and must be able to mount 
simultaneous immune responses.  As with GFP and mCherry, we immunized three llamas, but also 
injected two alpacas with dysferlin-GFP.  It was reasoned that the smaller size of alpacas to llamas 
could result in a relatively stronger immune response to the same antigen dose, and other groups 
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have successfully generated nanobodies from alpacas with no changes in protocol (Rothbauer et 
al., 2006; Maass et al., 2007). 
Overcoming the limitations of papain digestion 
Sera from immunized animals showed strong activity against EPHA2, CTLA4, and dysferlin, and 
VHH fractions and VHH sequencing data was obtained as before from sera and bone marrow 
samples.  However, in contrast to GFP and mCherry, we found that after affinity purification of 
antigen-specific VHH IgG, the papain digest used to release Fc fragments unavoidably led to 
complete proteolysis of immobilized EPHA2 and dysferlin.  It is well established that papain 
cleaves polypeptides with very broad specificity, with only moderate preference for bulky 
hydrophobic residues at one amino acid position in its active site (Kimmel and Smith, 1954; 
Schechter and Berger, 1967).  With careful titration however, papain preferentially targets the IgG 
hinge region, and has long been the standard protease used to cleave IgG into Fab and Fc fragments 
(Porter, 1959; Nisonoff et al., 1960; Parham, 1983).  With GFP and mCherry, two highly stable 
and compact beta-barrel proteins (Ormo et al., 1996; Yarbrough et al., 2001), bound VHH IgG 
could be readily digested with papain to release Fc, in easily optimized conditions in which the 
immobilized antigen was not degraded.  With less stable proteins however, it became clear that no 
digest conditions are available that allowed sufficient cleavage of IgG while avoiding excessive 
proteolysis of the antigen.  With the antigen degraded, no specific VHH binders can remain on the 
resin to be analyzed.  
To address this papain digestion problem, we first attempted to avoid the papain digestion step 
entirely.  In theory, this should leave intact IgG on the antigen resin, complete with both Fab and 
Fc regions.  When performing MS on these samples to identify nanobody candidates, the 
remaining highly conserved Fc region was expected to give abundant extraneous peptides that 
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could overwhelm detection of more diverse peptides from the VHH region, but with sufficient 
sensitivity, we anticipated adequate identification of the informative peptides.  However, 
performing these non-digest purifications with anti-GFP VHH as a control, we consistently found 
that while positive candidates could be detected, the candidate list had far more non-specific clones 
throughout, making it difficult to identify positives without impractically extensive screening 
(Figure A.1).  The reason for this increase in non-specific hits is unclear, but is presumably due to 
complications from additional peptides from either Fc domains, or from non-specific VHH regions 
that are no longer washed away as efficiently from the resin; as papain is no longer separating IgG 
molecules into monovalent variable domains, it is possible that the higher avidity of bivalent 
antibodies allows very weak binders to be retained.  It is also possible that sets of “sticky” non-
specific VHH binders always tend to associate with the antigen resin, but that papain could 
destabilize these by partial proteolysis, causing them to dissociate. 
Due to the disadvantages of both papain and complete omission of digestion, we sought an 
alternative protease to achieve more specific IgG cleavage.  A variety of papain alternatives have 
been suggested to offer more specific digestion of IgG hinge regions, including lysyl 
endopeptidase, V8 protease, or ficin (Mariani et al., 1991; Yamaguchi et al., 1995).  More recently 
though, a protease with strong site specificity for a sequence found in certain IgG hinges was 
identified from S. pyogenes, known as IdeS (von Pawel-Rammingen et al., 2002).  While this 
enzyme does not recognize every IgG subtype, it has no known non-IgG substrates, avoiding the 
risk of off target proteolysis in our method.  Upon testing commercially available IdeS on llama 
VHH fractions, we found that more than 90% of IgG was specifically cleaved, with no over-
digestion observed (with Junjie Wang, B. Chait lab) (Figure A.2a).  Additionally, no other proteins 
or antigens we tested were cleaved by IdeS, in stark contrast to papain (Figure A.2b).  We next  
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Figure A.1. Identification of verified anti-GFP nanobodies with papain, IdeS, or no digestion.  VHH 
affinity-purified over GFP resin was digested in different ways before MS analysis to identify 
nanobody candidates.  The resulting candidate lists were searched for the 26 verified LaG nanobody 
sequences.  The overall number of candidates searched (y-axis) was then plotted against the 
corresponding number of LaGs identified (x-axis).  
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Figure A.2. Efficient and specific IgG digestion by IdeS. (a) A VHH IgG fraction was purified 
over GFP sepharose, then digested on resin with IdeS.  Input, flow-through (FT) and ammonium 
hydroxide elutions were analyzed by SDS-PAGE.  Fc fragments were found at the predicted MW 
of 30-32 kDa, and VHH fragments at 15-25 kDa.  Variation in Fc and VHH sizes are consistent 
with short (IgG3) versus long (IgG2) hinge variants (Hamers-Casterman et al., 1993).  Bands 
corresponding to long hinge (1) and short hinge (2 and 3) VHH were analyzed by MS (Figure 3.1).  
(b) IgG, GFP, bovine serum albumin (BSA), and yeast alcohol dehydrogenase (ADH) were 
digested with 0, 50, or 500 ng of papain, or 67 units of IdeS.  All proteins were sensitive to papain, 
while only IgG was cleaved by IdeS. 
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tested IdeS-digested antigen-specific VHH by MS.  Using GFP as a control antigen, we saw far 
fewer non-specific sequences in the resulting candidate lists when compared to non-digested 
samples.  Confirmed GFP-binding sequences thus tended to rank much more highly, similar to our 
original papain results (Figure A.1). 
As we were able to recapitulate our original papain results for GFP using IdeS, we have now 
reanalyzed IdeS-digested samples for the previously problematic CTLA4, EPHA2, and dysferlin 
antigens.  With this new approach, we have successful identified many nanobody candidates, with 
positive hit rates averaging approximately 50% (Figure A.3).  We are now determining the binding 
characteristics of these nanobodies, and in the case of CTLA4 and EPHA2 nanobodies, providing 
them to collaborators to assess in vivo inhibitory function. 
Nanobodies targeting Protein A 
In the course of generating nanobody repertoires against various antigens, we observed that 
approximately half of identified nanobody clones bound robustly to Protein A (PrA), consistent 
with previous studies, but somewhat counterintuitive given PrA’s more commonly known affinity 
for IgG Fc domains (Frenken et al., 2000; Fridy et al., 2014).  PrA and its derivatives continue to 
be widely used biological tools, due to their high affinity for the Fc domain of many antibodies. It 
is a commonly used protein tag, with multiple copies of its five homologous antibody-binding 
domains often used to increase overall avidity to IgG binding partners (Uhlen et al., 1983; Rigaut 
et al., 1999).  Curiously, in addition to its well-known affinity for the Fc region, PrA has been 
found to bind certain immunoglobulins through their Fab domains using a distinct binding 
mechanism (Sasso et al., 1991; Jansson et al., 1998).  It has similarly been observed that 
recombinant nanobodies, which are derived from camelid heavy chain-only VHH antibody  
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Figure A.3. Verification of nanobody candidates against CTLA4 and EPHA2.  Llama 
antibodies against CTLA4 (LaCs) or EPHA2 (LaEs) were expressed in E. coli, and lysates were 
incubated with the corresponding antigen immobilized to sepharose resin, washed and 
eluted.  Input (I), flow-through (F), and SDS elutions (E) were analyzed by SDS-PAGE.  Five 
LaCs and four LaEs were found in elutions (red arrows), indicating positive antigen binding.
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variants, can sometimes bind PrA through their Fab-like single variable domain (Frenken et al., 
2000).   
To date, standard purified IgG protein has been the reagent of choice for isolating PrA-tagged 
complexes (Lindmark et al., 1983; Moks et al., 1986), recently supplemented by an engineered 
high affinity affibody (Lindborg et al., 2013).  However, the heterogeneous nature of IgG 
preparations, high molecular weight, lot-to-lot variation, and cost make these less than ideal for 
many applications, particularly in proteomics. Additionally, we have found that any particular 
recombinant protein used for affinity binding of a single target can display unpredictable off-target 
binding in certain systems, making it valuable to have more than one available option (Fridy et al., 
2014). Given the well-established ease of use and versatility of nanobodies, we sought to generate 
such a reagent with high affinity for PrA.  
When assessing the repertoire of nanobodies that we had previously identified, sequence 
alignments of PrA binders revealed highly conserved framework regions. These sequences all 
contained CDR loops specific for their original antigen, however, and to generate a nanobody with 
no extraneous binding activity, we synthesized four sequence variants derived from these 
consensus sequences with designed minimal or absent CDR loops (Figure A.4a). Once synthesized 
and expressed in E. coli with a periplasmic leader sequence, all four proteins (termed llama 
antibody against Protein A, or LaP 1-4) showed high levels of expression, and high solubility after 
periplasmic purification. These crude periplasm preparations were incubated with PrA-Sepharose, 
and all constructs displayed high affinity, particular LaP-1, which was selected for follow-up 
studies. In all cases, no detectable binding was observed for the original antigen (data not shown). 
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2xLaP-1 ka  2.9 x 105 4.5 x 105 4.0 x 105 
kd (s-1) 3.6 x 10-4 1.7 x 10-4 1.4 x 10-4 
KD (nM) 1.3±0.1 0.37±0.02 0.36±0.03 
(M-1s-1)
Figure A.4. Design and characterization of PrA nanobodies. (a) Highly conserved regions from 
multiple identified nanobody sequences were used as a framework for four engineered nanobodies 
against PrA (LaP-1-4), with varying minimal linkers used in place of existing CDR regions. 
Asterisks: residues whose mutation eliminates PrA binding. (b) SPR sensorgrams are shown for 
injections of multiple concentrations of 2xLaP-1 nanobody over immobilized 4xPrA. Curves fit 
from a Langmuir model are shown in black. (c) Binding constants determined by SPR for either 
LaP-1 nanobody or 2xLaP-1 dimerized nanobody against immobilized 1xPrA, 2xPrA, or 4xPrA. 
Corresponding association rates (ka), dissociation rates (kd), and dissociation constants (Kd) are 
shown.
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Surface plasmon resonance (SPR) analysis was performed to determine the binding kinetics of 
LaP-1’s interactions with multiple recombinant PrA constructs, containing 1, 2, or 4 repeats of the 
IgG-binding domain (Figure A.4c). Regardless of the number of PrA repeats, LaP-1 bound these 
proteins with a KD of 70-120 nM.  While suitable for many applications, it was reasoned that this 
affinity could be increased by generating a homodimeric form of the nanobody. Two copies of the 
LaP-1 sequence were therefore fused using a glycine-rich peptide linker (3 repeats of GGGGS). 
As the LaP-1 monomer is only 13 kDa, even this dimerized form remains a relatively small 27 
kDa. After purification, the PrA affinities of this 2xLaP-1 fusion protein were similarly assessed 
by SPR (Figure A.4b,c). When binding to 2xPrA or 4xPrA constructs, the affinity of the dimer 
was more than 300-fold stronger than the LaP-1 monomer, with a KD of 360-370 pM. 
Given the structural similarity of the nanobody variable region to other mammalian Fab fragments, 
it was hypothesized that the LaP-1 nanobodies interacted with PrA through an analogous binding 
surface, rather than an Fc-like binding mechanism (Desmyter et al., 1996; Jansson et al., 1998).  
To test this, mutagenesis was done across the homologous sequences corresponding to this binding 
region (Figure A.5a) (Graille et al., 2000). Mutations in two residues, R21 and N85, eliminated 
PrA binding. These are both present in the homologous binding region, and expected to be 
necessary for PrA binding via an Fab-like interaction. A model of the proposed PrA:LaP-1 
interaction was also generated via homology to a PrA:Fab crystal structure (PDB ID: 1DEE) 
(Graille et al., 2000) using the program I-TASSER (Zhang, 2008; Roy et al., 2010; Roy et al., 
2012), and is consistent with the mutagenesis results (Figure A.5b). 
To investigate the specificity and versatility of these anti-PrA nanobodies, we assessed their 
effectiveness in ex vivo affinity isolations of PrA-tagged protein complexes from yeast and 
bacteria. LaP-1 and 2xLaP-1 proteins were conjugated to magnetic beads and used to isolate tagged   
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Figure A.5. Mapping of PrA:LaP-1 binding interface. (a) LaP-1 nanobodies with the designated 
point mutant were expressed in bacteria, and periplasmic extracts were incubated with 
PrA-Sepharose. For each mutant, input (I), flow-through (F), and elution (E) samples from the 
Sepharose binding were run by SDS-PAGE and Coomassie-stained. (b) The PrA:LaP-1 
interaction was modeled using I-TASSER, via LaP-1’s homology to Fab in a PrA:Fab crystal 
structure (PDB ID: 1DEE). The structure was visualized in PyMOL. Grey: LaP-1; Beige: PrA; 
Red: R21 and N85 residues, which are required for PrA binding.
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RNA polymerase from E. coli (Westblade et al., 2008), the S. cerevisiae Nup84 subcomplex of the 
nuclear pore complex (NPC) (Brohawn et al., 2009; Fernandez-Martinez et al., 2012) and mRNA 
cytoplasmic cap binding complex (Goyer et al., 1989) (Figure A.6a). In all cases, both the 
monomeric and dimeric LaP-1 proteins were able to efficiently isolate the targeted complex with 
yield and purity comparable to control affinity isolations with polyclonal IgG, and negligible non-
specific binding or contamination. The tandem affinity purification (TAP) tag is a frequently used 
PrA alternative, containing two artificial PrA Z domains (Rigaut et al., 1999). However, consistent 
with other studies showing weak binding between this Z domain and Fab fragments (Ljungberg et 
al., 1993; Jansson et al., 1998), our LaP-1 proteins are only able to recover very limited amounts 
of TAP-tagged protein in affinity isolations. The PrA Z domains in the TAP tag have only a single 
glycine to alanine point mutation however, so binding should be restored by reverting this 
mutation. 
In addition to these original LaP-1 proteins, we generated constructs containing an additional free 
cysteine at the C-terminus. Thiol chemistry can thus be targeted to the C-terminus, which allowed 
us to reversibly immobilize LaP-1 to magnetic amine-coated Dynabeads using an N-Succinimidyl 
3-(2-pyridyldithio)-propionate (SPDP) crosslinker with a 12 unit PEG spacer. This produces a 
disulfide-containing crosslink to the bead, which is easily cleavable in mild reducing conditions 
(Carlsson et al., 1975; Kiefer, 1975).  Beads with LaP-1 immobilized in this manner were tested 
in isolations of RNA polymerase, Nup84, and Cdc33 as before. Again, yield and purity comparable 
to IgG was observed, and by a short incubation with 25 mM DTT, 40-90% of the isolated protein 
could be eluted (Figure A.6b). This level of elution efficiency is comparable to that seen in other 
native methods of PrA release (Rigaut et al., 1999; LaCava et al., 2013). The complex-to-complex 
difference in yield is also a consistent phenomenon, likely due to differences in interactions with  
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Figure A.6. Affinity isolations performed with LaP-1 nanobodies. (A) LaP-1, 2xLaP-1, or rabbit 
IgG were conjugated to epoxy-activated magnetic beads and used to isolate E. coli RpoC-PrA (an 
RNA polymerase subunit), as well as S. cerevisiae Nup84-PrA (an NPC subcomplex component) 
and Cdc33-PrA (a protein in the mRNA cytoplasmic cap binding complex). Bands previously 
determined by MS are labeled. (B) LaP-1 was reversibly immobilized to magnetic beads using 
SPDP crosslinker, and used for affinity isolations as in (A). Bound protein was first eluted in 25 
mM DTT (DTT), before release of remaining bound protein in LDS (LDS). The yield of protein 
recovered in the DTT elution step, as compared to total eluted protein, is listed with the s.e.m. All 
experiments were performed in duplicate. 
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the bead surface. This approach does necessarily lead to release of both PrA-associated and 
unassociated LaP-1 nanobody in the elution.  Due to the small size (13 kDa) of LaP-1 however, an 
additional purification step, such as gradient centrifugation, which is often necessary for sensitive 
downstream applications like electron microscopy, can easily remove unbound nanobody. 
In either monomeric or dimeric form, the LaP-1 nanobody is suitable for highly efficient isolation 
of PrA-tagged protein targets. As a small recombinant protein, it is an especially flexible reagent, 
as shown in its use in native elutions of protein complexes, making it a convenient option for any 
application making use of a PrA-based tag. 
  
146
References 
Abruzzi, K.C., Lacadie, S. and Rosbash, M., 2004, Biochemical analysis of TREX complex 
recruitment to intronless and intron-containing yeast genes. EMBO J 23, 2620-31. 
Alber, F., Dokudovskaya, S., Veenhoff, L.M., Zhang, W., Kipper, J., Devos, D., Suprapto, A., 
Karni-Schmidt, O., Williams, R., Chait, B.T., Rout, M.P. and Sali, A., 2007, Determining 
the architectures of macromolecular assemblies. Nature 450, 683-94. 
Alcazar-Roman, A.R., Tran, E.J., Guo, S. and Wente, S.R., 2006, Inositol hexakisphosphate and 
Gle1 activate the DEAD-box protein Dbp5 for nuclear mRNA export. Nat Cell Biol 8, 711-
6. 
Alexander, R.D., Barrass, J.D., Dichtl, B., Kos, M., Obtulowicz, T., Robert, M.C., Koper, M., 
Karkusiewicz, I., Mariconti, L., Tollervey, D., Kufel, J., Bertrand, E. and Beggs, J.D., 
2010, RiboSys, a high-resolution, quantitative approach to measure the in vivo kinetics of 
pre-mRNA splicing and 3'-end processing in Saccharomyces cerevisiae. RNA 16, 2570-
80. 
Alvarez-Rueda, N., Behar, G., Ferre, V., Pugniere, M., Roquet, F., Gastinel, L., Jacquot, C., Aubry, 
J., Baty, D., Barbet, J. and Birkle, S., 2007, Generation of llama single-domain antibodies 
against methotrexate, a prototypical hapten. Mol Immunol 44, 1680-90. 
Arava, Y., Wang, Y., Storey, J.D., Liu, C.L., Brown, P.O. and Herschlag, D., 2003, Genome-wide 
analysis of mRNA translation profiles in Saccharomyces cerevisiae. Proc Natl Acad Sci U 
S A 100, 3889-94. 
Arbabi-Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R. and Muyldermans, S., 1997, Selection 
and identification of single domain antibody fragments from camel heavy-chain antibodies. 
FEBS letters 414, 521-6. 
Arbabi-Ghahroudi, M., Tanha, J. and MacKenzie, R., 2005, Prokaryotic expression of antibodies. 
Cancer Metastasis Rev 24, 501-19. 
Austin, R.J., Xia, T., Ren, J., Takahashi, T.T. and Roberts, R.W., 2002, Designed arginine-rich 
RNA-binding peptides with picomolar affinity. J Am Chem Soc 124, 10966-7. 
Bachler, M., Schroeder, R. and von Ahsen, U., 1999, StreptoTag: a novel method for the isolation 
of RNA-binding proteins. RNA 5, 1509-16. 
Baejen, C., Torkler, P., Gressel, S., Essig, K., Soding, J. and Cramer, P., 2014, Transcriptome 
maps of mRNP biogenesis factors define pre-mRNA recognition. Mol Cell 55, 745-57. 
Bantscheff, M., Schirle, M., Sweetman, G., Rick, J. and Kuster, B., 2007, Quantitative mass 
spectrometry in proteomics: a critical review. Anal Bioanal Chem 389, 1017-31. 
Bardwell, V.J. and Wickens, M., 1990, Purification of RNA and RNA-protein complexes by an 
R17 coat protein affinity method. Nucleic Acids Res 18, 6587-94. 
147
Baron-Benhamou, J., Gehring, N.H., Kulozik, A.E. and Hentze, M.W., 2004, Using the lambdaN 
peptide to tether proteins to RNAs. Methods Mol Biol 257, 135-54. 
Barthelemy, F., Wein, N., Krahn, M., Levy, N. and Bartoli, M., 2011, Translational research and 
therapeutic perspectives in dysferlinopathies. Mol Med 17, 875-82. 
Batisse, J., Batisse, C., Budd, A., Bottcher, B. and Hurt, E., 2009, Purification of nuclear poly(A)-
binding protein Nab2 reveals association with the yeast transcriptome and a messenger 
ribonucleoprotein core structure. J Biol Chem 284, 34911-7. 
Battistutta, R., Negro, A. and Zanotti, G., 2000, Crystal structure and refolding properties of the 
mutant F99S/M153T/V163A of the green fluorescent protein. Proteins 41, 429-37. 
Becker, R.S. and Knight, K.L., 1990, Somatic diversification of immunoglobulin heavy chain VDJ 
genes: evidence for somatic gene conversion in rabbits. Cell 63, 987-97. 
Benner, R., Hijmans, W. and Haaijman, J.J., 1981, The bone marrow: the major source of serum 
immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol 46, 
1-8. 
Bertrand, E., Chartrand, P., Schaefer, M., Shenoy, S.M., Singer, R.H. and Long, R.M., 1998, 
Localization of ASH1 mRNA particles in living yeast. Mol Cell 2, 437-45. 
Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B.M., Lee, S.M., Lee, T., Pope, 
S.H., Riordan, G.S. and Whitlow, M., 1988, Single-chain antigen-binding proteins. Science 
242, 423-6. 
Bobola, N., Jansen, R.P., Shin, T.H. and Nasmyth, K., 1996, Asymmetric accumulation of Ash1p 
in postanaphase nuclei depends on a myosin and restricts yeast mating-type switching to 
mother cells. Cell 84, 699-709. 
Bousquet-Antonelli, C., Presutti, C. and Tollervey, D., 2000, Identification of a regulated pathway 
for nuclear pre-mRNA turnover. Cell 102, 765-75. 
Bregman, A., Avraham-Kelbert, M., Barkai, O., Duek, L., Guterman, A. and Choder, M., 2011, 
Promoter elements regulate cytoplasmic mRNA decay. Cell 147, 1473-83. 
Brohawn, S.G., Partridge, J.R., Whittle, J.R. and Schwartz, T.U., 2009, The nuclear pore complex 
has entered the atomic age. Structure 17, 1156-68. 
Butter, F., Scheibe, M., Morl, M. and Mann, M., 2009, Unbiased RNA-protein interaction screen 
by quantitative proteomics. Proc Natl Acad Sci U S A 106, 10626-31. 
Carey, J., Cameron, V., de Haseth, P.L. and Uhlenbeck, O.C., 1983, Sequence-specific interaction 
of R17 coat protein with its ribonucleic acid binding site. Biochemistry 22, 2601-10. 
Carlsson, J., Axen, R. and Unge, T., 1975, Reversible, covalent immobilization of enzymes by 
thiol-disulphide interchange. European journal of biochemistry / FEBS 59, 567-72. 
148
Carrillo Oesterreich, F., Preibisch, S. and Neugebauer, K.M., 2010, Global analysis of nascent 
RNA reveals transcriptional pausing in terminal exons. Molecular cell 40, 571-81. 
Casolari, J.M., Brown, C.R., Komili, S., West, J., Hieronymus, H. and Silver, P.A., 2004, Genome-
wide localization of the nuclear transport machinery couples transcriptional status and 
nuclear organization. Cell 117, 427-39. 
Castello, A., Fischer, B., Eichelbaum, K., Horos, R., Beckmann, B.M., Strein, C., Davey, N.E., 
Humphreys, D.T., Preiss, T., Steinmetz, L.M., Krijgsveld, J. and Hentze, M.W., 2012, 
Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149, 
1393-406. 
Chanarat, S., Seizl, M. and Strasser, K., 2011, The Prp19 complex is a novel transcription 
elongation factor required for TREX occupancy at transcribed genes. Genes Dev 25, 1147-
58. 
Chao, J.A., Patskovsky, Y., Almo, S.C. and Singer, R.H., 2008, Structural basis for the coevolution 
of a viral RNA-protein complex. Nat Struct Mol Biol 15, 103-5. 
Cheng, H., Dufu, K., Lee, C.S., Hsu, J.L., Dias, A. and Reed, R., 2006, Human mRNA export 
machinery recruited to the 5' end of mRNA. Cell 127, 1389-400. 
Cho, E.J., Takagi, T., Moore, C.R. and Buratowski, S., 1997, mRNA capping enzyme is recruited 
to the transcription complex by phosphorylation of the RNA polymerase II carboxy-
terminal domain. Genes Dev 11, 3319-26. 
Churchman, L.S. and Weissman, J.S., 2011, Nascent transcript sequencing visualizes transcription 
at nucleotide resolution. Nature 469, 368-73. 
Conrath, K.E., Lauwereys, M., Galleni, M., Matagne, A., Frere, J.M., Kinne, J., Wyns, L. and 
Muyldermans, S., 2001, Beta-lactamase inhibitors derived from single-domain antibody 
fragments elicited in the camelidae. Antimicrob Agents Chemother 45, 2807-12. 
Cordingley, M.G., Register, R.B., Callahan, P.L., Garsky, V.M. and Colonno, R.J., 1989, Cleavage 
of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia 
coli. J Virol 63, 5037-45. 
Cortez-Retamozo, V., Backmann, N., Senter, P.D., Wernery, U., De Baetselier, P., Muyldermans, 
S. and Revets, H., 2004, Efficient cancer therapy with a nanobody-based conjugate. Cancer 
Res 64, 2853-7. 
Cotten, M., Oberhauser, B., Brunar, H., Holzner, A., Issakides, G., Noe, C.R., Schaffner, G., 
Wagner, E. and Birnstiel, M.L., 1991, 2'-O-methyl, 2'-O-ethyl oligoribonucleotides and 
phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-
dependent mRNA processing event. Nucleic Acids Res 19, 2629-35. 
Couzin-Frankel, J., 2013, Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 
1432-3. 
149
Cristea, I.M., Williams, R., Chait, B.T. and Rout, M.P., 2005, Fluorescent proteins as proteomic 
probes. Molecular & cellular proteomics : MCP 4, 1933-41. 
Daigle, N. and Ellenberg, J., 2007, LambdaN-GFP: an RNA reporter system for live-cell imaging. 
Nat Methods 4, 633-6. 
DeGrasse, J.A., DuBois, K.N., Devos, D., Siegel, T.N., Sali, A., Field, M.C., Rout, M.P. and Chait, 
B.T., 2009, Evidence for a shared nuclear pore complex architecture that is conserved from 
the last common eukaryotic ancestor. Molecular & cellular proteomics : MCP 8, 2119-30. 
Dereeper, A., Audic, S., Claverie, J.M. and Blanc, G., 2010, BLAST-EXPLORER helps you 
building datasets for phylogenetic analysis. BMC Evol Biol 10, 8. 
Dereeper, A., Guignon, V., Blanc, G., Audic, S., Buffet, S., Chevenet, F., Dufayard, J.F., Guindon, 
S., Lefort, V., Lescot, M., Claverie, J.M. and Gascuel, O., 2008, Phylogeny.fr: robust 
phylogenetic analysis for the non-specialist. Nucleic acids research 36, W465-9. 
Desmyter, A., Transue, T.R., Ghahroudi, M.A., Thi, M.H., Poortmans, F., Hamers, R., 
Muyldermans, S. and Wyns, L., 1996, Crystal structure of a camel single-domain VH 
antibody fragment in complex with lysozyme. Nat Struct Biol 3, 803-11. 
Dieppois, G., Iglesias, N. and Stutz, F., 2006, Cotranscriptional recruitment to the mRNA export 
receptor Mex67p contributes to nuclear pore anchoring of activated genes. Mol Cell Biol 
26, 7858-70. 
Dieppois, G. and Stutz, F., 2010, Connecting the transcription site to the nuclear pore: a multi-
tether process that regulates gene expression. J Cell Sci 123, 1989-99. 
Dolman, N.J., Kilgore, J.A. and Davidson, M.W., 2013, A review of reagents for fluorescence 
microscopy of cellular compartments and structures, part I: BacMam labeling and reagents 
for vesicular structures. Curr Protoc Cytom Chapter 12, Unit 12 30. 
Domanski, M., Molloy, K., Jiang, H., Chait, B.T., Rout, M.P., Jensen, T.H. and LaCava, J., 2012, 
Improved methodology for the affinity isolation of human protein complexes expressed at 
near endogenous levels. Biotechniques 0, 1-6. 
Dong, S., Li, C., Zenklusen, D., Singer, R.H., Jacobson, A. and He, F., 2007, YRA1 autoregulation 
requires nuclear export and cytoplasmic Edc3p-mediated degradation of its pre-mRNA. 
Mol Cell 25, 559-73. 
Dorner, T. and Radbruch, A., 2007, Antibodies and B cell memory in viral immunity. Immunity 
27, 384-92. 
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L.G., 
Muyldermans, S., Wyns, L. and Matagne, A., 2002, Single-domain antibody fragments 
with high conformational stability. Protein Sci 11, 500-15. 
150
Els Conrath, K., Lauwereys, M., Wyns, L. and Muyldermans, S., 2001, Camel single-domain 
antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol 
Chem 276, 7346-50. 
Fabrizio, P., Dannenberg, J., Dube, P., Kastner, B., Stark, H., Urlaub, H. and Luhrmann, R., 2009, 
The evolutionarily conserved core design of the catalytic activation step of the yeast 
spliceosome. Mol Cell 36, 593-608. 
Fernandez-Martinez, J., Phillips, J., Sekedat, M.D., Diaz-Avalos, R., Velazquez-Muriel, J., 
Franke, J.D., Williams, R., Stokes, D.L., Chait, B.T., Sali, A. and Rout, M.P., 2012, 
Structure-function mapping of a heptameric module in the nuclear pore complex. The 
Journal of Cell Biology 196, 419-34. 
Fink, D., Wohrer, S., Pfeffer, M., Tombe, T., Ong, C.J. and Sorensen, P.H., 2010, Ubiquitous 
expression of the monomeric red fluorescent protein mCherry in transgenic mice. Genesis 
48, 723-9. 
Fortes, P., Inada, T., Preiss, T., Hentze, M.W., Mattaj, I.W. and Sachs, A.B., 2000, The yeast 
nuclear cap binding complex can interact with translation factor eIF4G and mediate 
translation initiation. Molecular cell 6, 191-6. 
Franklin, N.C., 1985, Conservation of Genome Form but Not Sequence in the Transcription 
Antitermination Determinants of Bacteriophage-Lambda, Bacteriophage-Phi-21 and 
Bacteriophage-P22. Journal of Molecular Biology 181, 75-84. 
Frenken, L.G., van der Linden, R.H., Hermans, P.W., Bos, J.W., Ruuls, R.C., de Geus, B. and 
Verrips, C.T., 2000, Isolation of antigen specific llama VHH antibody fragments and their 
high level secretion by Saccharomyces cerevisiae. J Biotechnol 78, 11-21. 
Fridy, P.C., Li, Y., Keegan, S., Thompson, M.K., Nudelman, I., Scheid, J.F., Oeffinger, M., 
Nussenzweig, M.C., Fenyo, D., Chait, B.T. and Rout, M.P., 2014, A robust pipeline for 
rapid production of versatile nanobody repertoires. Nat Methods 11, 1253-60. 
Fridy, P.C., Thompson, M.K., Ketaren, N.E. and Rout, M.P., 2015, Engineered high-affinity 
nanobodies recognizing staphylococcal Protein A and suitable for native isolation of 
protein complexes. Anal Biochem 477, 92-4. 
Fusco, D., Accornero, N., Lavoie, B., Shenoy, S.M., Blanchard, J.M., Singer, R.H. and Bertrand, 
E., 2003, Single mRNA molecules demonstrate probabilistic movement in living 
mammalian cells. Curr Biol 13, 161-7. 
Futcher, A.B. and Cox, B.S., 1984, Copy number and the stability of 2-micron circle-based 
artificial plasmids of Saccharomyces cerevisiae. J Bacteriol 157, 283-90. 
Gallouzi, I.E. and Steitz, J.A., 2001, Delineation of mRNA export pathways by the use of cell-
permeable peptides. Science 294, 1895-901. 
151
Gallwitz, D. and Sures, I., 1980, Structure of a split yeast gene: complete nucleotide sequence of 
the actin gene in Saccharomyces cerevisiae. P Natl Acad Sci USA 77, 2546-50. 
Galy, V., Gadal, O., Fromont-Racine, M., Romano, A., Jacquier, A. and Nehrbass, U., 2004, 
Nuclear retention of unspliced mRNAs in yeast is mediated by perinuclear Mlp1. Cell 116, 
63-73. 
Gavin, A.C., Aloy, P., Grandi, P., Krause, R., Boesche, M., Marzioch, M., Rau, C., Jensen, L.J., 
Bastuck, S., Dumpelfeld, B., Edelmann, A., Heurtier, M.A., Hoffman, V., Hoefert, C., 
Klein, K., Hudak, M., Michon, A.M., Schelder, M., Schirle, M., Remor, M., Rudi, T., 
Hooper, S., Bauer, A., Bouwmeester, T., Casari, G., Drewes, G., Neubauer, G., Rick, J.M., 
Kuster, B., Bork, P., Russell, R.B. and Superti-Furga, G., 2006, Proteome survey reveals 
modularity of the yeast cell machinery. Nature 440, 631-6. 
Gavin, A.C., Bosche, M., Krause, R., Grandi, P., Marzioch, M., Bauer, A., Schultz, J., Rick, J.M., 
Michon, A.M., Cruciat, C.M., Remor, M., Hofert, C., Schelder, M., Brajenovic, M., 
Ruffner, H., Merino, A., Klein, K., Hudak, M., Dickson, D., Rudi, T., Gnau, V., Bauch, 
A., Bastuck, S., Huhse, B., Leutwein, C., Heurtier, M.A., Copley, R.R., Edelmann, A., 
Querfurth, E., Rybin, V., Drewes, G., Raida, M., Bouwmeester, T., Bork, P., Seraphin, B., 
Kuster, B., Neubauer, G. and Superti-Furga, G., 2002, Functional organization of the yeast 
proteome by systematic analysis of protein complexes. Nature 415, 141-7. 
Gavrieli, M., Sedy, J., Nelson, C.A. and Murphy, K.M., 2006, BTLA and HVEM cross talk 
regulates inhibition and costimulation. Adv Immunol 92, 157-85. 
Geiger, T., Cox, J. and Mann, M., 2010, Proteomics on an Orbitrap benchtop mass spectrometer 
using all-ion fragmentation. Mol Cell Proteomics 9, 2252-61. 
Georgescu, J., Rehm, T., Wiehler, J., Steipe, B. and Holak, T.A., 2003, Backbone H(N), N, 
C(alpha) and C(beta) assignment of the GFPuv mutant. Journal of biomolecular NMR 25, 
161-2. 
Ghaemmaghami, S., Huh, W.K., Bower, K., Howson, R.W., Belle, A., Dephoure, N., O'Shea, E.K. 
and Weissman, J.S., 2003, Global analysis of protein expression in yeast. Nature 425, 737-
41. 
Gilbert, W. and Guthrie, C., 2004, The Glc7p nuclear phosphatase promotes mRNA export by 
facilitating association of Mex67p with mRNA. Mol Cell 13, 201-12. 
Gilbert, W., Siebel, C.W. and Guthrie, C., 2001, Phosphorylation by Sky1p promotes Npl3p 
shuttling and mRNA dissociation. RNA 7, 302-13. 
Gingras, A.C., Aebersold, R. and Raught, B., 2005, Advances in protein complex analysis using 
mass spectrometry. J Physiol 563, 11-21. 
Gingras, A.C., Raught, B. and Sonenberg, N., 1999, eIF4 initiation factors: effectors of mRNA 
recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68, 913-63. 
152
Goldflam, M., Tarrago, T., Gairi, M. and Giralt, E., 2012, NMR studies of protein-ligand 
interactions. Methods in molecular biology 831, 233-59. 
Gornemann, J., Kotovic, K.M., Hujer, K. and Neugebauer, K.M., 2005, Cotranscriptional 
spliceosome assembly occurs in a stepwise fashion and requires the cap binding complex. 
Mol Cell 19, 53-63. 
Goyer, C., Altmann, M., Trachsel, H. and Sonenberg, N., 1989, Identification and characterization 
of cap-binding proteins from yeast. The Journal of biological chemistry 264, 7603-10. 
Graille, M., Stura, E.A., Corper, A.L., Sutton, B.J., Taussig, M.J., Charbonnier, J.B. and 
Silverman, G.J., 2000, Crystal structure of a Staphylococcus aureus protein A domain 
complexed with the Fab fragment of a human IgM antibody: structural basis for recognition 
of B-cell receptors and superantigen activity. P Natl Acad Sci USA 97, 5399-404. 
Greenberg, A.S., Avila, D., Hughes, M., Hughes, A., McKinney, E.C. and Flajnik, M.F., 1995, A 
new antigen receptor gene family that undergoes rearrangement and extensive somatic 
diversification in sharks. Nature 374, 168-73. 
Grunwald, D. and Singer, R.H., 2010, In vivo imaging of labelled endogenous beta-actin mRNA 
during nucleocytoplasmic transport. Nature 467, 604-7. 
Grunweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V.A. and Kurreck, J., 2003, 
Comparison of different antisense strategies in mammalian cells using locked nucleic 
acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 
31, 3185-93. 
Gruter, P., Tabernero, C., von Kobbe, C., Schmitt, C., Saavedra, C., Bachi, A., Wilm, M., Felber, 
B.K. and Izaurralde, E., 1998, TAP, the human homolog of Mex67p, mediates CTE-
dependent RNA export from the nucleus. Mol Cell 1, 649-59. 
Gupta, R.A., Shah, N., Wang, K.C., Kim, J., Horlings, H.M., Wong, D.J., Tsai, M.C., Hung, T., 
Argani, P., Rinn, J.L., Wang, Y., Brzoska, P., Kong, B., Li, R., West, R.B., van de Vijver, 
M.J., Sukumar, S. and Chang, H.Y., 2010, Long non-coding RNA HOTAIR reprograms 
chromatin state to promote cancer metastasis. Nature 464, 1071-6. 
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E.B., 
Bendahman, N. and Hamers, R., 1993, Naturally occurring antibodies devoid of light 
chains. Nature 363, 446-8. 
Harmsen, M.M. and De Haard, H.J., 2007, Properties, production, and applications of camelid 
single-domain antibody fragments. Appl Microbiol Biotechnol 77, 13-22. 
Hartmuth, K., Urlaub, H., Vornlocher, H.P., Will, C.L., Gentzel, M., Wilm, M. and Luhrmann, R., 
2002, Protein composition of human prespliceosomes isolated by a tobramycin affinity-
selection method. Proc Natl Acad Sci U S A 99, 16719-24. 
153
Heim, R., Prasher, D.C. and Tsien, R.Y., 1994, Wavelength mutations and posttranslational 
autoxidation of green fluorescent protein. Proc Natl Acad Sci U S A 91, 12501-4. 
Hereford, L.M. and Rosbash, M., 1977, Number and distribution of polyadenylated RNA 
sequences in yeast. Cell 10, 453-62. 
Hieronymus, H. and Silver, P.A., 2003, Genome-wide analysis of RNA-protein interactions 
illustrates specificity of the mRNA export machinery. Nat Genet 33, 155-61. 
Hilleren, P., McCarthy, T., Rosbash, M., Parker, R. and Jensen, T.H., 2001, Quality control of 
mRNA 3'-end processing is linked to the nuclear exosome. Nature 413, 538-42. 
Ho, Y., Gruhler, A., Heilbut, A., Bader, G.D., Moore, L., Adams, S.L., Millar, A., Taylor, P., 
Bennett, K., Boutilier, K., Yang, L., Wolting, C., Donaldson, I., Schandorff, S., 
Shewnarane, J., Vo, M., Taggart, J., Goudreault, M., Muskat, B., Alfarano, C., Dewar, D., 
Lin, Z., Michalickova, K., Willems, A.R., Sassi, H., Nielsen, P.A., Rasmussen, K.J., 
Andersen, J.R., Johansen, L.E., Hansen, L.H., Jespersen, H., Podtelejnikov, A., Nielsen, 
E., Crawford, J., Poulsen, V., Sorensen, B.D., Matthiesen, J., Hendrickson, R.C., Gleeson, 
F., Pawson, T., Moran, M.F., Durocher, D., Mann, M., Hogue, C.W., Figeys, D. and Tyers, 
M., 2002, Systematic identification of protein complexes in Saccharomyces cerevisiae by 
mass spectrometry. Nature 415, 180-3. 
Hocine, S., Raymond, P., Zenklusen, D., Chao, J.A. and Singer, R.H., 2013, Single-molecule 
analysis of gene expression using two-color RNA labeling in live yeast. Nature methods 
10, 119-21. 
Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, 
R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eertwegh, A.J., Lutzky, 
J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbe, C., 
Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, 
G.M., Hoos, A. and Urba, W.J., 2010, Improved survival with ipilimumab in patients with 
metastatic melanoma. N Engl J Med 363, 711-23. 
Hogan, D.J., Riordan, D.P., Gerber, A.P., Herschlag, D. and Brown, P.O., 2008, Diverse RNA-
binding proteins interact with functionally related sets of RNAs, suggesting an extensive 
regulatory system. PLoS Biol 6, e255. 
Hogg, J.R. and Collins, K., 2007, RNA-based affinity purification reveals 7SK RNPs with distinct 
composition and regulation. RNA 13, 868-80. 
Hogg, J.R. and Goff, S.P., 2010, Upf1 senses 3'UTR length to potentiate mRNA decay. Cell 143, 
379-89. 
Holstege, F.C., Jennings, E.G., Wyrick, J.J., Lee, T.I., Hengartner, C.J., Green, M.R., Golub, T.R., 
Lander, E.S. and Young, R.A., 1998, Dissecting the regulatory circuitry of a eukaryotic 
genome. Cell 95, 717-28. 
154
Huang, L., Muyldermans, S. and Saerens, D., 2010, Nanobodies(R): proficient tools in diagnostics. 
Expert Rev Mol Diagn 10, 777-85. 
Huang, Y., Verheesen, P., Roussis, A., Frankhuizen, W., Ginjaar, I., Haldane, F., Laval, S., 
Anderson, L.V., Verrips, T., Frants, R.R., de Haard, H., Bushby, K., den Dunnen, J. and 
van der Maarel, S.M., 2005, Protein studies in dysferlinopathy patients using llama-derived 
antibody fragments selected by phage display. Eur J Hum Genet 13, 721-30. 
Hurt, E., Luo, M.J., Rother, S., Reed, R. and Strasser, K., 2004, Cotranscriptional recruitment of 
the serine-arginine-rich (SR)-like proteins Gbp2 and Hrb1 to nascent mRNA via the TREX 
complex. Proc Natl Acad Sci U S A 101, 1858-62. 
Hurt, E., Strasser, K., Segref, A., Bailer, S., Schlaich, N., Presutti, C., Tollervey, D. and Jansen, 
R., 2000, Mex67p mediates nuclear export of a variety of RNA polymerase II transcripts. 
J Biol Chem 275, 8361-8. 
Huston, J.S., Levinson, D., Mudgetthunter, M., Tai, M.S., Novotny, J., Margolies, M.N., Ridge, 
R.J., Bruccoleri, R.E., Haber, E., Crea, R. and Oppermann, H., 1988, Protein Engineering 
of Antibody-Binding Sites - Recovery of Specific Activity in an Anti-Digoxin Single-
Chain Fv Analog Produced in Escherichia-Coli. P Natl Acad Sci USA 85, 5879-5883. 
Hutchins, J.R., Toyoda, Y., Hegemann, B., Poser, I., Heriche, J.K., Sykora, M.M., Augsburg, M., 
Hudecz, O., Buschhorn, B.A., Bulkescher, J., Conrad, C., Comartin, D., Schleiffer, A., 
Sarov, M., Pozniakovsky, A., Slabicki, M.M., Schloissnig, S., Steinmacher, I., Leuschner, 
M., Ssykor, A., Lawo, S., Pelletier, L., Stark, H., Nasmyth, K., Ellenberg, J., Durbin, R., 
Buchholz, F., Mechtler, K., Hyman, A.A. and Peters, J.M., 2010, Systematic analysis of 
human protein complexes identifies chromosome segregation proteins. Science 328, 593-
9. 
Iglesias, N. and Stutz, F., 2008, Regulation of mRNP dynamics along the export pathway. FEBS 
Lett 582, 1987-96. 
Iglesias, N., Tutucci, E., Gwizdek, C., Vinciguerra, P., Von Dach, E., Corbett, A.H., Dargemont, 
C. and Stutz, F., 2010, Ubiquitin-mediated mRNP dynamics and surveillance prior to 
budding yeast mRNA export. Genes Dev 24, 1927-38. 
Inoue, H., Hayase, Y., Imura, A., Iwai, S., Miura, K. and Ohtsuka, E., 1987, Synthesis and 
hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides. Nucleic 
acids research 15, 6131-48. 
Jahnichen, S., Blanchetot, C., Maussang, D., Gonzalez-Pajuelo, M., Chow, K.Y., Bosch, L., De 
Vrieze, S., Serruys, B., Ulrichts, H., Vandevelde, W., Saunders, M., De Haard, H.J., Schols, 
D., Leurs, R., Vanlandschoot, P., Verrips, T. and Smit, M.J., 2010, CXCR4 nanobodies 
(VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication 
and mobilize stem cells. Proc Natl Acad Sci U S A 107, 20565-70. 
155
Jansen, R., Bussemaker, H.J. and Gerstein, M., 2003, Revisiting the codon adaptation index from 
a whole-genome perspective: analyzing the relationship between gene expression and 
codon occurrence in yeast using a variety of models. Nucleic Acids Res 31, 2242-51. 
Jansen, R.P., Dowzer, C., Michaelis, C., Galova, M. and Nasmyth, K., 1996, Mother cell-specific 
HO expression in budding yeast depends on the unconventional myosin myo4p and other 
cytoplasmic proteins. Cell 84, 687-97. 
Jansson, B., Uhlen, M. and Nygren, P.A., 1998, All individual domains of staphylococcal protein 
A show Fab binding. FEMS Immunol Med Microbiol 20, 69-78. 
Jimeno, S., Rondon, A.G., Luna, R. and Aguilera, A., 2002, The yeast THO complex and mRNA 
export factors link RNA metabolism with transcription and genome instability. The EMBO 
journal 21, 3526-35. 
Jorgensen, P., Edgington, N.P., Schneider, B.L., Rupes, I., Tyers, M. and Futcher, B., 2007, The 
size of the nucleus increases as yeast cells grow. Mol Biol Cell 18, 3523-32. 
Kafri, M., Metzl-Raz, E., Jona, G. and Barkai, N., 2016, The Cost of Protein Production. Cell Rep 
14, 22-31. 
Khan, F., Stott, K. and Jackson, S., 2003, 1H, 15N and 13C backbone assignment of the green 
fluorescent protein (GFP). Journal of biomolecular NMR 26, 281-2. 
Kiefer, H., 1975, Separation of antigen-specific lymphocytes. A new general method of releasing 
cells bound to nylon mesh. Eur J Immunol 5, 624-8. 
Kim Guisbert, K., Duncan, K., Li, H. and Guthrie, C., 2005, Functional specificity of shuttling 
hnRNPs revealed by genome-wide analysis of their RNA binding profiles. RNA 11, 383-
93. 
Kimmel, J.R. and Smith, E.L., 1954, Crystalline papain. I. Preparation, specificity, and activation. 
The Journal of biological chemistry 207, 515-31. 
Kirchhofer, A., Helma, J., Schmidthals, K., Frauer, C., Cui, S., Karcher, A., Pellis, M., 
Muyldermans, S., Casas-Delucchi, C.S., Cardoso, M.C., Leonhardt, H., Hopfner, K.P. and 
Rothbauer, U., 2010, Modulation of protein properties in living cells using nanobodies. 
Nature structural & molecular biology 17, 133-8. 
Knight, K.L., 1992, Restricted VH gene usage and generation of antibody diversity in rabbit. Annu 
Rev Immunol 10, 593-616. 
Kohler, A. and Hurt, E., 2007, Exporting RNA from the nucleus to the cytoplasm. Nat Rev Mol 
Cell Biol 8, 761-73. 
Kotovic, K.M., Lockshon, D., Boric, L. and Neugebauer, K.M., 2003, Cotranscriptional 
recruitment of the U1 snRNP to intron-containing genes in yeast. Molecular and cellular 
biology 23, 5768-79. 
156
Kozak, M. and Nathans, D., 1972, Translation of the genome of a ribonucleic acid bacteriophage. 
Bacteriol Rev 36, 109-34. 
Kress, T.L., Krogan, N.J. and Guthrie, C., 2008, A single SR-like protein, Npl3, promotes pre-
mRNA splicing in budding yeast. Mol Cell 32, 727-34. 
Krissinel, E. and Henrick, K., 2007, Inference of macromolecular assemblies from crystalline state. 
Journal of molecular biology 372, 774-97. 
Krogan, N.J., Cagney, G., Yu, H., Zhong, G., Guo, X., Ignatchenko, A., Li, J., Pu, S., Datta, N., 
Tikuisis, A.P., Punna, T., Peregrin-Alvarez, J.M., Shales, M., Zhang, X., Davey, M., 
Robinson, M.D., Paccanaro, A., Bray, J.E., Sheung, A., Beattie, B., Richards, D.P., 
Canadien, V., Lalev, A., Mena, F., Wong, P., Starostine, A., Canete, M.M., Vlasblom, J., 
Wu, S., Orsi, C., Collins, S.R., Chandran, S., Haw, R., Rilstone, J.J., Gandi, K., Thompson, 
N.J., Musso, G., St Onge, P., Ghanny, S., Lam, M.H., Butland, G., Altaf-Ul, A.M., Kanaya, 
S., Shilatifard, A., O'Shea, E., Weissman, J.S., Ingles, C.J., Hughes, T.R., Parkinson, J., 
Gerstein, M., Wodak, S.J., Emili, A. and Greenblatt, J.F., 2006, Global landscape of protein 
complexes in the yeast Saccharomyces cerevisiae. Nature 440, 637-43. 
Krutchinsky, A.N., Kalkum, M. and Chait, B.T., 2001, Automatic identification of proteins with a 
MALDI-quadrupole ion trap mass spectrometer. Anal Chem 73, 5066-77. 
Kumar, R., Singh, S.K., Koshkin, A.A., Rajwanshi, V.K., Meldgaard, M. and Wengel, J., 1998, 
The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-
LNA. Bioorg Med Chem Lett 8, 2219-22. 
Lacadie, S.A. and Rosbash, M., 2005, Cotranscriptional spliceosome assembly dynamics and the 
role of U1 snRNA:5'ss base pairing in yeast. Mol Cell 19, 65-75. 
LaCava, J., Chandramouli, N., Jiang, H. and Rout, M.P., 2013, Improved native isolation of 
endogenous Protein A-tagged protein complexes. Biotechniques 54, 213-6. 
Larsen, H.J., Bentin, T. and Nielsen, P.E., 1999, Antisense properties of peptide nucleic acid. 
Biochim Biophys Acta 1489, 159-66. 
Larson, D.R., Singer, R.H. and Zenklusen, D., 2009, A single molecule view of gene expression. 
Trends Cell Biol 19, 630-7. 
Leach, D.R., Krummel, M.F. and Allison, J.P., 1996, Enhancement of antitumor immunity by 
CTLA-4 blockade. Science 271, 1734-6. 
Lei, E.P. and Silver, P.A., 2002, Intron status and 3'-end formation control cotranscriptional export 
of mRNA. Genes & development 16, 2761-6. 
Lewis, J.D., Gorlich, D. and Mattaj, I.W., 1996, A yeast cap binding protein complex (yCBC) acts 
at an early step in pre-mRNA splicing. Nucleic Acids Res 24, 3332-6. 
157
Lewis, J.D. and Izaurralde, E., 1997, The role of the cap structure in RNA processing and nuclear 
export. Eur J Biochem 247, 461-9. 
Lim, F., Downey, T.P. and Peabody, D.S., 2001, Translational repression and specific RNA 
binding by the coat protein of the Pseudomonas phage PP7. The Journal of biological 
chemistry 276, 22507-13. 
Lindborg, M., Dubnovitsky, A., Olesen, K., Bjorkman, T., Abrahmsen, L., Feldwisch, J. and Hard, 
T., 2013, High-affinity binding to staphylococcal protein A by an engineered dimeric 
Affibody molecule. Protein Eng Des Sel 26, 635-44. 
Lindmark, R., Thoren-Tolling, K. and Sjoquist, J., 1983, Binding of immunoglobulins to protein 
A and immunoglobulin levels in mammalian sera. J Immunol Methods 62, 1-13. 
Ljungberg, U.K., Jansson, B., Niss, U., Nilsson, R., Sandberg, B.E. and Nilsson, B., 1993, The 
interaction between different domains of staphylococcal protein A and human polyclonal 
IgG, IgA, IgM and F(ab')2: separation of affinity from specificity. Mol Immunol 30, 1279-
85. 
Long, R.M., Gu, W., Lorimer, E., Singer, R.H. and Chartrand, P., 2000, She2p is a novel RNA-
binding protein that recruits the Myo4p-She3p complex to ASH1 mRNA. EMBO J 19, 
6592-601. 
Lopes, T.S., Klootwijk, J., Veenstra, A.E., van der Aar, P.C., van Heerikhuizen, H., Raue, H.A. 
and Planta, R.J., 1989, High-copy-number integration into the ribosomal DNA of 
Saccharomyces cerevisiae: a new vector for high-level expression. Gene 79, 199-206. 
Lund, M.K. and Guthrie, C., 2005, The DEAD-box protein Dbp5p is required to dissociate 
Mex67p from exported mRNPs at the nuclear rim. Mol Cell 20, 645-51. 
Maass, D.R., Sepulveda, J., Pernthaner, A. and Shoemaker, C.B., 2007, Alpaca (Lama pacos) as a 
convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol 
Methods 324, 13-25. 
Maleki, L.A., Baradaran, B., Majidi, J., Mohammadian, M. and Shahneh, F.Z., 2013, Future 
prospects of monoclonal antibodies as magic bullets in immunotherapy. Hum Antibodies 
22, 9-13. 
Mariani, M., Camagna, M., Tarditi, L. and Seccamani, E., 1991, A new enzymatic method to 
obtain high-yield F(ab)2 suitable for clinical use from mouse IgGl. Mol Immunol 28, 69-
77. 
Masuda, S., Das, R., Cheng, H., Hurt, E., Dorman, N. and Reed, R., 2005, Recruitment of the 
human TREX complex to mRNA during splicing. Genes Dev 19, 1512-7. 
Mattick, J.S. and Makunin, I.V., 2006, Non-coding RNA. Hum Mol Genet 15 Spec No 1, R17-29. 
158
Matz, M.V., Fradkov, A.F., Labas, Y.A., Savitsky, A.P., Zaraisky, A.G., Markelov, M.L. and 
Lukyanov, S.A., 1999, Fluorescent proteins from nonbioluminescent Anthozoa species. 
Nature biotechnology 17, 969-73. 
Merz, K., Hondele, M., Goetze, H., Gmelch, K., Stoeckl, U. and Griesenbeck, J., 2008, Actively 
transcribed rRNA genes in S. cerevisiae are organized in a specialized chromatin associated 
with the high-mobility group protein Hmo1 and are largely devoid of histone molecules. 
Genes Dev 22, 1190-204. 
Moks, T., Abrahmsen, L., Nilsson, B., Hellman, U., Sjoquist, J. and Uhlen, M., 1986, 
Staphylococcal protein A consists of five IgG-binding domains. European journal of 
biochemistry / FEBS 156, 637-43. 
Mumberg, D., Muller, R. and Funk, M., 1995, Yeast vectors for the controlled expression of 
heterologous proteins in different genetic backgrounds. Gene 156, 119-22. 
Muyldermans, S., 2013, Nanobodies: Natural Single-Domain Antibodies. Annual Review of 
Biochemistry 82, 775-97. 
Muyldermans, S., Baral, T.N., Retamozzo, V.C., De Baetselier, P., De Genst, E., Kinne, J., 
Leonhardt, H., Magez, S., Nguyen, V.K., Revets, H., Rothbauer, U., Stijlemans, B., Tillib, 
S., Wernery, U., Wyns, L., Hassanzadeh-Ghassabeh, G. and Saerens, D., 2009, Camelid 
immunoglobulins and nanobody technology. Vet Immunol Immunopathol 128, 178-83. 
Neri, D., Momo, M., Prospero, T. and Winter, G., 1995, High-affinity antigen binding by chelating 
recombinant antibodies (CRAbs). Journal of molecular biology 246, 367-73. 
Newman, J.R., Ghaemmaghami, S., Ihmels, J., Breslow, D.K., Noble, M., DeRisi, J.L. and 
Weissman, J.S., 2006, Single-cell proteomic analysis of S. cerevisiae reveals the 
architecture of biological noise. Nature 441, 840-6. 
Niedner, A., Muller, M., Moorthy, B.T., Jansen, R.P. and Niessing, D., 2013, Role of Loc1p in 
assembly and reorganization of nuclear ASH1 messenger ribonucleoprotein particles in 
yeast. P Natl Acad Sci USA 110, E5049-58. 
Nisonoff, A., Wissler, F.C., Lipman, L.N. and Woernley, D.L., 1960, Separation of univalent 
fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch 
Biochem Biophys 89, 230-44. 
Obado, S.O., Brillantes, M., Uryu, K., Zhang, W., Ketaren, N.E., Chait, B.T., Field, M.C. and 
Rout, M.P., 2016, Interactome Mapping Reveals the Evolutionary History of the Nuclear 
Pore Complex. PLoS Biol 14, e1002365. 
Oda, Y., Huang, K., Cross, F.R., Cowburn, D. and Chait, B.T., 1999, Accurate quantitation of 
protein expression and site-specific phosphorylation. Proc Natl Acad Sci U S A 96, 6591-
6. 
159
Oeffinger, M., 2012, Two steps forward--one step back: advances in affinity purification mass 
spectrometry of macromolecular complexes. Proteomics 12, 1591-608. 
Oeffinger, M., Wei, K.E., Rogers, R., DeGrasse, J.A., Chait, B.T., Aitchison, J.D. and Rout, M.P., 
2007, Comprehensive analysis of diverse ribonucleoprotein complexes. Nat Methods 4, 
951-6. 
Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. and Nishimune, Y., 1997, 'Green mice' as a 
source of ubiquitous green cells. FEBS Lett 407, 313-9. 
Old, W.M., Meyer-Arendt, K., Aveline-Wolf, L., Pierce, K.G., Mendoza, A., Sevinsky, J.R., 
Resing, K.A. and Ahn, N.G., 2005, Comparison of label-free methods for quantifying 
human proteins by shotgun proteomics. Mol Cell Proteomics 4, 1487-502. 
Olivier, C., Poirier, G., Gendron, P., Boisgontier, A., Major, F. and Chartrand, P., 2005, 
Identification of a conserved RNA motif essential for She2p recognition and mRNA 
localization to the yeast bud. Mol Cell Biol 25, 4752-66. 
Ong, S.E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey, A. and Mann, M., 
2002, Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and 
accurate approach to expression proteomics. Mol Cell Proteomics 1, 376-86. 
Oricchio, E., Nanjangud, G., Wolfe, A.L., Schatz, J.H., Mavrakis, K.J., Jiang, M., Liu, X., Bruno, 
J., Heguy, A., Olshen, A.B., Socci, N.D., Teruya-Feldstein, J., Weis-Garcia, F., Tam, W., 
Shaknovich, R., Melnick, A., Himanen, J.P., Chaganti, R.S. and Wendel, H.G., 2011, The 
Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147, 554-64. 
Ormo, M., Cubitt, A.B., Kallio, K., Gross, L.A., Tsien, R.Y. and Remington, S.J., 1996, Crystal 
structure of the Aequorea victoria green fluorescent protein. Science 273, 1392-5. 
Pardon, E., Laeremans, T., Triest, S., Rasmussen, S.G., Wohlkonig, A., Ruf, A., Muyldermans, S., 
Hol, W.G., Kobilka, B.K. and Steyaert, J., 2014, A general protocol for the generation of 
Nanobodies for structural biology. Nature protocols 9, 674-93. 
Parham, P., 1983, On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c 
mice. J Immunol 131, 2895-902. 
Pasero, C. and Olive, D., 2013, Interfering with coinhibitory molecules: BTLA/HVEM as new 
targets to enhance anti-tumor immunity. Immunol Lett 151, 71-5. 
Pleiss, J.A., Whitworth, G.B., Bergkessel, M. and Guthrie, C., 2007, Transcript specificity in yeast 
pre-mRNA splicing revealed by mutations in core spliceosomal components. PLoS Biol 5, 
e90. 
Porter, R.R., 1959, The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. 
Biochem J 73, 119-26. 
160
Poser, I., Sarov, M., Hutchins, J.R., Heriche, J.K., Toyoda, Y., Pozniakovsky, A., Weigl, D., 
Nitzsche, A., Hegemann, B., Bird, A.W., Pelletier, L., Kittler, R., Hua, S., Naumann, R., 
Augsburg, M., Sykora, M.M., Hofemeister, H., Zhang, Y., Nasmyth, K., White, K.P., 
Dietzel, S., Mechtler, K., Durbin, R., Stewart, A.F., Peters, J.M., Buchholz, F. and Hyman, 
A.A., 2008, BAC TransgeneOmics: a high-throughput method for exploration of protein 
function in mammals. Nat Methods 5, 409-15. 
Pratt, J.M., Simpson, D.M., Doherty, M.K., Rivers, J., Gaskell, S.J. and Beynon, R.J., 2006, 
Multiplexed absolute quantification for proteomics using concatenated signature peptides 
encoded by QconCAT genes. Nat Protoc 1, 1029-43. 
Prochasson, P., Florens, L., Swanson, S.K., Washburn, M.P. and Workman, J.L., 2005, The HIR 
corepressor complex binds to nucleosomes generating a distinct protein/DNA complex 
resistant to remodeling by SWI/SNF. Genes Dev 19, 2534-9. 
Querido, E. and Chartrand, P., 2008, Using fluorescent proteins to study mRNA trafficking in 
living cells. Methods Cell Biol 85, 273-92. 
Rappsilber, J., Ishihama, Y. and Mann, M., 2003, Stop and go extraction tips for matrix-assisted 
laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in 
proteomics. Anal Chem 75, 663-70. 
Renier, N., Wu, Z., Simon, D.J., Yang, J., Ariel, P. and Tessier-Lavigne, M., 2014, iDISCO: a 
simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 
896-910. 
Revets, H., De Baetselier, P. and Muyldermans, S., 2005, Nanobodies as novel agents for cancer 
therapy. Expert Opin Biol Ther 5, 111-24. 
Ries, J., Kaplan, C., Platonova, E., Eghlidi, H. and Ewers, H., 2012, A simple, versatile method 
for GFP-based super-resolution microscopy via nanobodies. Nature Methods 9, 582-4. 
Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M. and Seraphin, B., 1999, A generic 
protein purification method for protein complex characterization and proteome 
exploration. Nature biotechnology 17, 1030-2. 
Rodriguez-Navarro, S., Fischer, T., Luo, M.J., Antunez, O., Brettschneider, S., Lechner, J., Perez-
Ortin, J.E., Reed, R. and Hurt, E., 2004, Sus1, a functional component of the SAGA histone 
acetylase complex and the nuclear pore-associated mRNA export machinery. Cell 116, 75-
86. 
Rodriguez, A.J., Condeelis, J., Singer, R.H. and Dictenberg, J.B., 2007, Imaging mRNA 
movement from transcription sites to translation sites. Semin Cell Dev Biol 18, 202-8. 
Romer, T., Leonhardt, H. and Rothbauer, U., 2011, Engineering antibodies and proteins for 
molecular in vivo imaging. Curr Opin Biotechnol 22, 882-7. 
161
Roovers, R.C., Vosjan, M.J., Laeremans, T., el Khoulati, R., de Bruin, R.C., Ferguson, K.M., 
Verkleij, A.J., van Dongen, G.A. and van Bergen en Henegouwen, P.M., 2011, A 
biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer 
129, 2013-24. 
Rothbauer, U., Zolghadr, K., Tillib, S., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N., 
Conrath, K., Muyldermans, S., Cardoso, M.C. and Leonhardt, H., 2006, Targeting and 
tracing antigens in live cells with fluorescent nanobodies. Nat Methods 3, 887-9. 
Rout, M.P., Aitchison, J.D., Suprapto, A., Hjertaas, K., Zhao, Y. and Chait, B.T., 2000, The yeast 
nuclear pore complex: composition, architecture, and transport mechanism. The Journal of 
cell biology 148, 635-51. 
Roy, A., Kucukural, A. and Zhang, Y., 2010, I-TASSER: a unified platform for automated protein 
structure and function prediction. Nat Protoc 5, 725-38. 
Roy, A., Yang, J. and Zhang, Y., 2012, COFACTOR: an accurate comparative algorithm for 
structure-based protein function annotation. Nucleic Acids Res 40, W471-7. 
Saavedra, C.A., Hammell, C.M., Heath, C.V. and Cole, C.N., 1997, Yeast heat shock mRNAs are 
exported through a distinct pathway defined by Rip1p. Genes & development 11, 2845-56. 
Sachs, A.B., Davis, R.W. and Kornberg, R.D., 1987, A single domain of yeast poly(A)-binding 
protein is necessary and sufficient for RNA binding and cell viability. Mol Cell Biol 7, 
3268-76. 
Said, N., Rieder, R., Hurwitz, R., Deckert, J., Urlaub, H. and Vogel, J., 2009, In vivo expression 
and purification of aptamer-tagged small RNA regulators. Nucleic Acids Res 37, e133. 
Sasso, E.H., Silverman, G.J. and Mannik, M., 1991, Human IgA and IgG F(ab')2 that bind to 
staphylococcal protein A belong to the VHIII subgroup. J Immunol 147, 1877-83. 
Schechter, I. and Berger, A., 1967, On the size of the active site in proteases. I. Papain. 
Biochemical and biophysical research communications 27, 157-62. 
Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y., Pietzsch, J., Fenyo, 
D., Abadir, A., Velinzon, K., Hurley, A., Myung, S., Boulad, F., Poignard, P., Burton, D.R., 
Pereyra, F., Ho, D.D., Walker, B.D., Seaman, M.S., Bjorkman, P.J., Chait, B.T. and 
Nussenzweig, M.C., 2011, Sequence and structural convergence of broad and potent HIV 
antibodies that mimic CD4 binding. Science 333, 1633-7. 
Schmid, M., Olszewski, P., Pelechano, V., Gupta, I., Steinmetz, L.M. and Jensen, T.H., 2015, The 
Nuclear PolyA-Binding Protein Nab2p Is Essential for mRNA Production. Cell Rep 12, 
128-39. 
Schmid, M., Poulsen, M.B., Olszewski, P., Pelechano, V., Saguez, C., Gupta, I., Steinmetz, L.M., 
Moore, C. and Jensen, T.H., 2012, Rrp6p controls mRNA poly(A) tail length and its 
decoration with poly(A) binding proteins. Mol Cell 47, 267-80. 
162
Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W. and Selbach, 
M., 2011, Global quantification of mammalian gene expression control. Nature 473, 337-
42. 
Segref, A., Sharma, K., Doye, V., Hellwig, A., Huber, J., Luhrmann, R. and Hurt, E., 1997, 
Mex67p, a novel factor for nuclear mRNA export, binds to both poly(A)+ RNA and nuclear 
pores. EMBO J 16, 3256-71. 
SenGupta, D.J., Zhang, B., Kraemer, B., Pochart, P., Fields, S. and Wickens, M., 1996, A three-
hybrid system to detect RNA-protein interactions in vivo. Proc Natl Acad Sci U S A 93, 
8496-501. 
Seraphin, B. and Rosbash, M., 1989, Identification of functional U1 snRNA-pre-mRNA 
complexes committed to spliceosome assembly and splicing. Cell 59, 349-58. 
Shagin, D.A., Barsova, E.V., Yanushevich, Y.G., Fradkov, A.F., Lukyanov, K.A., Labas, Y.A., 
Semenova, T.N., Ugalde, J.A., Meyers, A., Nunez, J.M., Widder, E.A., Lukyanov, S.A. 
and Matz, M.V., 2004, GFP-like proteins as ubiquitous metazoan superfamily: evolution 
of functional features and structural complexity. Mol Biol Evol 21, 841-50. 
Shaner, N.C., Steinbach, P.A. and Tsien, R.Y., 2005, A guide to choosing fluorescent proteins. 
Nat Methods 2, 905-9. 
Sharp, P.M. and Li, W.H., 1987, The codon Adaptation Index--a measure of directional 
synonymous codon usage bias, and its potential applications. Nucleic Acids Res 15, 1281-
95. 
Sheth, U. and Parker, R., 2006, Targeting of aberrant mRNAs to cytoplasmic processing bodies. 
Cell 125, 1095-109. 
Shi, Y., Pellarin, R., Fridy, P.C., Fernandez-Martinez, J., Thompson, M.K., Li, Y., Wang, Q.J., 
Sali, A., Rout, M.P. and Chait, B.T., 2015, A strategy for dissecting the architectures of 
native macromolecular assemblies. Nat Methods 12, 1135-8. 
Shu, X., Shaner, N.C., Yarbrough, C.A., Tsien, R.Y. and Remington, S.J., 2006, Novel 
chromophores and buried charges control color in mFruits. Biochemistry 45, 9639-47. 
Silva, J.C., Gorenstein, M.V., Li, G.Z., Vissers, J.P. and Geromanos, S.J., 2006, Absolute 
quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell 
Proteomics 5, 144-56. 
Silverman, J., Liu, Q., Bakker, A., To, W., Duguay, A., Alba, B.M., Smith, R., Rivas, A., Li, P., 
Le, H., Whitehorn, E., Moore, K.W., Swimmer, C., Perlroth, V., Vogt, M., Kolkman, J. 
and Stemmer, W.P., 2005, Multivalent avimer proteins evolved by exon shuffling of a 
family of human receptor domains. Nature biotechnology 23, 1556-61. 
Simon, D.N. and Rout, M.P., 2014, Cancer and the nuclear pore complex. Adv Exp Med Biol 773, 
285-307. 
163
Skerra, A. and Pluckthun, A., 1988, Assembly of a functional immunoglobulin Fv fragment in 
Escherichia coli. Science 240, 1038-41. 
Slobodin, B. and Gerst, J.E., 2010, A novel mRNA affinity purification technique for the 
identification of interacting proteins and transcripts in ribonucleoprotein complexes. RNA 
16, 2277-90. 
Smith, T.C., Fridy, P.C., Li, Y., Basil, S., Arjun, S., Friesen, R.M., Leszyk, J., Chait, B.T., Rout, 
M.P. and Luna, E.J., 2013, Supervillin binding to myosin II and synergism with anillin are 
required for cytokinesis. Mol Biol Cell 24, 3603-19. 
Smits, A.H., Jansen, P.W., Poser, I., Hyman, A.A. and Vermeulen, M., 2013, Stoichiometry of 
chromatin-associated protein complexes revealed by label-free quantitative mass 
spectrometry-based proteomics. Nucleic Acids Res 41, e28. 
Snay-Hodge, C.A., Colot, H.V., Goldstein, A.L. and Cole, C.N., 1998, Dbp5p/Rat8p is a yeast 
nuclear pore-associated DEAD-box protein essential for RNA export. EMBO J 17, 2663-
76. 
Spivak, M., Weston, J., Bottou, L., Kall, L. and Noble, W.S., 2009, Improvements to the percolator 
algorithm for Peptide identification from shotgun proteomics data sets. J Proteome Res 8, 
3737-45. 
Srisawat, C. and Engelke, D.R., 2001, Streptavidin aptamers: affinity tags for the study of RNAs 
and ribonucleoproteins. RNA 7, 632-41. 
Strasser, K., Bassler, J. and Hurt, E., 2000, Binding of the Mex67p/Mtr2p heterodimer to FXFG, 
GLFG, and FG repeat nucleoporins is essential for nuclear mRNA export. J Cell Biol 150, 
695-706. 
Strasser, K. and Hurt, E., 2000, Yra1p, a conserved nuclear RNA-binding protein, interacts directly 
with Mex67p and is required for mRNA export. EMBO J 19, 410-20. 
Strasser, K., Masuda, S., Mason, P., Pfannstiel, J., Oppizzi, M., Rodriguez-Navarro, S., Rondon, 
A.G., Aguilera, A., Struhl, K., Reed, R. and Hurt, E., 2002, TREX is a conserved complex 
coupling transcription with messenger RNA export. Nature 417, 304-8. 
Tackett, A.J., DeGrasse, J.A., Sekedat, M.D., Oeffinger, M., Rout, M.P. and Chait, B.T., 2005, I-
DIRT, a general method for distinguishing between specific and nonspecific protein 
interactions. J Proteome Res 4, 1752-6. 
Tardiff, D.F., Lacadie, S.A. and Rosbash, M., 2006, A genome-wide analysis indicates that yeast 
pre-mRNA splicing is predominantly posttranscriptional. Molecular cell 24, 917-29. 
Taylor, M.S., LaCava, J., Mita, P., Molloy, K.R., Huang, C.R., Li, D., Adney, E.M., Jiang, H., 
Burns, K.H., Chait, B.T., Rout, M.P., Boeke, J.D. and Dai, L., 2013, Affinity proteomics 
reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell 
155, 1034-48. 
164
Thompson, M.K., Fridy, P.C., Keegan, S., Chait, B.T., Fenyo, D. and Rout, M.P., 2016, 
Optimizing selection of large animals for antibody production by screening immune 
response to standard vaccines. J Immunol Methods 430, 56-60. 
Tollervey, D., 1987, A yeast small nuclear RNA is required for normal processing of pre-ribosomal 
RNA. EMBO J 6, 4169-75. 
Trcek, T., Larson, D.R., Moldon, A., Query, C.C. and Singer, R.H., 2011, Single-molecule mRNA 
decay measurements reveal promoter- regulated mRNA stability in yeast. Cell 147, 1484-
97. 
Tsai, B.P., Wang, X., Huang, L. and Waterman, M.L., 2011, Quantitative profiling of in vivo-
assembled RNA-protein complexes using a novel integrated proteomic approach. Mol Cell 
Proteomics 10, M110 007385. 
Tseng, S.S., Weaver, P.L., Liu, Y., Hitomi, M., Tartakoff, A.M. and Chang, T.H., 1998, Dbp5p, a 
cytosolic RNA helicase, is required for poly(A)+ RNA export. EMBO J 17, 2651-62. 
Tuck, A.C. and Tollervey, D., 2013, A transcriptome-wide atlas of RNP composition reveals 
diverse classes of mRNAs and lncRNAs. Cell 154, 996-1009. 
Udayakumar, D., Zhang, G., Ji, Z., Njauw, C.N., Mroz, P. and Tsao, H., 2011, EphA2 is a critical 
oncogene in melanoma. Oncogene 30, 4921-9. 
Uhlen, M., Nilsson, B., Guss, B., Lindberg, M., Gatenbeck, S. and Philipson, L., 1983, Gene fusion 
vectors based on the gene for staphylococcal protein A. Gene 23, 369-78. 
Ulrichts, H., Silence, K., Schoolmeester, A., de Jaegere, P., Rossenu, S., Roodt, J., Priem, S., 
Lauwereys, M., Casteels, P., Van Bockstaele, F., Verschueren, K., Stanssens, P., 
Baumeister, J. and Holz, J.B., 2011, Antithrombotic drug candidate ALX-0081 shows 
superior preclinical efficacy and safety compared with currently marketed antiplatelet 
drugs. Blood 118, 757-65. 
Upadhyay, A., Dixit, U., Manvar, D., Chaturvedi, N. and Pandey, V.N., 2013, Affinity capture and 
identification of host cell factors associated with hepatitis C virus (+) strand subgenomic 
RNA. Mol Cell Proteomics 12, 1539-52. 
Van Bockstaele, F., Holz, J.B. and Revets, H., 2009, The development of nanobodies for 
therapeutic applications. Curr Opin Investig Drugs 10, 1212-24. 
Vanlandschoot, P., Stortelers, C., Beirnaert, E., Ibanez, L.I., Schepens, B., Depla, E. and Saelens, 
X., 2011, Nanobodies(R): new ammunition to battle viruses. Antiviral Res 92, 389-407. 
Vasudevan, S. and Steitz, J.A., 2007, AU-rich-element-mediated upregulation of translation by 
FXR1 and Argonaute 2. Cell 128, 1105-18. 
165
Velculescu, V.E., Zhang, L., Zhou, W., Vogelstein, J., Basrai, M.A., Bassett, D.E., Jr., Hieter, P., 
Vogelstein, B. and Kinzler, K.W., 1997, Characterization of the yeast transcriptome. Cell 
88, 243-51. 
Venema, J. and Tollervey, D., 1999, Ribosome synthesis In Saccharomyces cerevisiae. Ann. Rev. 
Gen. 33, 261-311. 
Vinciguerra, P., Iglesias, N., Camblong, J., Zenklusen, D. and Stutz, F., 2005, Perinuclear Mlp 
proteins downregulate gene expression in response to a defect in mRNA export. EMBO J 
24, 813-23. 
Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S. and Conrath, K., 
2009, General strategy to humanize a camelid single-domain antibody and identification 
of a universal humanized nanobody scaffold. J Biol Chem 284, 3273-84. 
von Pawel-Rammingen, U., Johansson, B.P. and Bjorck, L., 2002, IdeS, a novel streptococcal 
cysteine proteinase with unique specificity for immunoglobulin G. The EMBO journal 21, 
1607-15. 
Walzthoeni, T., Leitner, A., Stengel, F. and Aebersold, R., 2013, Mass spectrometry supported 
determination of protein complex structure. Curr Opin Struct Biol 23, 252-60. 
Wang, Z., Gerstein, M. and Snyder, M., 2009, RNA-Seq: a revolutionary tool for transcriptomics. 
Nat Rev Genet 10, 57-63. 
Ward, E.S., Gussow, D., Griffiths, A.D., Jones, P.T. and Winter, G., 1989, Binding activities of a 
repertoire of single immunoglobulin variable domains secreted from Escherichia coli. 
Nature 341, 544-6. 
Warner, J.R., 1999, The economics of ribosome biosynthesis in yeast. Trends Biochem Sci 24, 
437-40. 
Weirich, C.S., Erzberger, J.P., Flick, J.S., Berger, J.M., Thorner, J. and Weis, K., 2006, Activation 
of the DExD/H-box protein Dbp5 by the nuclear-pore protein Gle1 and its coactivator 
InsP6 is required for mRNA export. Nat Cell Biol 8, 668-76. 
Westblade, L.F., Minakhin, L., Kuznedelov, K., Tackett, A.J., Chang, E.J., Mooney, R.A., 
Vvedenskaya, I., Wang, Q.J., Fenyo, D., Rout, M.P., Landick, R., Chait, B.T., Severinov, 
K. and Darst, S.A., 2008, Rapid isolation and identification of bacteriophage T4-encoded 
modifications of Escherichia coli RNA polymerase: a generic method to study 
bacteriophage/host interactions. Journal of proteome research 7, 1244-50. 
Will, C.L. and Luhrmann, R., 2011, Spliceosome structure and function. Cold Spring Harb 
Perspect Biol 3. 
Wodicka, L., Dong, H., Mittmann, M., Ho, M.H. and Lockhart, D.J., 1997, Genome-wide 
expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 15, 1359-67. 
166
Worn, A. and Pluckthun, A., 2001, Stability engineering of antibody single-chain Fv fragments. 
Journal of molecular biology 305, 989-1010. 
Xia, N.S., Luo, W.X., Zhang, J., Xie, X.Y., Yang, H.J., Li, S.W., Chen, M. and Ng, M.H., 2002, 
Bioluminescence of Aequorea macrodactyla, a common jellyfish species in the East China 
Sea. Mar Biotechnol (NY) 4, 155-62. 
Xu, Z., Wei, W., Gagneur, J., Perocchi, F., Clauder-Munster, S., Camblong, J., Guffanti, E., Stutz, 
F., Huber, W. and Steinmetz, L.M., 2009, Bidirectional promoters generate pervasive 
transcription in yeast. Nature 457, 1033-7. 
Yamaguchi, Y., Kim, H., Kato, K., Masuda, K., Shimada, I. and Arata, Y., 1995, Proteolytic 
fragmentation with high specificity of mouse immunoglobulin G. Mapping of proteolytic 
cleavage sites in the hinge region. J Immunol Methods 181, 259-67. 
Yarbrough, D., Wachter, R.M., Kallio, K., Matz, M.V. and Remington, S.J., 2001, Refined crystal 
structure of DsRed, a red fluorescent protein from coral, at 2.0-A resolution. P Natl Acad 
Sci USA 98, 462-7. 
Zacharias, D.A., Violin, J.D., Newton, A.C. and Tsien, R.Y., 2002, Partitioning of lipid-modified 
monomeric GFPs into membrane microdomains of live cells. Science 296, 913-6. 
Zenklusen, D., Larson, D.R. and Singer, R.H., 2008, Single-RNA counting reveals alternative 
modes of gene expression in yeast. Nat Struct Mol Biol 15, 1263-71. 
Zenklusen, D., Vinciguerra, P., Wyss, J.C. and Stutz, F., 2002, Stable mRNP formation and export 
require cotranscriptional recruitment of the mRNA export factors Yra1p and Sub2p by 
Hpr1p. Mol Cell Biol 22, 8241-53. 
Zhang, Y., 2008, I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 
40. 
Zhou, Z., Luo, M.J., Straesser, K., Katahira, J., Hurt, E. and Reed, R., 2000, The protein Aly links 
pre-messenger-RNA splicing to nuclear export in metazoans. Nature 407, 401-5. 
Zid, B.M. and O'Shea, E.K., 2014, Promoter sequences direct cytoplasmic localization and 
translation of mRNAs during starvation in yeast. Nature 514, 117-21. 
Zuiderweg, E.R., 2002, Mapping protein-protein interactions in solution by NMR spectroscopy. 
Biochemistry 41, 1-7. 
 
 
167
